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Abstract 
Studies as early as in the 70s showed that the gut and its intrinsic gut 
microbiota is a possible site of drug modification and later studies confirmed that 
human microbiota metabolism with its diverse set of genes can be a cause for drug 
side effects. Yet, our knowledge of the biochemical capabilities of gut bacteria to 
interact with or metabolize therapeutic drugs remains largely incomplete. To our 
knowledge, there has not been any systematic screen of xenobiotic-microbial 
interactions elucidating how wide-spread bacterial drug modification is across 
therapeutic drugs or the gut microbiota. In my PhD work, I tested, under 
anaerobic conditions, 450 bacteria-drug interactions covering 25 metabolically 
diverse gut bacteria and 18 structurally diverse FDA-approved drugs. This 
revealed almost 50 novel bioaccumulation or biotransformation links between 19 
bacterial species and 10 drugs. The implicated bacteria are phylogenetically 
diverse, including commensals, probiotics and bacteria associated with diseases. 
The affected drugs span diverse indication areas, from asthma (montelukast) to 
depression (duloxetine and aripiprazole). As a case in point, the results from this 
bacteria-drug interaction study are followed upon in more details through 
investigation of interactions involving duloxetine – a widely used antidepressant. I 
found that duloxetine induces higher diversity in synthetic bacterial communities, 
and its bioaccumulation by community members affects the community 
dynamics. Following, I found that duloxetine affects the native metabolism of B. 
uniformis and C. saccharolyticum, in particular the purine metabolism. These 
interactions might in turn influence bacterial behavior in a community. To find 
the direct protein targets of duloxetine in C. saccharolyticum, I used click 
chemistry-based methods and proteomics. Two of the five strongly enriched 
binding proteins are part of a NADH:quinone dehydrogenase complex. Two 
potential underlying mechanisms for duloxetine interactions are suggested: i) 
Duloxetine inhibits NADH:quinone dehydrogenase by binding to its quinone 
binding site. The resulting NADH excess leads to a change in downstream 
pathways like purine metabolism. ii) Duloxetine binds competitively on the 
NADH binding site of NADH:quinone dehydrogenase and other proteins. 
In addition to discovering new xenobiotic interactions, the study highlights a 
new dimension to gut microbiota-drug interactions, namely bioaccumulation, 
which so far has been largely overlooked. My results suggest that bioaccumulation 
of drug compounds might be a common feature to many gut bacteria and thus 
have broad and far-reaching implications for drug dosage decisions and 
personalized medicine.
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Zusammenfassung 
Bereits in den 70er Jahren zeigten Studien, dass der Darm und sein 
intrinsisches Darmmikrobiom ein möglicher Ort für die Modifikation von 
Medikamenten ist. Spätere Studien bestätigten, dass der Stoffwechsel des 
menschlichen Mikrobiom mit seinen im vergleich zum menschlichen Genom 
unterschiedlichen Satz an Genen eine Ursache für Medikamentenneben-
wirkungen sein kann. Unser Wissen über die biochemischen Fähigkeiten von 
Darmbakterien mit therapeutischen Wirkstoffen in Wechselwirkung zu treten 
oder diese zu metabolisieren, bleibt jedoch weitgehend unvollständig. Unseres 
Wissens nach gibt es bis jetzt keine systematische Studie von xenobiotisch-
mikrobiellen Wechselwirkungen, die darlegen könnte, wie weit verbreitet 
bakterielle Modifikation von therapeutische Arzneimitteln durch das 
Darmmikrobiom ist. In meiner Doktorarbeit habe ich unter anaeroben 
Bedingungen 450 Bakterien-Wirkstoff-Wechselwirkungen getestet, die 25 
metabolisch verschiedene Darmbakterien und 18 strukturell verschiedene, FDA-
zugelassene Medikamente abdecken. Dies zeigte fast 50 neue Zusammenhänge, 
Bioakkumulationen oder Biotransformationen, zwischen 19 Bakterienarten und 
10 Wirkstoffen auf. Die betroffenen Bakterien sind phylogenetisch 
unterschiedlich, einschließlich Kommensalen, probiotischen Bakterien und 
Bakterien, die mit Krankheiten assoziiert sind. Die betroffenen Medikamente 
erstrecken sich über diverse Indikationsbereiche, von Asthma (Montelukast) bis 
hin zu Depression (Duloxetin und Aripiprazol). Als typisches Beispiel werden die 
Ergebnisse dieser Bakterien-Wirkstoff-Wechselwirkungsstudie anhand von 
Wechselwirkungen mit Duloxetin, einem weit verbreiteten Antidepressivum, 
genauer untersucht. Duloxetin induziert eine höhere Diversität in synthetischen 
Bakteriengemeinschaften, und seine Bioakkumulation durch Gemeinschafts-
mitglieder beeinflusst die Gemeinschaftsdynamik. Weiterhin beeinflusst 
Duloxetin den nativen Metabolismus von B. uniformis und C. saccharolyticum, 
insbesondere den Purinstoffwechsel. Diese Wechselwirkungen könnten wiederum 
das bakterielle Verhalten in einer Gemeinschaft beeinflussen. Um die direkten 
Proteintargets von Duloxetin in C. saccharolyticum zu finden, verwendete ich 
Klick-Chemie-basierte Methoden und Proteomics. Zwei der fünf stark 
angereicherten Proteine sind Teil eines NADH:Quinone-Dehydrogenase-
Komplexes. Zwei mögliche zugrundeliegende Mechanismen für Duloxetin-
Wechselwirkungen werden vorgeschlagen: i) Duloxetin hemmt NADH:Quinone-
Dehydrogenase durch Bindung an seine Quinone-Bindungsstelle. Der 
resultierende NADH-Überschuss führt zu einer Veränderung in Downstream-
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Stoffwechselwegen wie dem Purinstoffwechsel. ii) Duloxetin bindet kompetitiv an 
der NADH-Bindungsstelle von NADH:Quinone-Dehydrogenase. 
Neben der Entdeckung neuer xenobiotischer Wechselwirkungen unterstreicht 
die Studie eine neue Dimension der Mikrobiota-Wirkstoff-Wechselwirkungen, 
nämlich die der Bioakkumulation, die bisher weitgehend übersehen wurde. Meine 
Ergebnisse legen nahe, dass die Bioakkumulation von Wirkstoffen ein 
gemeinsames Merkmal vieler Darmbakterien sein kann und somit breite und weit 
reichende Implikationen für Arzneimitteldosierungsentscheidungen und 
personalisierte Medizin aufweist. 
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1 Introduction 
The text of the following chapter sections 1.1-1.5 has mainly been taken from the 
review Klünemann et al. (2014) and has been originally written by myself. I 
modified and updated it according to the needs of this thesis introduction. 
1.1 The human gut microbiota and its xenometabolism 
1.1.1 The human gut microbiota  
With the help of metagenomics tools, it is now possible to determine the 
identity of a large fraction of the microbial species colonizing the human gut (Qin 
et al. 2010; Human Microbiome Project Consortium. 2012). These tools are also 
revealing the genetic repertoire of the gut microbiome in an unprecedented detail. 
The resulting rich datasets are enabling the characterization of the gut microbial 
communities and their association with health (Blaser et al. 2013).  
The gut microbiota has been shown to modify or metabolize several kinds of 
xenobiotics, from novel cancer drugs through millennia old analgesics to dietary 
components (Goldman et al. 1974; Azad Khan et al. 1983; Sousa et al. 2008; 
Wallace et al. 2010; Zheng et al. 2013; Clayton et al. 2009). Recent studies have 
also highlighted the feasibility of exploiting and manipulating this microbial-
mediated xenometabolism to improve the host health or to prohibit medicinal 
side effects. For example, Wallace et al. showed that a deleterious 
biotransformation of the cancer drug Irinotecan can be averted by inhibiting 
bacterial β–glucuronidase (Wallace et al. 2010). On a more general level, probiotic 
bacteria like Lactobacillus sp. have been shown to ease C. difficile-associated 
diseases, diarrhea and other side effects of antibiotics (Cimperman et al. 2011; 
Hickson 2011). 
Thanks to the advances in various omics technologies, molecular pathways of 
xenometabolism and other xenobiotic interactions in the gut microbiota have now 
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started to unfold through the identification of responsible microorganisms and 
enzymes (Ravcheev & Thiele 2016; Wang et al. 2011; Haiser et al. 2013). In parallel 
to these advances stemming from metagenomics, more and more evidence is 
piling up supporting the key role of gut microbiota in xenometabolism (Sousa et 
al. 2008; Clayton et al. 2009; Zheng et al. 2013). In particular, metabolomics has 
made it possible to trace the metabolic fate of xenobiotic compounds (Segata et al. 
2013; Wikoff & Anfora 2009; van Duynhoven et al. 2011), which, together with 
metagenomics, is leading to the recent resurge in the research on xenometabolism 
(Sowada et al. 2014; Johnson et al. 2012; Wilson & Nicholson 2016). 
Understanding xenobiotic interactions in the gut is a highly challenging task 
due to three main reasons: the widespread promiscuity of metabolic enzymes, the 
compositional complexity of the gut microbiota, and the interactions between the 
host and the microbial-mediated xenometabolism. Due to the widespread 
promiscuity of metabolic enzymes (Khersonsky & Tawfik 2010; Ekins 2004; Oguri 
1994), the number of possible routes through which a xenobiotic compound can 
interact with or get metabolized or modified by increases combinatorially with the 
enzymatic repertoire of the microbiota. The compositional diversity and spatial 
heterogeneity of the microbiota and the host-microbiota interaction through the 
enterohepatic cycle adds another layer to this complexity. 
1.1.2 Hierarchy of xenometabolic interactions in the gut 
Xenometabolism is the enzyme-mediated biochemical transformation of a 
xenobiotic, meaning non-native, compound. Other xenometabolic interactions 
can involve the disturbance of native metabolism by the xenobiotic compound. 
The general metabolic interactions that a xenobiotic compound can undergo in 
the gut microbiota can be conceptually organized into three levels: community, 
species and enzymes (Figure 1). Complex xenometabolic pathways often emerge 
through the functional interplay within and across these hierarchical levels. At the 
outermost level, the spatial and compositional structure of the microbial 
community influences the survival, activity and procreation of species in the gut 
environment, and hence the overall xenometabolism (Figure 1c). At the 
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intermediate level, individual species determine and control the enzyme 
availability for the xenometabolism (Figure 1b). At the innermost level, the 
enzymes perform the actual biotransformations owing to their promiscuity 
(Figure 1a).  
 
Figure 1: Hierarchal organization of xenobiotic interactions with the human gut microbiota. 
(a) Enzyme-level xenometabolism. Promiscuous enzymes like cytochrome P450 have broad substrate 
specificities and can biotransform different xenobiotics. Enzyme moonlighting can also lead to different 
modifications of a given xenobiotic compound. (b) Species-level xenometabolism. Xenometabolic enzymes 
are usually found in the cytosol of microbial cells, but some can be secreted as well. A xenobiotic compound 
can undergo different biotransformations within a microbe before its metabolites are exported into the gut 
lumen, or used by the microorganism as a nutrient. (c) Community-level xenometabolism. A xenobiotic or its 
derivatives can be absorbed and/or modified by the host, excreted from the gut, or modified by the gut 
microbiota in many alternative ways. Different species in the microbiota can transform a given xenobiotic 
into different compounds, which can be further metabolized by the same or different microbes. Depending 
on the metabolic status of certain bacteria, a xenobiotic might be degraded or not. The xenobiotics and the 
degradation intermediates are also affected by the structure of the microbiota and vice versa. Figure adapted 
from (Klünemann et al. 2014) 
 
As a consequence, the gut microbiome can alter the disposition, toxicity, and 
efficacy of therapeutic drugs in different ways (Swanson 2015): 1) Activation or 
Inactivation of a xenobiotic by metabolic modification. 2) Sequestration or 
bioaccumulation by binding the xenobiotic. 3) Reactivate a xenobiotic already 
detoxified by liver metabolism. 4) Generating metabolic intermediates, which are 
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metabolized to toxic compounds by the host. 5) Microbial metabolites and 
xenobiotics compete directly for host enzymes. The following chapter will focus 
on potential mechanism behind gut microbial xenobiotic metabolism and its 
consequences on the host while also highlighting how xenobiotics influence the 
gut microbiota in return. The different levels of regulation conceptualized in 
Figure 1 structure the following parts of introduction. 
1.2 Promiscuous enzymes drive and enlarge 
xenometabolic interactions 
Enzymes can often bind to more compounds (substrate promiscuity) and 
catalyze more reactions (functional moonlighting) than those listed in traditional 
databases like KEGG (Kanehisa et al. 2014), and thus may exhibit functions and 
biochemical features beyond the current description (Khersonsky & Tawfik 2010; 
Ekins 2004). This promiscuity is the key driver of xenobiotic metabolism (Figure 
1a). Indeed, xenobiotic metabolism in the liver is also driven by highly 
promiscuous enzymes like cytochrome P450 oxidases and gluthathione S-
transferases (Jakoby & Ziegler 1990). In microbial systems, enzyme promiscuity 
has been as yet mainly investigated in the context of bioremediation of toxic 
compounds from the environment (Wu et al. 2012), or, in the context of 
biotechnological production of valuable chemical compounds (Soni C Banerjee 
2005; Gao et al. 2011). For a comprehensive review on the biotransformation of 
xenobiotics mediated by the gut microbial enzymes and its similarity to 
bioremediation, see Haiser & Turnbaugh (2013). 
Specific links between xenometabolism and the responsible enzyme are 
scarcely known for gut microbes. However, numerous enzyme-xenobiotic 
compound relationships have been described in other biological systems, 
particularly in the context of liver metabolism (Jakoby & Ziegler 1990; Holzhütter 
et al. 2012; Valerio & Long 2010). To obtain an overview of the bacterial enzymes 
relevant for xenobiotic metabolism, I compiled a xenobiotic-enzyme network for 
exemplary xenobiotics (Figure 2) based on interactions obtained from the 
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BRENDA database (Schomburg et al. 2013). The densely populated columns in 
Figure 2, such as EC3.1 (esterases) and EC1.7 (nitrate reductases), highlight the 
enzyme classes that might be of broad relevance for xenobiotic biotransformation. 
This network also underlines the notion that enzymes with similar biochemical 
functionality often process structurally similar molecules. However, the large 
enzymatic repertoire and the complexity of the gut microbiota require 
consideration of xenobiotic metabolism beyond single-step biotransformations 
(Figure 1b). 
 
Figure 2: Examples of promiscuous enzyme-drug interactions in bacteria. 
Each column corresponds to a different enzyme class according to the Enzyme Commission (EC) 
nomenclature. Enzyme promiscuity is the key driver of xenobiotic metabolism, whereby a xenobiotic 
compound can often be transformed by several different enzymes and vice versa. The shown examples were 
obtained from the BRENDA database (Schomburg et al. 2013). Abbreviations: A, Activating; I, Inhibiting; P, 
Product; S, Substrate. Figure from (Klünemann et al. 2014) 
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1.3 Enzyme availability and interaction between xeno- 
and native metabolism 
1.3.1 Bacterial metabolism can change xenobiotics 
One of the well-known examples of xenometabolism that is specific to a 
particular gut bacterium is the metabolism of Digoxin by Eggerthella lenta (Haiser 
et al. 2013). Although such specificity of xenometabolism is scarcely known for 
other compounds, links between bacterial species and metabolites have been 
observed in several studies (Zheng et al. 2013; Wang et al. 2011; Mahmood et al. 
2015; Shu et al. 1991). Not only metabolic interactions can be species specific but 
also sequestration. For example, the binding of L-DOPA to surface proteins of 
Heliobacter pylori interferes with the treatment of Parkinson’s disease and it 
improves again after eradication of the pathogen (Pierantozzi et al. 2006; Niehues 
& Hensel 2009). Such correlations can be used to narrow down the list of potential 
biotransforming species for a given xenobiotic compound. 
While the nature and the abundance of different enzymes harbored by a 
species will determine the possibilities and limits of the xenobiotic interactions 
and xenometabolism, the interactions between xeno- and native metabolism will 
impact the dynamics and efficiency of the actual xenometabolic pathways. One 
step towards understanding species level xenometabolic interactions is to assess its 
enzymatic repertoire and map the corresponding metabolic network. 
1.3.2 Xenobiotics can change bacterial metabolism 
The metabolic activity status of a bacterium can also have a strong influence 
on the probability of biotransformations, which can subsequently impact the 
entire community (Allison et al. 2011; Tamura et al. 2013; Cai et al. 2015). Some 
xenobiotics can also directly influence the microbial metabolism, e.g. by invoking 
changes in gene expression (Maurice et al. 2013; de Freitas et al. 2016). Such feed-
forward phenomena increase the challenges for investigating xenometabolic 
interactions. Metatranscriptomic and metaproteomic studies can help to identify 
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the metabolic state of a given species and to understand the response of microbial 
native metabolism to the perturbations introduced by xenobiotics (Booijink et al. 
2010; Kolmeder et al. 2012; Pérez-Cobas et al. 2013; Cai et al. 2015). Another 
method to investigate if and how bacterial native metabolism is affected makes use 
of recent advances in (meta)metabolomics (Jacobs et al. 2008; Davey et al. 2013; 
Johnson et al. 2012; Vernocchi et al. 2016). Thus, xenobiotics can alter the 
composition of the intestinal microbiota as well as the microbial gene expression 
and metabolism. 
1.4 Community structure influences xenometabolic 
interactions 
1.4.1 Community structure determines possible interactions 
A typical gut microbiota consists of hundreds of diverse microbial species 
(Human Microbiome Project Consortium. 2012; Qin et al. 2010). This 
compositional complexity, combined with the spatial heterogeneity of the 
microbiota (Rey et al. 2013; Dunne 2001; Yang et al. 2005; Hao & Lee 2004) poses 
arguably the biggest challenge for investigating the xenometabolism in the gut. A 
microbial consortium can interact with and transform a certain xenobiotic 
compound in qualitatively different ways than any single species (Figure 1c). A 
community is especially more likely to perform multiple consecutive 
transformation steps due to the larger enzymatic repertoire and thus the 
likelihood is higher that at least some of the many species would express a given 
enzyme under a given condition. 
The spatial structure of the gut microbiota is a critical factor for 
xenometabolism (Donaldson et al. 2015; Rey et al. 2013; Yang et al. 2005; Dunne 
2001). For example, a biotransformation of a xenobiotic might require an acidic 
environment and thus would be performed by microbes residing closer to or in 
the small intestine, whereas microbes in the distal colon would perform 
subsequent steps of the xenometabolism. 
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The composition of the gut microbiota is strongly influenced by several 
environmental and host-dependent factors including nutrient supply, peristaltic 
movements and the host’s immune system (Hao & Lee 2004; Hooper et al. 2012). 
In turn, the gut microbiota can act as an ecosystem engineer influencing some of 
these factors (Costello & Stagaman 2012). Regarding species composition, 
individual gut microbiota are often considerably different from each other 
(Human Microbiome Project Consortium. 2012). Interestingly, these diverse 
microbiotas can converge regarding their functional repertoire, for example, when 
seen from the viewpoint of the represented metabolic capabilities (Human 
Microbiome Project Consortium. 2012; Abubucker et al. 2012). Accordingly, in a 
recent metaproteomic analysis, Kolmeder et al. (2012) observed temporally stable 
expression for a core protein pool of the human intestinal microbiota. From a 
xenometabolism perspective, these observations suggest that different microbiota 
may exhibit common functionalities despite compositional dissimilarities. 
However, the dependency of xenometabolism on the microbial community 
composition can be highly complex (Figure 1c). It has been shown that differences 
in microbial composition is associated with differences in xenometabolic gene 
capacity (Das et al. 2016). Hence the functional implications of the convergent 
metabolic potential remain to be evaluated. 
A source of diversity in xenometabolism that can arise even between species 
with similar metabolic capabilities is the disparity in their ability to secrete 
enzymes, and to uptake/excrete xenobiotics and derivative xenometabolites 
(Nikaido 1996; Lee et al. 2010; Sorg et al. 2014). A given xenometabolic process 
may involve a complex combination of intra- and extra-cellular biotransformation 
processes (Figure 1b). In the gut lumen, secreted enzymes can transform the 
original xenobiotic compound or its metabolic derivatives secreted by other 
microbes. Inside the cells, biotransformation is limited to the enzyme repertoire of 
the respective bacterium, but likelihood of biotransformation may be higher due 
to higher proximity between the xenobiotic and the transforming enzyme(s). 
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1.4.2 Xenobiotics influence gut microbiota composition and 
structure 
Secreted enzymes, native metabolites and xenometabolites can positively or 
negatively impact the whole community (Lee et al. 2010; Riley & Wertz 2002; Sorg 
et al. 2014). Thus, the xenometabolic processes and the gut microbiota can 
reciprocally impact each other. Many examples of xenobiotic influence on gut 
microbiota composition have been described in recent years (Catry et al. 2015; 
Jackson et al. 2016; Cai et al. 2015; Davey et al. 2013). Particular noteworthy is a 
study which disentangled the effect of metformin, an antidiabetic drug, on the gut 
microbiome composition from the effect of diabetes or metabolic syndrome 
(Forslund et al. 2015). Effects of proton pump inhibitors or antidepressants have 
also been shown in large cohort studies (Jackson et al. 2016; Zhernakova et al. 
2016). In a few studies, which investigated a cause for a shift in microbiome 
composition, an effect of the xenobiotic on bacterial gene expression or 
metabolism was observed (Cai et al. 2015; Catry et al. 2015; Kaufman & Griffiths 
2009). However, most of these changes have been observed in host-mediated 
systems, thus the shift in microbiota composition could also be caused by the host 
and not by the xenobiotic directly interacting with the bacteria. 
1.5 Host-microbiota co-metabolism of xenobiotics 
After ingestion and passage of xenobiotics through the stomach, the 
alkalization of the intestinal content is critical for the enzyme activity and 
subsequently for xenometabolism within the small intestine. Absorption to the 
bloodstream can occur by many different ways such as active transport, facilitated 
diffusion, pinocytosis or passive diffusion. Absorbed substances are transported 
via the portal vein to the liver, where metabolism of most xenobiotics takes place 
(Chhabra 1979; Gad 2007). Following the absorption of drugs from the stomach 
and gut, biotransformation in the gastrointestinal epithelial tissue and liver can 
drastically alter their bioavailability and pharmacokinetics (Chhabra 1979). This 
so-called first pass metabolism consists of two phases and it alters the activity of 
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xenobiotics and/or converts them into more water-soluble compounds, often 
leading to detoxification and eventual excretion (Chhabra 1979; Gad 2007). In 
phase I it is usually mediated by cytochrome P450 enzymes and it introduces 
reactive or polar chemical groups enabling further detoxification reactions. In 
phase II the enzymes catalyze conjugation reactions to transform compounds to 
less toxic forms and increase the water-solubility for easier excretion. In many 
cases, this so-called ‘first-pass metabolism’ not only includes metabolism by the 
liver but also that by the gut microbiota (Björkholm et al. 2009). 
The co-metabolism by the liver and the gut microbiota can also lead to the 
circulation of xenobiotics between these two metabolic compartments, 
constituting the enterohepatic cycle. During the enterohepatic circulation, an 
unchanged xenobiotic or its biotransformed metabolite can be excreted back into 
the small intestines via the bile (Gad 2007; Kaminsky & Zhang 2003). Xenobiotics 
can be biotransformed first either by the liver or the microbiota and then further 
modifications can occur in the other system (Clayton et al. 2009; Wallace et al. 
2010). Together, the intestinal absorption barrier, phase I and II metabolism and 
excretion constitute the defense mechanism of the human body against foreign 
(toxic) substances. 
The intestinal microbiota adds to the possibilities and complexity of human 
metabolism in general and xenometabolism particularly. In general, the 
microbiota has a strong impact on human metabolism, immune system and 
potentially behavior (Wikoff & Anfora 2009; Hooper et al. 2012; Heijtz et al. 2011; 
Cai et al. 2015). In particular, the interconnectivity between the intestinal tract 
and other metabolic compartments makes it essential to view xenometabolic 
processes as a co-metabolism by the host and the microbiota (Swanson 2015). The 
examples of such co-metabolism include pro-drugs like mesalazine, which are 
activated by the gut microbiota and then detoxified by the liver (Azad Khan et al. 
1983). Another prominent example is irinotecan, a cancer drug, which is first 
glucuronidated by the liver and then, through enterohepatic circulation, 
transferred back to the gut, where it is further metabolized by the gut microbiota 
(Wallace et al. 2010). Intriguingly, the xenobiotic co-metabolism can be further 
 27 
interconnected by the mutual regulation of host and microbiota gene expression 
in response to a xenobiotic. For example, the intestinal microbiota can mediate 
changes in the hepatic gene expression and the xenometabolism thereof in 
response to a xenobiotic (Björkholm et al. 2009). For a extensive review of gut 
microbiota-host xenobiotic co-metabolism see Carmody & Turnbaugh (2014). 
1.6 The gut-brain axis and depression 
An intriguing example where all different factors of host system, microbiota 
and drug interactions act in concert is the gut-brain axis, which is particularly 
relevant for the development and treatment of depression. The human gut 
microbiota, the gut and the central nervous system are closely connected through 
an exchange of numerous metabolites and hormones (Collins & Bercik 2009; 
O’Mahony et al. 2015). In particular at the functional level, the gut microbiota 
plays an important role in maturation of the immune and nervous system (Sharon 
et al. 2016). Microglia, the immune cells of the brain, and the blood-brain-barrier 
are potentially trained and influenced by the microbiota. Newly emerging data 
suggest the importance of communication between the gut and the brain in 
disorders as diverse as anxiety, depression, cognition, and autism spectrum 
disorder (Sharon et al. 2016). Other data from animal studies indicate that 
changes in behavior can change the microbiome composition, and that these 
changes have effects on inflammation signals in the GI tract (Collins & Bercik 
2009). In turn, prebiotics and probiotics have a mood lightening effect or effects 
on brain activity in human subjects (Schmidt et al. 2014; Tillisch et al. 2013). 
Especially serotonin synthesis is closely connected to the gut and 90% of serotonin 
is located in the enterochromaffin cells in the GI tract, where it regulates intestinal 
movements (Berger et al. 2009). Additionally, the gut microbiome is able to 
modulate host tryptophan metabolism, which in turn affects serotonin synthesis 
and production of neuroactive metabolites (O’Mahony et al. 2015). Thus, there is 
substantial overlap between behaviors influenced by the gut microbiota and those, 
which rely on intact serotonergic neurotransmission like mood or appetite. 
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The development of depression seems to be closely linked with a change in 
microbiota (Foster & McVey Neufeld 2013). Patients with major depressive 
disorder have a different gut microbiome than healthy subjects (Zheng et al. 
2016), and also in comparison to patients in remission (Jiang et al. 2015). Mice 
treated with feces from patients showed depressive-like symptoms (Jiang et al. 
2015; Zheng et al. 2016). However, in both cases the studies did not control for the 
use of antidepressants, thus a change in microbiome might be induced by 
medication. Two studies that investigated population cohorts found an 
association between certain antidepressant treatments and changes in the diversity 
of gut bacteria (Falcony et al. 2016; Zhernakova et al. 2016). In turn these studies 
did not control for depression among subjects.  
Another factor to be considered is that many antipsychotics induce weight 
gain (Dent et al. 2012). Weight gain can be caused by a change in microbiota 
(Musso et al. 2011) or because of differences in life style and nutrition change the 
microbiota (Turnbaugh et al. 2009; Zhernakova et al. 2016). Thus, on the one 
hand the observed changes in microbiome composition in patients with 
depression could be caused by the weight gain induced by antidepressive 
treatment. On the other hand, the weight gain might be caused through 
medication changing the microbiome (Davey et al. 2013; Morgan et al. 2014). 
Differences in weight gain can be observed between medications from the same 
class. For example duloxetine induces weight gain, while the structurally similar 
antidepressant fluoxetine does not (Dent et al. 2012).  
Interestingly, many antipsychotic drugs have antimicrobial properties and can 
in vitro augment the efficacy of antibiotics (Jeyaseeli et al. 2012; Jeyaseeli et al. 
2006; Ayaz et al. 2015; Munoz-Bellido et al. 2000). For antidepressants, which act 
as serotonin reuptake inhibitors blocking a molecular pump, these effects have 
been associated with blocking drug efflux pumps in bacteria (Bohnert et al. 2011). 
Different antidepressants affect bacteria with different efficiencies (Munoz-Bellido 
et al. 2000; Kalaycı et al. 2015). Additionally, as some antidepressants have 
antimicrobial effects on their own they have to directly affect bacterial physiology 
as well (Munoz-Bellido et al. 2000). 
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Taking these studies together, an interaction between depression, medication 
and gut microbiota is likely, but cause and consequence are yet difficult to assess. 
In the next part I will shortly introduce the specific antidepressant duloxetine, as 
much of the following study is based on it. 
1.6.1 Duloxetine and its pharmacokinetics and -dynamics 
Antidepressants are widely prescribed medications treating various forms of 
depression and anxiety, and the number of patients receiving antidepressive 
treatment is on the rise worldwide. In the US, duloxetine (Trade name: Cymbalta) 
is one of the most commonly prescribed antidepressant, and is in the top 20 
pharmaceutical products by sales volume in 2013 (PMLive 2015). It is a 
norepinephrine and serotonin reuptake inhibitor (SNRI), which leads to a longer 
exposition of synapses to these neurotransmitters, which in turn has a mood-
lightening effect. Duloxetine binds selectively with high affinity to both 
norepinephrine (NE) and serotonin (5-HT) transporters and lacks affinity for 
monoamine receptors within the central nervous system (Wernicke et al. 2005). It 
is also in use or investigated for treating stress-induced urinary incontinence. 
Common side effects are nausea, insomnia, and dizziness, which are consistent 
with the pharmacology of the molecule as it interacts with the hormonal and 
nervous system (Wernicke et al. 2005). Another side effect of duloxetine that is 
common to many antidepressants is weight gain (Dent et al. 2012) but also 
constipation. Chemically, it is a naphthalene with a sulfur hetero cycle and an 
secondary amine group attached (Figure 3). 
 
Figure 3: Chemical structure of duloxetine. 
Duloxetine is a thiophene derivative. It acts as a selective neurotransmitter reuptake inhibitor for serotonin 
and noradrenalin (SNRI).  
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Duloxetine has a long half-life after oral administration of around 11h, and its 
metabolites are systemically cleared only after up to 120 hours (Lantz et al. 2003). 
It is mainly metabolized in the liver, and is hepatotoxic in higher doses. 
Duloxetine interacts with many cytochrome P450 enzymes, but is mainly 
metabolized by CYP1A2 and CYP2D6. Duloxetine’s main metabolites are 
excreted to 70% in urine and to 20% in feces after extensive first and second phase 
detoxifying metabolism. The major biotransformation pathways for duloxetine 
involve oxidation of the naphthyl ring at either the 4-, 5-, or 6-positions followed 
by further oxidation, methylation, and/or conjugation. Conjugated metabolites 
are mainly found in the urine. In feces, 4-hydroxy duloxetine and an unidentified 
polar metabolite are the main metabolites (Lantz et al. 2003). Duloxetine’s 
metabolites 5-hydroxyduloxetine, 6-hydroxyduloxetine and 6-hydroxy-5-
methoxyduloxetine have been shown to inhibit 5HT and/or NE transporters and 
hence are possibly contributing to duloxetine’s therapeutic impact (Kuo et al. 
2004). Chan et al. (2011) reported that the hepatotoxicity of duloxetine is possibly 
not related to the bioactivation of its thiophene moiety, or its transient binding of 
CYP1A2, but might be due to the epoxidation of its naphthyl ring. As all 
experiments are performed with the pure compound, it should be noted that 
duloxetine is sensitive to neutral, acidic and alkaline hydrolysis, but stable to 
oxidative stress (Sinha et al. 2009) 
1.7 Aims and Outline of the Thesis 
1.7.1 Aims  
Studies as early as in the 70s showed that the gut and its intrinsic gut 
microbiota is a possible site of drug modification (Goldman et al. 1974) and later 
studies confirmed that human microbiota metabolism with its diverse set of genes 
can be a cause for drug side effects (Wallace et al. 2010; Haiser et al. 2014; Sousa et 
al. 2008). The general metabolic processes a xenobiotic compound can potentially 
undergo in the gut are known in principle (Wilson & Nicholson 2016; Koppel & 
Balskus 2016). However, the specifics of when, where, and how are often unclear. 
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The biomodification of a xenobiotic compound is hard to predict from the 
compound structure alone, since it is also dependent on the chemical 
environment and enzyme availability (Nicholson 2002). Thus, our knowledge of 
the biochemical capabilities of gut bacteria to interact with or metabolize 
therapeutic drugs remains largely incomplete.  
The goal of this study was to conduct a systematic screen of xenobiotic-
microbial interactions elucidating the potential of gut bacteria to modify or 
sequester host-targeted drugs. Insights into gut bacterial-drug interactions can 
facilitate prediction of xenobiotic biotransformation, which is highly valuable 
since it can reduce the cost of developing drugs and prevent unnecessary testing 
for toxicity (Klünemann et al. 2014). Furthermore, together with other data from 
metagenomic sequencing this knowledge can foster personalized dosage (for 
better pharmacokinetics) and personalized medicine, thus reducing side effects 
(Clayton et al. 2006). In conclusion, the aim of my PhD work is to find gut 
bacteria-drug interactions in vitro and then investigate potential underlying 
mechanisms. 
1.7.2 Outline 
In chapter 2, I present results from a bacteria-drug interaction screen and 
investigations into the mode of bacterial drug depletion. Results from this 
interaction study are followed upon in more details through investigation of gut 
bacterial interactions with the antidepressant duloxetine. As gut bacteria live as 
part of a community, interactions of duloxetine with different bacterial targets 
within a defined community context are assessed and presented in chapter 3. In 
chapter 4, I present results from investigating the effect of duloxetine on bacterial 
native metabolism, which may in turn influence bacterial behavior in a 
community. In chapter 5, to find a mechanistic explanation for bacteria-
duloxetine interactions, I explored the direct protein targets of duloxetine using 
click-chemistry based methods and proteomics. In the last chapter I give a 
summary of all findings, discuss how they connect to current research and 
propose further research directions. 
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2 Human gut bacteria interactions with host-
targeted drugs 
In this chapter I will describe the experimental basis for the rest of my PhD 
work presented in this thesis. I will explain why and how a gut bacteria-drug 
interaction screen and follow-up on the depletion-mode of bacterial drug 
depletion is conducted. I will describe the results from both experiments 
separately and give summary of findings fro both screens in the end. Then I will 
discuss the limitations and implications of the results for specific bacteria-drug 
interactions. In the end I will give a short outlook on further experiments. 
2.1 Introduction 
2.1.1 Why investigate bacteria-drug interactions? 
Studies in the 70s showed that the gut and its intrinsic gut microbiota is a 
possible site of drug degradation (Goldman et al. 1974) and later studies 
confirmed that human microbiota metabolism with its diverse set of genes can be 
a cause for side effects (Wallace et al. 2010; Haiser et al. 2014). It has been shown 
recently that xenobiotics-gut microbiota-host interactions have major impacts on 
health in a microbiota dependent manner (Zheng et al. 2013). Additionally, the 
drugs can influence the human microbiota itself, which might cause side effects 
(Forslund et al. 2015). Prediction of xenobiotic biotransformation is highly 
valuable since it can reduce the cost of developing drugs and prevent unnecessary 
testing for toxicity. Furthermore, in context with other data from metagenomic 
sequencing and detailed knowledge of the pharmacodynamics/kinetics of the drug 
it can foster personalized dosage boosting treatment efficiency. Knowing the 
effects of a drug on the microbiota and its effect on the drug can lead to 
development of new treatment strategies having the microbiota as its primary 
target (Swanson 2015). To predict efficacy or potential toxic side effects one has 
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thus to investigate how the xenobiotic metabolism of gut bacteria influences the 
degradation and absorption of the drugs. 
The general metabolic processes a xenobiotic compound can potentially 
undergo in the gut are known in principle. However, the specifics of when, where, 
and how are often unclear. The biodegradation of a xenobiotic compound is hard 
to predict from the compound structure alone, since it is also dependent on the 
chemical environment and enzyme availability. Thus, for most current drugs it is 
not known if and how they are affected by the human gut microbiota and in turn 
how the microbiota is affected by drugs (Patterson & Turnbaugh 2014).  
To our knowledge, there has not been any systematic study of xenobiotic-
microbial interactions elucidating how wide-spread bacterial drug interaction is 
across therapeutic drugs or the gut microbiota. We therefore planned a medium-
scale systematic study researching the interactions between therapeutic drugs and 
human gut bacteria in vitro in monocultures. We aimed to investigate around 500 
pairwise interactions, one drug-bacteria interaction at a time.  
2.1.2 Human gut bacteria investigated in this study 
In this study, I used a subset of a panel of cultivatable human gut bacteria (96 
strains representing 74 species) being used in a variety of projects at EMBL-
Heidelberg. These were rationally selected to cover a broad range of phylogenetic 
and metabolic characteristics of the human gut microbiota. Parameters for 
selection included: i) relative abundance higher than 10-5, ii) prevalence higher 
than 90% in metagenomic datasets of healthy persons, iii) cultivability in 
monocultures, and iv) availability of an annotated genome. Additional species 
were included to cover probiotics, opportunistic pathogens and species 
representing particular metabolic features like mucin degradation or xenobiotic 
biotransformation. A subset of this selection was used in the bacteria-drug 
interaction screen presented in this study. Besides covering the main phyla present 
in the human gut, the focus here was to cover potentially metabolic diverse but 
phylogenetically similar species. This focus allows narrowing down quickly on 
relevant genes potentially involved in a bacteria-drug interaction. Additionally, 
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bacteria known to involved in xenobiotic interactions like E. lenta were included 
(Haiser et al. 2014). The final selection used in the screen can be found in Table 1. 
Bacteria strains were purchased from ATCC or DMSZ strain collections. 
 
Table 1: Selection of species in bacteria-drug interaction screen. 
Gram stain Phylum Species Strain NCBI tax ID 
negative Bacteroidetes Bacteroides fragilis EN-2; VPI 2553 272559 
negative Bacteroidetes Bacteroides thetaiotaomicron E50(VPI 5482) 226186 
negative Bacteroidetes Bacteroides uniformis VPI 0061 411479 
negative Bacteroidetes Bacteroides uniformis HM-715 CL03T00C23 997889 
negative Bacteroidetes Bacteroides uniformis HM-716 CL03T12C37 997890 
negative Bacteroidetes Bacteroides vulgatus DSM-1447 435590 
positive Actinobacteria Bifidobacterium animalis subsp. lactis BI-07 742729 
positive Actinobacteria Bifidobacterium longum subsp. infantis S12 391904 
positive Actinobacteria Bifidobacterium longum subsp. longum E194b (Variant a)  
positive Firmicutes Clostridium bolteae WAL 16351 411902 
positive Firmicutes Clostridium ramosum 113-I; VPI 0427 445974 
positive Firmicutes Clostridium saccharolyticum WM1 610130 
positive Firmicutes Coprococcus comes VPI CI-38 470146 
positive Actinobacteria Eggerthella lenta 1899 B; VPI 0255 479437 
negative Proteobacteria Escherichia coli ED1a ED1a 585397 
negative Proteobacteria Escherichia coli IAI1 IAI1 585034 
positive Firmicutes Eubacterium rectale A1-86 657318 
negative Fusobacteria Fusobacterium nucleatum 1612A; VPI 4355 190304 
positive Firmicutes Lactobacillus gasseri AM 63 324831 
positive Firmicutes Lactobacillus paracasei LPC-37  
positive Firmicutes Lactobacillus plantarum WCFS1 220668 
positive Firmicutes Lactococcus lactis IL1403 272623 
positive Firmicutes Ruminococcus gnavus VPI C7-9 411470 
positive Firmicutes Ruminococcus torques VPI B2-51 411460 
positive Firmicutes Streptococcus salivarius 275  
 
2.1.3 Experimental setup of bacteria-drug interaction screen 
and depletion-mode assay  
The number of interactions investigated was mainly limited by the detection 
method for the drugs. For detection the drug is separated from media compounds 
by liquid chromatography, thus each drug has a different chromatographic 
method. As all drugs need to be detected in the same screen, establishing the 
different methods using the same buffer system was challenging and time-
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consuming. Within the constraints of analytics, I selected drugs to investigate a 
broad diversity of them spanning a wide therapeutic area and a spectrum of 
chemical structures. For a detailed description of drug selection and experimental 
conditions refer to method section 7.3 on page 133. 
The experimental investigation was set up in two parts: first a screening part 
investigating a broad range of potential bacteria-drug interactions and then 
assaying the depletion hits from the screen to determine the mode of depletion 
(Figure 4). The bacteria-drug interaction screen was conducted in 96 well plates 
with 150µl of medium, growth was monitored during 48h anaerobic incubation, 
and bacteria were removed by centrifugation before extracting the spent medium 
in organic phases to measure the drug concentration. Extraction protocol was 
implemented with a pipetting robot. As shown in the plate outline in Figure 4, I 
used one bacteria-free control per plate and drug, but triplicates for each bacteria-
drug interaction. All bacteria-drug interactions were screened in biological 
duplicates. 
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Figure 4: Experimental outline bacteria-drug interaction screen and depletion-mode assay. 
Interactions were studied in two ways: first a screen in 96-well plates to find potential bacteria-drug 
interactions and then a depletion-mode assay of the hits to distinguish between bioaccumulation and 
metabolism of drug compounds. For indirect drug detection, bacterial cultures were removed by 
centrifugation and the supernatant was extracted and analyzed. 
 
As bacteria are removed before extraction of the spent medium, drug 
compounds can be depleted in the screen for multiple reasons: compounds can be 
bound to bacteria or to secreted extracellular proteins, compounds can be taken 
up by bacteria and stored inside, or compounds can be metabolized, either 
completely or biotransformed to a different, maybe less bacteriotoxic form. 
Whereas the first two effects are bioaccumulations and have implications mainly 
on drug dosage and maybe bacterial physiology and community dynamics, the 
latter can create compounds toxic to humans and lead to serious side effects 
(Zheng et al. 2013). Hence I designed a depletion-mode assay to distinguish 
between bioaccumulation of drug compounds by bacteria and a 
biotransformation of drug compounds by bacteria. 
In the depletion-mode assay I extract the same culture in two different ways: 
indirectly by removing first the bacteria using centrifugation and then extracting 
the drug from the spent media and directly by adding the extraction solvent 
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directly to the whole culture consisting of bacteria, extracellular components and 
spent media (Figure 4). Indirect extraction hits would confirm the interaction 
found in the bigger bacteria-drug interaction screen whereas hits from direct 
extractions point to a metabolic interaction as the original drug compound is 
removed from the whole culture. The assay was conducted in 2ml eppendorf tubes 
with 1ml of medium, and after 48h incubation under agitation samples were split 
for direct and indirect extraction. This way the same samples could be used to 
investigate if the drug-bacteria interaction was bioaccumulation or 
biotransformation of the drug. Each interaction and their controls were assayed at 
least in triplicates. 
Bacteria-drug interaction screen and depletion-mode assay both used a drug 
concentration of 50µM, which in most cases approximates the concentration of 
one pill (0.02-3mmol) diluted in the volume of the gut (approx. 2.5L). The 
inoculation OD578 of 0.01 and incubation of the bacteria anaerobically for 48h at 
37°C was also the same. 
The concentrations of all drug compounds in the bacteria-drug interaction 
screen and depletion-mode assay are determined by UV-UPLC methods. The 
methods applied here use UV absorption and elution time for identification by 
comparison to a standard. To be able to measure all selected drugs within one 
screen with the available instrument, chromatographic conditions needed to be 
optimized using a maximum of 4 different mobile phases, while one of them 
needed to be pure water and one an organic phase respectively. Another 
parameter for optimization was time. For optimal separation of compounds a 
longer chromatography with a less steep gradient is usually preferable, but would 
increase the measurement time for the whole screen strongly since approximately 
6000 injections were to be expected. 
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2.2 Results 
2.2.1 Drug Selection 
The aim of this drug selection was to get a diverse set of drugs for screening, 
representing different medical indications and structural drug classes, while also 
selecting the drugs that are causing microbiota-associated side effects. I focused 
on host-targeted drugs, excluding antibiotics on purpose as those are studied in 
bacterial context heavily already and in these cases drug-to-bacteria interactions 
were deemed more likely than bacteria-to-drug interactions. An overview of the 
drug selection procedure is shown in Figure 5a. In general, information about 
drug side effects are taken from SIDER database (Kuhn et al. 2016), information 
about drug pharmacology from DrugBank (Law et al. 2014). 
Using the side effect database SIDER (Kuhn et al. 2010), I selected around 90 
drugs with a directly gut microbiota related side effect (e.g. bloating, diarrhea) and 
120 drugs with a more indirectly gut microbiota related side effect (e.g. 
arteriosclerosis, weight gain). Furthermore, drugs without any gut related side 
effects and drugs known to be metabolized by bacteria were added to the selection 
as controls. From these compounds with a molecular weight higher than 500 
Dalton were generally excluded to focus on small molecule drugs. I only selected 
orally administered drugs as they have a higher chance of passing into the gut in 
high concentrations compared to intravenously applied drugs. Furthermore, 
drugs which are taken regularly to treat chronic diseases or in high dosage or have 
a long half-life and poor bioavailability are also more likely to reach the gut. 
Finally, an emphasis was put on drugs with high market revenue, thus increasing 
the relevance of potential findings to a broader population.  
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Figure 5: Drug Selection workflow and result. 
a) Drug selection started with approximately 1000 annotated drugs from the SIDER side effect database 
(Kuhn et al. 2016), which were filtered for their gut related side effects. Drug selection was enriched from 
another database (Saad et al. 2012) for known or suspected interactions with the gut microbiome, before 
filtered for oral administration and manually curated for overall interest. Final selection was filtered for 
availability from vendors and establishment of UPLC methods. b) Pie chart classifying selected compounds by 
disease indication. 
 
 
After this selection procedure 30 drugs were left, and for 18 of them a 
chromatographic method with the same buffer system and internal standard could 
be established. 3 of the final 18 drugs are drugs with known specific bacterial 
interactions, which serve as positive and negative controls to recapitulate known 
biological interactions. The selected drugs, the therapeutic indication and the 
primary reason for selection (e.g. control) are shown in Table 2 and different 
therapeutic indications covered are shown in Figure 5b.  
 
  
Table 2: D
rugs selected for the Bacteria-D
rug Interaction Screen. 
Chem
bl ID
 
D
rug 
Indication 
Acute/chronic 
Selection 
pKa* 
Stock conc.  
Solvent 
CH
EM
BL112 
Acetam
inophen 
M
inor pain; Fever 
acute 
U
sage widely spread; high dosage 
9.38 
50 m
M
 
water 
CH
EM
BL1112 
Aripiprazole 
Psychosis; D
epression 
chronic 
W
eight fluctuations; top selling product 
7.46 
50 m
M
 
D
M
SO
 
CH
EM
BL1751 
D
igoxin 
Arrhythm
ia 
acute 
N
egative control; only depleted by E. lenta 
4.43 
50 m
M
 
D
M
SO
 
CH
EM
BL502 
D
onepezil H
Cl  
Alzheim
er's disease 
chronic 
Long half-life; gastrointestinal side effects 
8.62 
23 m
M
 
water 
CH
EM
BL1175 
D
uloxetine H
Cl 
D
epression; Anxiety disorders 
chronic 
W
eight gain; top selling product 
9.7 
100 m
M
 
D
M
SO
 
CH
EM
BL1138 
Ezetim
ibe 
Cholesterol reduction 
chronic 
H
igh %
 fecal excretion; top selling product 
9.7 
10 m
M
 
D
M
SO
 
CH
EM
BL1454 
Levam
isole H
Cl 
Parasitic worm
 infections; tested 
for cancer treatm
ent 
acute 
W
ithdrawn due to coagulation side effects; in 
trial as colon cancer drug; bacterial m
etabolism
 
6.98 
50 m
M
 
water 
CH
EM
BL841 
Loperam
ide H
Cl 
D
iarrhea; IBD
 
both 
U
sage very com
m
on 
9.41 
50 m
M
 
D
M
SO
 
CH
EM
BL137 
M
etronidazole H
Cl 
Antibiotic for anaerobic bacteria  
acute 
Positive control: degradation and growth 
3.09 
50 m
M
 
water 
CH
EM
BL787 
M
ontelukast N
a 
Acute asthm
a; Seasonal allergies 
chronic 
G
astrointestinal disturbances; chronic use  
4.3 
50 m
M
 
D
M
SO
 
CH
EM
BL1790041 
Ranitidine H
Cl 
Peptic ulcer 
acute 
V
itam
in B12 deficiency; bacterial m
etabolism
 
8.08 
100 m
M
 
D
M
SO
 
CH
EM
BL193240 
Roflum
ilast 
Asthm
a; CO
PD
 
chronic 
G
astrointestinal side effects are dose lim
iting 
8.74 
10 m
M
 
D
M
SO
 
CH
EM
BL121 
Rosiglitazone 
D
iabetes 
chronic 
W
ithdrawn due to increase in heart attacks 
6.23 
100 m
M
 
D
M
SO
 
CH
EM
BL1496 
Rosuvastatin Ca 
Cholesterol reduction 
chronic 
M
echanism
 of action unclear; top selling  
3.8 
10 m
M
 
D
M
SO
 
CH
EM
BL1064 
Sim
vastatin 
Cholesterol reduction; 
H
yperlipidaem
ia 
chronic 
M
echanism
 of action of statins unclear; top 
selling product 
13.5 
100 m
M
 
D
M
SO
 
CH
EM
BL421 
Sulfasalazine 
Rheum
atoid Athritis; IBD
 
chronic 
Positive control; m
etabolized by m
any bacteria 
2.4 
100 m
M
 
D
M
SO
 
CH
EM
BL483 
Tenofovir 
D
isoproxil Fum
arate 
H
IV
 
chronic 
Flatulence; top selling product 
2.07 
10 m
M
 
D
M
SO
 
CH
EM
BL1020 
Tolm
etin Sodium
 
Rheum
atoid Arthritis,  
both 
M
ild coronary and gastrointestinal side effects 
3.5 
100 m
M
 
water 
*Sources of m
ost basic pKa values are D
rugbank (Law et al. 2014), CH
EM
BL (Bento et al. 2014), and Toxnet (W
exler 2001) databases. 
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Special emphasis has been put to select proper controls for the bacteria-drug 
interaction screen to be able to estimate the biological relevance of screening 
results and compare them to known biology. Metronidazole, sulfasalazine and 
digoxin are drugs with known and well-described bacterial interaction 
mechanisms. Metronidazole is an antibiotic against anaerobic bacteria, which 
upon reduction of its nitro group by bacteria inhibits their growth by introducing 
DNA double strand breaks. It serves as a control both for growth inhibition and 
drug depletion. Sulfasalazine is an inflammation inhibitor used in the treatment of 
ulcerative colitis. It is a prodrug, which becomes active upon cleavage of its 
azobond by bacterial azoreductases, and thus serves as a control for bacterial drug 
depletion without strong effects on their growth. As most bacteria possess 
azoreductases a broad interaction with many bacteria in the screen is expected 
(Mahmood et al. 2015). Digoxin has been shown to be metabolically modified 
only by a specific strain of Eggerthella lenta (Haiser et al. 2013; Haiser et al. 2014). 
Thus, it serves as a negative control with no expected interaction with other 
bacteria than E. lenta and provides clues about the specificity of the screen. For 
levamisole and ranitidine metabolic bacteria-drug interactions have been reported 
previously as well (Shu et al. 1991; Basit & Lacey 2001), although mechanism and 
specificity is less clear as for the dedicated controls metronidazole, sulfasalazine 
and digoxin. This bacteria-drug interaction screen can aid in elucidating 
specificity in their bacterial interactions and also show the impact of levamisole 
and ranitidine on bacterial growth. 
2.2.2 Bacteria-Drug Interaction Screen 
The aim of the bacteria-drug interaction screen was to test if gut bacteria 
deplete drugs in their growth medium and if this depletion is impacting the 
growth of the respective bacteria. Drugs and respective controls had been selected 
as described before (see results 2.2.1), and an UPLC readout after extraction had 
been established for them (see methods 7.2.). Growth was monitored by OD578 
readout, every 2 hours for the first 12h and then approximately every 8h until the 
end of the 48h growth curves. The following describes in short the analysis and 
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results of the interaction screen. First I will describe results from investigating 
bacterial drug depletion, and then I will describe the impact of the screened drugs 
on the growth of bacteria. 
 
Drug depletion in the bacteria-drug interaction screen 
UPLC methods had been established to separate drugs from medium 
compounds and estimate their concentration based on area under the curve. As 
shown in Figure 6, double injections of the same sample have a high correlation 
for each respective drug detection method. However, throughout the screen it 
became apparent that between-sample variability can be high and is mostly 
dependent on different LC columns. LC columns are susceptible to clogging up 
and breakdown of their matrix, and need to be exchanged regularly otherwise the 
LC method looses sensitivity. Peak shape and thus area under the curve of the 
respective drug peak are highly dependent on the performance state of LC 
column. Thus, comparing samples measured on different LC columns or even at 
different measurement times on the same column is difficult. 
A way to analyze data from the screen and compare results between different 
LC columns or between samples measured on the same column but at different 
usage stages is to focus on one biological replicate at a time, and then compare 
results from different biological replicates. Samples from one biological replicate 
of bacteria-drug interaction are on the same 96-well plate, which is measured in 
one LC run, and thus samples from one biological replicate are measured on the 
same LC column. Variability within one biological replicate is therefore minimal, 
but comparatively high between different biological replicates. Thus, I decided to 
calculate the depletion of bacteria-drug interaction in comparison to its respective 
control from the same LC run. 
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Figure 6: Technical replicates of UPLC injections from bacteria-drug interaction screen.  
Dots represent double injections of drug control, containing no bacteria. Axes show area under curve of drug 
peak normalized by peak of internal standard caffeine from UPLC measurements. Throughout the screen 
different LC columns have been used, indicated by the different colors. 
 
The density distribution of drug depletion in comparison to the replicate-
specific control (Figure 7) shows that the positive controls for degradation 
metronidazole and sulfasalazine are depleted in most interactions. Furthermore, 
the negative control digoxin is only depleted in its specific interaction with 
Eggerthella lenta. Thus, the bacteria-drug interaction screen is recapitulating 
expected results and might allow exploration of additional biologically relevant 
interactions. 
Similar to digoxin five other drugs like tolmetin or rosuvastatin have a very 
small distribution centered on zero. Drugs with this kind of density distribution 
show no bacterial depletion and might be considered inert in respect to gut 
bacterial degradation. Acetaminophen and ezetimibe have a narrow distribution 
around zero as well but show specific and relatively strong interactions with 
Escherichia coli iAi1 or Clostridium as they form a separate distribution. 
Acetaminophen is completely depleted, ezetimibe to 60%.  
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Interestingly, 8 of the 15 tested drugs show a shift of their density towards 
depletion, indicating interactions with many bacteria. These interactions might be 
relatively minor like in the case of ranitidine or montelukast or strong as in the 
case of simvastatin. Duloxetine, aripiprazole and roflumilast show a depletion of 
up to 50% in many cases but almost no example of an interaction that is stronger 
than that. Levamisole on the other hand seems to have not only weak interactions 
but also strong interactions with some bacteria, indicated by an additional density 
around 80% depletion.  
 
Figure 7: Density distribution of drug depletion in bacteria-drug interaction screen. 
Density distribution of drug depletion in comparison to bacteria-free control for each drug respectively. Ticks 
in the rug below indicate different replicates, colored by genus of the respective tested species. Background 
colors indicate positive (green) and negative (blue) drug controls for depletion. Dashed lines in each plot 
mark a 30% threshold for bacteria-drug interaction. 
 
Some drugs show a high variability in their density distribution of depletion, 
with a shift to the right indicating an increase of drug concentration in 
comparison to the replicate-specific control. In most cases these seem to be non-
repetitive outliers, which might be cause by a failing column. But in some cases 
like simvastatin, aripiprazole or roflumilast these can be indicative of a 
problematic LC method and results from these interactions should be considered 
with caution.  
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The density distribution of the negative control digoxin shows a biological or 
screening variability of around ±30%. Within this cutoff no bacteria show an 
interaction with digoxin except the expected interaction with E. lenta. Also other 
drugs like tenofovir or ezetimibe vary this much, having their density distributed 
mainly between 30% depletion and 30% increase. Thus, I decided to apply a 
threshold of at least 30% depletion when comparing the different bacteria-drug 
interactions between biological replicates. A study by Haiser et al. on digoxin 
showed that a depletion of this degree could lead to implications in mammalian 
drug efficacy, which gives additional support for this decision (Haiser et al. 2013). 
If a bacteria-drug interaction showed at least 30% depletion in both biological 
replicates, it was considered biologically interesting and is considered a drug 
depletion hit in this gut bacteria-drug interaction screen. Two tables listing all the 
specific interactions can be found in the appendix B. In summary, 55 novel 
interactions were found encompassing 20 different bacterial strains and 11 
different drugs. If interactions from simvastatin are excluded because of its poor 
robustness in LC quality, these numbers change to 49 interactions encompassing 
19 bacterial strains.  
 
Growth effects in the bacteria-drug interaction screen 
Growth curves were recorded using optical density of the bacterial cultures in 
each well at a wavelength of 578nm as readout. To correct for noisy growth the 
maximum OD reached within each growth curve was annotated and manually 
curated. Noisy growth was often associated with an aggregation of bacteria and 
can vary across different drug conditions for the same bacterium, but this was not 
further quantified. After annotation, fold changes in comparison to the respective 
solvent control were calculated for each bacteria-drug interaction (Student’s t test, 
alpha < 0.05). The reproducibility of significant changes in bacterial growth is 
high (Figure 8). Many changes are lethal or lead to a strong decrease in maximum 
OD. However, a few drugs seem to induce better growth than in control 
conditions.  
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Figure 8: Reproducibility of significant growth fold changes in bacteria-drug interaction screen. 
Log2 fold changes of maximum OD at 578nm adsorption wavelength of two biological replicates for 
significantly changed interactions (Student’s t test, alpha < 0.05; Spearman correlation). Interactions with a 
log2 fold change above 0.5 are considered strong. Data analyzed by Sergej Andrejev. 
 
As expected the antibiotic metronidazole shows strong growth inhibition of 
many bacteria (Figure 9). Still, some bacteria like E. coli ED1a or L. gasseri are not 
influenced in their maximum OD by 50µM metronidazole. Also as expected when 
screening non-antibiotics, most drugs show very little effect on the growth of most 
bacteria. Unexpectedly, quite a lot of interactions tend to induce a weak growth 
advantage in comparison to the control. A possible explanation is differences in 
the cytotoxic solvent DMSO, which is 0.5% in the control but depending on the 
drug compound varies between 0.05% to 0.5% (Table 2). However, this effect is 
certainly also bacteria-specific as mostly E. rectale and E. lenta seem to benefit. 
Interestingly, loperamide and duloxetine affect the growth of a number of 
bacteria (Figure 9). Both kill E. rectale, negatively affect E. coli IAI1 and support 
the growth of L. lactis and possibly B. longum subsp. longum. Loperamide 
additionally strongly impacts the growth of B. longum subsp. infantis. This is 
especially interesting as those two bacteria are closely related but show opposite 
drug responses. Digoxin increase the growth of its degrader E. lenta, while weakly 
inhibiting the growth of E. coli IAI1 and R. torques (Figure 9). 
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Figure 9: Heatmap of growth effects in bacteria-drug interaction screen. 
Letters indicated significant changes (student’s t test, alpha < 0.05): L-lethal; N-strong negative; n-weak 
negative; p-weak positive. Interactions with a log2 fold change above 0.5 are considered strong. Clustering 
based on average linking. Data analyzed by Sergej Andrejev. 
 
Some bacteria like R. torques and E. coli IAI1 are influenced by several drugs 
(Figure 9). In the case of E. coli IAI1 the effects are not strong but because its 
growth curves are very smooth, they are highly reproducible. Interestingly though 
E. coli ED1a, a close relative with comparably smooth growth curves, is not 
significantly influenced in its growth by any drug. R. torques grows slowly and has 
a comparatively long lag phase. This might increase its sensitivity to drug 
interactions. L. lactis shows significant growth promotion in response to two 
different drugs, loperamide and levamisole, and is not negatively influenced by 
other drugs.  
In general, clustering of the growth profile reveals Bacteroides tend to have 
more similar, common drug responses, while phyla like Firmicutes and 
Actinobacteria are more diverse in their drug response (Figure 9). However, 
phylogenetic clusters are not strong and even closely related species like E. coli 
IAI1 and E. coli Ed1a or B. uniformis HM715 and B. uniformis HM716 do differ in 
their drug response. Interestingly, the two Actinobacteria E. lenta and B. longum 
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infantis cluster closely and have growth profile distinct from all other bacteria in 
the screen. 
 
Summary 
In summary, the gut bacteria-drug interaction screen revealed many potential 
bacteria-drug interactions, showing that many bacteria potentially deplete drugs 
from their growth medium as well as that some drugs can impact growth of 
several bacteria. However, during the screening process it became apparent that 
those interactions are highly sensitive to environmental conditions like differences 
in medium composition and anaerobicity. Also technical difficulties around the 
stability of UPLC measurements throughout screening increased the variability of 
the screen and cast doubt on some results. Additionally, these results brought 
about the question if the drug depletion is a metabolic degradation or 
modification as in the case of sulfasalazine or digoxin, or rather a bioaccumulation 
of the drug from the medium without any structural modification by the bacteria. 
Thus, we decided to implement an assay to address this question and to confirm 
and estimate the robustness of interactions found in the screen. 
2.2.3 Depletion-mode assay 
The depletion-mode assay was aimed to characterize the hits of the previous 
bacteria-drug interaction screen to distinguish between bioaccumulation of the 
drug and bacterial metabolic biotransformation. To reach this aim bacterial 
cultures were extracted in two different ways: indirectly after removing bacteria by 
centrifugation, and directly with all bacterial cells and extracellular proteins still 
present. After extraction, drug concentration was measured by UPLC. For drug 
depletion, 49 novel interactions were found in the screen encompassing 19 
different bacteria and 10 different drug compounds. Of those I tested 28 
interactions in the assay, encompassing all 10 drugs and 13 different bacteria 
strains. As control also known metabolic interactions between bacteria and 
sulfasalazine and the specific interaction between E. lenta and digoxin were tested. 
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All interactions were tested at least in triplicates, confirmed interactions often 
repeated additionally. 
For the controls all interactions could be confirmed in the depletion-mode 
assay conditions. Controls showed depletion in indirect and direct extractions 
(appendix B). 19 of the tested 28 novel interactions showed depletion in at least 
the indirect extraction, meaning roughly 70% of the interactions from the 
bacteria-drug interaction screen could be confirmed. For 11 interactions a 
significant depletion (FDR controlled Student’s t-test, alpha < 0.05) was also 
found in direct extractions. However, applying an additional threshold of at least 
20% depletion leaves only 7 interactions with potentially metabolic modifications 
of the drug compound. Four of these direct interactions are with levamisole, and 
two with montelukast (Figure 10). While all interactions of levamisole are 
potentially metabolic modifications, most other interactions of montelukast are 
bioaccumulations. Only in its interaction with R. gnavus and B. longum subsp. 
infantis montelukast was consistently confirmed to be depleted when directly 
extracted. Levamisole is likely to be metabolically modified by all bacteria 
depleting it, while montelukast is sequestered or modified depending on the 
bacterium it interacts with. 
The other mentioned direct interaction is donepezil and F. nucleatum. Two 
additional interactions show a significant depletion only in the direct extraction, 
but not in the indirect extraction. This is usually caused by an unusual high 
variation in the indirect extraction, and the respective mean is still indicating 
depletion (appendix B). 
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Figure 10: Examples of bacterial drug degradation from the depletion-mode assay. 
Boxplots show normalized values for each bacteria-drug interaction and different metabolite extraction 
methods. Plate: Extractions from bacteria-drug interaction screen; Indirect: Extractions of supernatant in 
depletion-mode assay; Direct: Extraction of whole bacterial culture in depletion-mode assay. AUC 
normalized by mean of respective controls from each batch or plate. Dashed line indicates mean of bacteria-
free controls. 
 
Ezetimibe showed very specific interactions in the bacteria-drug interaction 
screen being only depleted by two bacteria: B. animalis subsp. lactis and C. 
ramosum. Interestingly, the strong interaction with C. ramosum could not be 
confirmed by the depletion-mode assay, the weaker interaction with B. animalis 
subsp. lactis however shows a weak depletion in both assay extractions as well.  
Duloxetine is another interesting case, as it shows eight interactions in the 
interaction screen, of which five were tested in the depletion-mode assay: B. 
uniformis, C. bolteae, C. comes, C. saccharolyticum and R. gnavus. Additionally, I 
tested S. salivarius as it showed a strong tendency for depletion in one biological 
replicate, and B. thetaiotaomicron as a negative control as it showed no depletion 
in the screen (Figure 10). The depletion-mode assay confirmed all interactions but 
made clear that most interactions of bacteria with duloxetine are 
bioaccumulations, as most of the drug can be recovered after extracting the whole 
bacteria culture. Curiously however, the in the bacteria-drug interaction screen 
inert interaction between duloxetine and B. thetaiotaomicron is now positive, in 
 51 
indirect and direct extractions. This happens similarly for the interaction of L. 
gasseri and levamisole, which is also inert in the screen but shows depletion in a 
direct extraction in the depletion-mode assay. 
Thus, while roughly 70% of the interactions from the bacteria-interaction 
screen could be confirmed with the depletion-mode assay and 35% of those are 
likely biotransformations, it also became clear that the screen is not finding all 
possible potential bacteria-drug interactions.  
2.2.4 Summary: Bacteria-Drug interactions are specific 
The bacteria-drug interaction screen and the following depletion-mode assay 
showed that many bacteria could interact with human-targeted therapeutic drugs. 
The results from both experiments are summarized in Figure 11. The screen 
showed that 20 out of 25 tested bacteria deplete at least one drug compound in 
their growth medium, and 11 out of 15 drug compounds are depleted by at least 
one bacterium. From 375 tested bacteria-drug interactions 49 revealed a depletion 
of a drug in the medium, and 22 an effect on the maximum growth capacity of 
bacteria. The single tested Fusobacterium F. nucleatum accounts for 15% of the 
found drug depletion interactions. Bacteroidetes phyla on the other hand accounts 
for 24% of the interactions tested, but only for 16% of the depletion interactions 
found. With the exception of E. coli IAI1, therapeutic drugs mainly affect the 
growth of gram-positive bacteria. 
Interestingly, only in six interactions the same drug, which is depleted from 
the medium, affects also the growth of the respective bacterium. Digoxin is 
promoting the growth of E. lenta, montelukast is promoting B. uniformis HM715 
growth and duloxetine is inhibiting growth of C. saccharolyticum. All three drugs, 
which are depleted by E. coli IAI1, are also inhibiting its growth. E. coli IAI1 is 
relatively sensitive to both kinds of drug interaction, especially in comparison to 
E. coli ED1a, which only depletes acetaminophen (Figure 11). 
 
  
 
Figure 11: Bacteria-drug interactions. 
Bacteria-drug interactions found in the screen. D
rug bioaccum
ulation: at least 30%
 depletion in both biological replicates. G
rowth effect: student’s t test, alpha<0.05, hit in both biological 
replicates. D
rug biotransform
ations found in depletion-m
ode assay indicated in black. Interactions from
 bacteria-drug interaction screen only and are not corrected for non-hits from
 
depletion-m
ode assay as not all hits were tested. G
rowth data analyzed by Sergej Andrejev. 
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An unexpectedly divergent response when comparing drugs is the bacterial 
response to simvastatin and rosuvastatin. Both drugs act similarly in humans, but 
rosuvastatin interacts with no bacterium in any tested way, whereas simvastatin is 
depleted by ten different bacteria and inhibits the growth of one. Contrasting this 
finding both duloxetine and aripiprazole, which are both antidepressant drugs, 
interact with a diverse set of bacteria having an impact both on depletion and 
growth (Figure 11). Bacteria not interacting with any drug besides controls are B. 
fragilis, B. longum subsp. longum and S. salivarius. The only drug not interacting 
with any bacterium is tenofovir. 
Besides single bacteria, I also tested two bacterial communities consisting of 
five members each in the bacteria-drug interaction screen. One community 
consisted of bacteria showing strong depletion of drugs in the first tested 
biological replicate of the bacteria-drug interaction screen (Mix Depletion in 
Figure 11), the other of bacteria showing little to no depletion (Mix NoDepletion 
in Figure 11). Strikingly, a mix of bacteria not depleting drugs on their own 
depletes ezetimibe in a community. Bacteria depleting duloxetine or ranitidine on 
their own loose this ability in community. However, as community composition 
cannot be interfered from growth alone this might also be caused by a loss of 
specific depleting bacteria from the community. 
2.3 Discussion and Outlook 
The aim of the bacteria-drug interaction screen was to test if gut bacteria 
deplete drugs in their growth medium and if this depletion is impacting the 
growth of respective bacteria. Additionally, assaying the mode of depletion found 
in the screen we wanted to address the question if the drug depletion is a 
metabolic degradation or modification as in the case of sulfasalazine or digoxin, or 
rather a sequestration or bioaccumulation of the drug from the medium without 
any structural modification by the bacteria. 
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In summary, the results from the bacteria-drug interaction screen and the 
depletion-mode assay show a broad potential of human gut bacteria to interact 
with human-targeted drugs in a specific manner. Bacterial growth is affected in a 
drug-species specific manner. Some drugs like loperamide and duloxetine affect a 
broader bacteria spectrum, and act both as inhibitor and promoter of bacterial 
growth depending on the bacterial species and strain. Bioaccumulation of drug 
compounds from the medium might be a common feature of many bacteria-drug 
interactions, and some drugs like duloxetine or montelukast show a strong 
tendency to interact with bacteria in this manner. Interestingly, bacteria, which 
deplete drug compounds from the medium, are usually not affected in their 
growth by those compounds. Thus, this bacteria-drug interaction screen shows a 
new dimension to microbiota interactions, which so far has often been 
overlooked.  
However, unfortunately the bacteria-drug interaction screen and also the 
depletion-mode assay suffered from methodological difficulties comprised of LC 
hypersensitivity and medium-batch dependent variation. To improve on this kind 
of screen a growth medium less sensitive to batch-to-batch variations is 
recommended as well as a LC detection method, which relies less on retention 
time but more on the inherent features of each compound, like mass 
spectrometry. Additionally, OD measurements should be performed at least every 
hour if possible to improve sensitivity in growth curves comparison for the 
already highly variably growth of natural isolates. This would also allow correcting 
the strength of drug depletion for the amount of biomass in the culture. I will now 
discuss specific interactions, which proved to be stable across most conditions, in 
more detail and then give an outlook for further experiments.  
For levamisole and ranitidine metabolic interactions with bacteria have been 
shown before albeit the specific bacterial players remained unclear (Shu et al. 
1991; Basit & Lacey 2001). Bacterial metabolism opens the thiazole-ring of 
levamisole, and cleaves the N-oxide bond of ranitidine. Shu et al. suggest that 
mainly Clostridiales and Bacteroides species are responsible for the levamisole 
ring opening. Besides those species, the bacteria-drug interaction screen suggests 
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also Bifidobacteria and other Firmicutes like C. comes and L. gasseri can modify 
levamisole. Basit and Lacey do not suggest specific bacteria for ranitidine 
metabolism, but my screen suggests a diverse set of bacteria interact with it except 
Bacteroides species. However, when replicated in the depletion-mode assay only 
F. nucleatum truly degraded ranitidine, whereas for all other interactions it could 
be recovered after extracting the whole culture. Thus, different to what the authors 
suggest in their study, ranitidine metabolism might not be widely common but 
relatively specific to some microbiota containing the low prevalent species F. 
nucleatum (Li et al. 2014). 
Montelukast is a leukotriene receptor antagonist used in the treatment of 
asthma, with common side effects like diarrhea and inflammation of the 
gastrointestinal tract. Glucuronidated metabolites of montelukast have been 
found and it gets mainly eliminated via bile and thereafter feces. However, in rats 
enterohepatic cycling has not been shown for montelukast (FDA 1997), although 
colonic metabolites of drug detoxification are expected (Balani et al. 1997). In the 
bacteria-drug interaction screen and following depletion-mode assay montelukast 
is sequestered by many bacteria, biotransformed by R. gnavus and B. longum 
subsp. infantis, and shows a weak growth promoting effect on B. uniformis 
HM715. In a different screen testing for growth effects only, similar species were 
affected (Lisa Maier (Typas group EMBL), personal communication). This 
suggests that montelukast is selectively interacting with bacteria. If montelukast is 
exposed to gut bacteria, its side effects might be caused by bacterial interactions. 
Bacterial metabolites of montelukast might be toxic to enterocytes causing an 
inflammation, or it has an effect on the bacterial community structure as a whole 
leading to diarrhea. The only reported interaction of montelukast with bacteria so 
far is an increase of bacterial growth in nasal cavity of mice treated with 
montelukast (Khoury et al. 2006). 
Three lipid-lowering agents were tested in the bacteria-drug interaction 
screen: simvastatin and ezetimibe are commonly given together as standard 
therapy against high cholesterol, rosuvastatin usually alone. As cardiovascular 
diseases are highly prevalent in westernized cultures, with almost every fourth 
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person over the age of 40 in the USA using a statin drug (Gu et al. 2014). All 
statins act as inhibitors of HMG-CoA reductase in the liver preventing production 
of cholesterol, whereas ezetimibe likely binds NPC1L1 in gut and liver preventing 
absorption of cholesterol into systemic cycling. Side effects of simvastatin and 
ezetimibe are diarrhea and gastritis, whereas the only gut related side effect of 
rosuvastatin is constipation. Interestingly, ezetimibe and simvastatin are strongly 
depleted by gut bacteria, whereas rosuvastatin shows no interaction with any. For 
simvastatin no information about drug modification was obtained. However, it is 
a prodrug and roughly 60% of its original dose is excreted in feces, making 
activation in the gut a likely explanation for its gastrointestinal side effects. 
Colonic metabolism of simvastatin has been shown already (Aura et al. 2011). 
Additionally, simvastatin and ezetimibe treatment does change relative abundance 
of Lactobacillus species in the gut microbiota of mice (Catry et al. 2015). Thus, 
especially simvastatin but also ezetimibe might have unfavorable impacts on the 
microbiota whereas the synthetic statin rosuvastatin might be free of these effects 
and thus a preferred treatment option for long-term treatment in cardiovascular 
diseases. 
Loperamide is a non-selective calcium blocker used as antidiarrheal 
treatment. It is not strongly absorbed from the gut, and is thus mainly excreted 
unmetabolized with the feces. A recent study showed that loperamide could 
weaken the membrane of gram-negative pathogenic bacteria, but is not as 
effective as an antibiotic adjuvant against gram-positive bacteria (Ejim et al. 2011). 
However, in my bacteria-drug interaction screen besides E. coli IAI1 it mainly 
affects the growth of gram-positive bacteria. Interestingly, duloxetine has a similar 
growth effect profile as loperamide but in contrast is depleted by many bacteria. It 
is classified as an inhibitor of sodium-dependent transporters. Thus, it is possible 
that duloxetine has a similar destabilizing effect on the bacterial cell membrane 
but caused by a different underlying mechanism than in loperamide. 
To be specific, duloxetine is an antidepressant of the class selective serotonin-
norepinephrine reuptake inhibitor (Lantz et al. 2003). Another antipsychotic drug 
in the screen is aripiprazole, a serotonin reuptake inhibitor with dopaminergic 
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effects acting on different enzymes than duloxetine (Burris et al. 2002). Both drugs 
have side effects like weight fluctuations, constipation and diarrhea. Duloxetine is 
heavily metabolized and mainly detoxified through the liver, but 20% of its 
metabolites are excreted in feces. Aripiprazole is also detoxified hepaticly, but 
around 18% of the original dose is excreted unchanged in feces. Both drugs show a 
range of interactions in the bacteria-drug interaction screen and depletion-mode 
assay, both affect bacterial growth, are depleted and possibly modified. Other 
researchers found that aripiprazole and fluoxetine, a drug structurally very similar 
to duloxetine, and also a number of other antidepressants could act as inhibitors 
of intracellular bacterial pathogens (Czyż et al. 2014). Additionally, many 
antidepressants have antimicrobial activity or enhance the action of antibiotics 
(Munoz-Bellido et al. 2000; Kalaycı et al. 2015). These findings together suggest 
that interactions between antidepressants and bacteria might be a robust 
phenomenon. Interestingly, recent metagenomic deep sequencing studies showed 
that use of antidepressants is associated with a change in microbiota composition 
(Zhernakova et al. 2016; Falcony et al. 2016). Thus, the observed gastrointestinal 
side effects of duloxetine and aripiprazole might be caused by bacterial 
interactions in the gut. Recently, more evidence is accumulating that gut 
microbiota and depression are linked with each other (Jiang et al. 2015; Foster & 
McVey Neufeld 2013; Heijtz et al. 2011). Antidepressive medication might play a 
role in this link, and so far few studies have investigated interactions between 
medication, disease and the gut microbiota as a whole. 
The findings from bacteria-drug interaction screen and depletion-mode assay 
suggest that sequestration of drug compounds from the medium might be a 
common feature of many bacteria-drug interactions, and for specific drugs this 
bioaccumulation might lead to gastrointestinal side effects potentially caused by a 
change in gut microbiota composition. Thus, further investigations into bacterial 
drug and native metabolism and drug effects on bacterial communities could help 
elucidate potential causes of drug side effects. In general, these findings show a 
new dimension to microbiota interactions, which so far has often been 
overlooked. 
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2.4 Clarification of contribution 
I designed the bacteria-drug interaction screen in collaboration with Manuel 
Banzhaf (Typas group, EMBL). Extractions of screening plates were conducted 
together with Manuel, otherwise I conducted all experiments from the screen and 
depletion-mode assay in this chapter. I setup the UPLC methods, and analyzed 
and interpreted the resulting depletion data. Sergej Andrejev (Patil group, EMBL) 
analyzed the growth curves. Melanie Tramontano (Patil group, EMB) and Lisa 
Maier (Typas group, EMBL) provided a lot of feedback and discussions for data 
interpretation and screen/assay optimization.  
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3 Duloxetine affects bacterial growth and 
induces changes in bacterial communities 
In this chapter I investigate the effects of one drug compound, the widely used 
antidepressant duloxetine, on a synthetic bacterial community. I first explain why 
I selected duloxetine and why I test in a synthetic community. After explaining the 
experimental set up, I describe the growth effects of duloxetine on bacteria grown 
in monoculture and then its effect on bacterial community composition. In the 
end, I discuss potential explanations derived from ecological principles for a 
change in bacterial community composition upon duloxetine exposure and 
suggest further possibilities for research. 
3.1 Introduction 
3.1.1 Why investigate bacterial interactions with duloxetine?  
Results from the bacteria-drug interaction screen and depletion-mode assay 
suggest that sequestration of drug compounds from the medium might be a 
common and specific feature of many bacteria-drug interactions. Additionally, the 
mixed bacteria communities tested in the screen suggest that bacteria might 
behave different in community than in monocultures. To gain insights into how 
drug bioaccumulation would impact at the level of a community, I decided to 
focus on the specific example of duloxetine. Findings from my bacteria-drug 
interaction screen and from literature suggest that interactions between 
antidepressants and bacteria might be a robust phenomenon (Zhernakova et al. 
2016; Czyż et al. 2014; Munoz-Bellido et al. 2000). Furthermore, the gut 
microbiota plays an important role in the development of depression and other 
mental diseases (Jiang et al. 2015; Foster & McVey Neufeld 2013). Antidepressive 
medication might play a role in this link. Side effects of antidepressive medication 
often include changes in the weight of patients (Dent et al. 2012), a morbidity 
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often associated with the microbiome as well (Musso et al. 2011). So far only few 
studies have investigated interactions between medication, disease and the gut 
microbiota as a whole for any disease, diabetes and metformin treatment being a 
well researched exception (Forslund et al. 2015).  
In the bacteria-drug interaction screen described in the previous chapter two 
antidepressants, duloxetine and aripiprazole, were investigated, both showing 
several interactions with gut bacteria. In the screen, the SSRI duloxetine is 
sequestered by nine different bacterial strains, one of them likely transforming it, 
and inhibits the growth of three strains, one of them also sequestering it (Figure 
11). The partial dopamine agonist aripiprazole is sequestered by three different 
strains, all of which also sequester duloxetine, and inhibits the growth of two other 
strains (Figure 11). Preliminary experiments showed that duloxetine is also 
sequestered when exposed to bacteria resting in PBS, but not by the spent medium 
of bacteria usually sequestering duloxetine. Preliminary experiments with 
aripiprazole showed that its interaction in many cases is sensitive to changing 
environmental conditions like differences in oxygen or medium composition, and 
additionally its LC method was instable. Thus, I decided to subsequently focus on 
gut bacterial interactions with duloxetine. A detailed introduction to duloxetine is 
given in the introduction chapter 1.6.1 on page 29. 
3.1.2 Why investigate interactions in a synthetic community? 
A natural bacterial community is usually complex and often not completely 
defined. In case of the human gut microbiota the community can consist of up to 
a thousand bacterial strains (Human Microbiome Project Consortium. 2012). This 
complexity is hard to disentangle as specific members are hard to manipulate and 
other community members can counterbalance specific bacterial interactions. In 
an experiment the final read-out from a community is thus an integral of all 
interactions taking place within the community. To address this challenge a 
simplified synthetic community can guide the discovery of underlying principles 
and inter-species dependencies. If communities are constructed with isolates from 
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a natural system, the evolved co-dependencies can often be preserved (Stadie et al. 
2013; Ponomarova & Patil 2015).  
One way to investigate bacterial community dynamics is in the context of 
adaptive laboratory evolution (ALE). ALE can be as easily implemented with 
communities as with single strains, and usually involves repeated transfers of 
inoculum from a growing culture into fresh medium with the same or sequentially 
stronger selective pressure. ALE is typically used to explore evolutionary dynamics 
of single strains towards a specific or unspecific selective pressure (Lenski et al. 
1991). It is a common tool especially in microbial synthetic bioengineering to 
adapt a genetically modified organism like yeast or E. coli to a production 
environment and to investigate the cause of those adaptions (Dragosits & 
Mattanovich 2013). However, it is also increasingly used in basic science to 
investigate co-dependencies in evolving communities. Especially structured 
environments like biofilms with distinct evolutionary pressures can be well 
investigated with this approach (Martin et al. 2016). A selective and distinct 
evolutionary pressure like drug exposure should allow a fast adaption of the 
community towards the pressure by selecting for less affected members or 
members beneficial for the whole community. In a long-term experiment genetic 
adaptions might additionally occur. 
3.1.3 Aims and Experimental outline 
To investigate whether duloxetine has an effect on bacterial communities, I 
decided to assemble a synthetic community consisting of bacteria sequestering 
duloxetine and bacteria being affected in their growth by duloxetine. These 
communities were exposed to duloxetine and as control to its solvent DMSO 
respectively (Figure 12). Every 48h, an inoculum of the evolved community was 
transferred into fresh medium containing either duloxetine or DMSO. The 
remaining bacterial community from each transfer was pelleted and subjected to 
16s barcode sequencing to estimate the relative abundance of community 
members. Additionally, the duloxetine concentration in the bacteria-free spent 
medium was determined. Thus, the experiment allowed following the 
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establishment of a potentially stable community. From similar experiments within 
our research group we expected a relatively stable community within five 
transfers, whereas stochastic population bottleneck and founder effects seem to 
dominate the first two transfers. 
 
Figure 12: Community assembly assay outline. 
Two different communities were tested in a community assembly assay: a five-member bacterial community 
without B. uniformis and a six-member community with B. uniformis. Communities were inoculated with a 
total OD578 of 0.01 in GMM with or without duloxetine but respective solvent. An inoculum from the evolved 
culture was transferred every 48h to fresh media conditions. Each culture was 16s barcode sequenced and the 
duloxetine remaining in the medium was assessed. 
 
I designed two different bacterial communities to not only assess the effect of 
duloxetine on a community, but also to investigate if duloxetine bioaccumulation 
can affect the community structure. Duloxetine bioaccumulation by community 
members could potentially aid in the survival of bacterial species, which are 
growth sensitive to duloxetine. One of the bacteria depleting duloxetine the 
strongest was B. uniformis. It is highly prevalent and abundant in the gut 
microbiome (Qin et al. 2010; Li et al. 2014) and has been associated with 
improved metabolic functions of the microbiome (Gauffin Cano et al. 2012). 
Thus, I designed a community with and without B. uniformis (Figure 12). Other 
community members sequesetering duloxetine consisted of S. salivarius and B. 
thetaiotaomicron, the latter is potentially additionally modifying duloxetine. As a 
species inhibited in growth by duloxetine E. rectale was included in the 
community. L. gasseri and R. torques, which so far had not shown any interactions 
with duloxetine, were added to increase the likelihood that a community 
consisting of more than one member species was formed. The species selection 
represents the main phyla in the gut, Bacteroidetes and Firmicutes, and are 
distinguishable by 16s barcode sequencing. 
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Duloxetine bioaccumulation and biotransformation by single species had 
been assessed with the bacteria-drug interaction screen and depletion-mode assay 
as described in the previous chapter. However, as techniques for growth readout 
had improved in the lab and in the screen only one concentration of duloxetine 
was assessed, I decided to also assess the growth sensitivity of synthetic 
community members to duloxetine. A better characterization of bacterial 
response to duloxetine can reveal more details about differences between bacterial 
species and might allow an easier interpretation of results from the community 
assembly assay. 
3.2 Results 
3.2.1 Growth effects of duloxetine 
The aim of the duloxetine dilution growth curves was to estimate the 
sensitivity of bacteria towards duloxetine, which were later used in the community 
assembly assay. Sensitivity is recorded as concentration inhibiting 50% of the 
effective growth (IC50). The strongest effect on growth by duloxetine was usually 
seen around the inflection point of the exponential growth phase. To approximate 
this point in each bacterial species, I first estimated the time point at which the 
bacteria not exposed to duloxetine reached half the maximum OD. For this time 
point I recorded the respective OD of all duloxetine exposed growth curves and 
fitted a local regression from which I estimated the IC50 (Figure 13). B. 
thetaiotaomicron, B. uniformis, L. gasseri and R. torques all have an IC50 around 
100 µM for duloxetine. S. salivarius is more sensitive with an IC50 of 40 µM, and 
E. rectale is the most duloxetine sensitive species with an IC50 around 30 µM.  
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Figure 13: IC50s for duloxetine. 
Dilution series of duloxetine in 1% DMSO. Underlying growth curves taken for 24h in GMM in triplicates. 
OD at half maximum OD time point of control used as effect response. Dashed line indicates 50% of half-
maximum OD, to estimate corresponding inhibitory concentration (IC50). Curves are fitted with R function 
“loess”, span parameter equals 0.5. 
 
Sensitivity to a drug is not always reflected only in a shift in exponential 
growth but also in a prolonged lag phase or a reduced maximum OD (Figure 14). 
The community assembly assay concentration is 50 µM duloxetine. At this 
concentration only B. uniformis is not affected in its growth, all other bacteria 
have growth deficiencies. As expected from the IC50, E. rectale is strongly delayed 
in growth. Interestingly, it recovers half of the growth when reducing the 
duloxetine concentration by just 20% to 40 µM. Even though B. thetaiotaomicron 
has a much higher IC50, its growth rate is affected already at the lower duloxetine 
concentration of 50 µM. Some bacteria besides being affected in lag or exponential 
phase have a noisier growth with duloxetine than without, e.g. L. gasseri or R. 
torques. This seemed to correspond to a stronger aggregation of bacteria in the 
culture as observed by eye. However, this effect could not be quantified so far. 
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Figure 14: Growth curves with duloxetine. 
24h growth curves in GMM with respective concentration of duloxetine with 1% DMSO as solvent. Curves 
fitted for triplicates with local regression using R’s loess function. 
 
3.2.2 Bacterial community shifts induced by duloxetine 
The aim of the community assembly assay was to investigate first whether 
duloxetine has an effect on bacterial community composition, and second 
whether bacteria sequestering duloxetine modify this effect. The presence of 
duloxetine in the medium increases the community diversity in both bacterial 
communities (Figure 15). Without duloxetine, two or three bacteria respectively 
dominate the community from the second transfer on, whereas with duloxetine 
four or five bacteria respectively coexist in the community. Interestingly, in both 
communities E. rectale, the bacterium most sensitive to duloxetine, is relatively 
abundant in the presence of duloxetine, whereas without duloxetine it is 
superseded in most transfers. Also L. gasseri profits from the presence of 
duloxetine, whereas R. torques is below detection limit in any bacterial 
community.  
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Figure 15: Community composition of duloxetine assembly assay. 
Species abundance after transfer and 48h growth in bacterial community with and without duloxetine. Mean 
of relative abundance from triplicates after 16s DNA sequencing. a) Community of five bacteria, without 
strongly sequestering species B. uniformis. b) Community of six bacteria, with strongly sequestering species B. 
uniformis. DNA extraction and 16s library preparation by Melanie Tramontano (Patil group, EMBL). 
Analysis and visualization by Yongkyu Kim (Patil group, EMBL). 
 
In general, the community without B. uniformis (Figure 15a) seems to be 
more stable over time than the one with B. uniformis (Figure 15b). In bacterial 
communities with B. uniformis, changes in relative composition can be observed 
during all transfers whereas without it a relatively stable state seems to be reached 
after the first transfer. Interestingly, in the community with B. uniformis not 
exposed to duloxetine, E. rectale seems to regain community membership after 
being depressed below detection limit in transfer 2 and 3 (Figure 15b). In the same 
community exposed to duloxetine E. rectale is slowly diminishing in relative 
abundance across all transfers. The opposite is true for B. uniformis. It slowly 
 67 
diminishes in relative abundance without duloxetine, while gaining in the 
community exposed to duloxetine. 
 
Duloxetine is depleted in all transfers except for the first transfer of the 
community without B. uniformis (Figure 16a). Duloxetine is always stronger 
depleted in the community with B. uniformis than without it. This corresponds to 
a higher fraction of duloxetine sequesetering bacteria (B. thetaiotaomicron, B. 
uniformis, S. salivarius) in the community with B. uniformis than in the one 
without it (Figure 16b).  
 
Figure 16: Duloxetine depletion in community assembly assay. 
a) Duloxetine depletion (indirect extraction) at the end of each transfer of bacterial community. Dashed line 
indicates mean of control. b) Percentage of bacteria sequestering duloxetine in each transfer, as assessed with 
16s DNA sequencing. All interactions tested in triplicates. 
 
3.3 Summary and Discussion  
The aim of these experiments was to investigate whether duloxetine and 
duloxetine sequestering bacteria have an effect on bacterial community 
composition and whether this effect could be explained by the effect duloxetine 
has on bacteria grown in monocultures. It was found that duloxetine induced a 
higher diversity within the tested bacterial synthetic communities. Unexpectedly, 
E. rectale, the community member most sensitive to duloxetine, showed a stronger 
survival in bacterial communities exposed to duloxetine. Additionally, 
communities with duloxetine-sequester B. uniformis seem to be less stable over 
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transfers, potentially caused by E. rectale and B. uniformis competing with each 
other.  
A shift induced by xenobiotics has been observed before in host-mediated 
communities (Cai et al. 2015; Catry et al. 2015; Davey et al. 2013) and as such a 
shift in community composition upon duloxetine exposure was to be expected. A 
change in bacterial community might be associated with side effects of duloxetine, 
such as weight fluctuations (Bahra et al. 2015). Changes in gut microbiome have 
also been implicated in development of depression and other mental diseases 
(Sharon et al. 2016). As literature regarding this has been reviewed in the chapter 
before and in the introduction to this chapter, I would like to focus in the 
following on the ecological interpretation of the conducted experiments. 
Ecological theory can give ideas as to the reason of the change in bacterial 
community composition (for an review on ecological theory in microbiology see 
Hibbing et al. 2010). The stress-gradient hypothesis suggests that competitive 
interactions between species dominate in resource-rich environments 
(competitive exclusion principle) whereas facilitative, complementary interactions 
are often seen in stressful environments. Here, they enhance the realized niches of 
species, which cannot persist in highly competitive environments, e.g. through 
cross-feeding or motility (Maestre et al. 2009; Malkinson & Tielbörger 2010) For 
bacteria this theory has been successfully tested in soil communities (Li et al. 
2013).  
All bacteria except possibly B. uniformis are stressed by duloxetine (Figure 
14). Additionally, subinhibitory concentrations of xenobiotics have been shown to 
change the metabolism or behavior of bacteria (de Freitas et al. 2016; Cecil et al. 
2011). Thus, some of the community members might secrete additional nutrients 
or change their metabolism or behavior otherwise, which reduces competition 
and hence induces a better survival of E. rectale and L. gasseri. Additionally, E. 
rectale recovers most from little changes in duloxetine concentration (Figure 14). 
In both duloxetine treated communities duloxetine sequestering species are the 
majority and twenty to thirty percent of duloxetine is sequestered from the 
medium. Thus, E. rectale might recover the most from a disturbance of their 
 69 
bacterial physiology by the presence of duloxetine-depleting bacteria and gain a 
competitive advantage, but only in presence of duloxetine. 
In structured environments like biofilms but also non-shaking lab cultures 
differences in competition can be observed in comparison to free-living or well 
mixed communities (Hibbing et al. 2010). Structured environments allow for 
different niches to be formed, as gradients of nutrient and other supplies like 
oxygen establish. Additionally, a common good trait like siderophore production 
for iron scavenging or other excreted enzymes like proteases mainly benefits 
closely related neighboring cells (Hibbing et al. 2010).  
The experiment was set up as a non-shaken culture, furthermore duloxetine 
potentially induces aggregation. A noisier growth with duloxetine than without 
was observed for L. gasseri or R. torques in monocultures, and corresponded to a 
stronger aggregation of bacteria in the culture as observed by eye. Thus, 
aggregation and consequently escape from competition by occupying a new niche 
might contribute to the survival of L. gasseri in the duloxetine treated samples. E. 
rectale could be similarly affected, although the effect in monocultures is not as 
pronounced as for L. gasseri. Bacteroides cultures in turn are well dispersed in 
monoculture and duloxetine seems not to induce aggregation in these species. 
Thus, they might not gain an advantage in niche specialization. 
It has also been shown that bacteria do act very differently in community than 
in monoculture (Chiu et al. 2014; Lawrence et al. 2012). Within a community a 
shift in metabolic state and hence a shift in the member species’ sensitivity 
towards duloxetine is conceivable. Therefore, a prediction of community 
composition from monoculture growth data is not always possible. 
To test some of the suggested hypothesis, new experiments should be 
designed. The community assembly assay showed to be a suitable and 
reproducibly robust tool to investigate bacterial communities. However, a five or 
six member community might still be too large to disentangle the underlying 
interactions. To test whether duloxetine and duloxetine sequestering bacteria have 
an effect, a three-member community could be designed. One duloxetine sensitive 
species, e.g. E. rectale, one sequestering species, e.g. B. uniformis, and one not 
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affected species e.g. B. vulgatus could be used to test duloxetine effects. Potentially, 
B. uniformis can be substituted in a community with its not-sequestering strain B. 
uniformis HM715. Besides using a smaller community, treatments in evolved 
communities could be reverted after five transfers. A duloxetine-exposed evolved 
community should revert to a state similar to non-exposed communities as soon 
as the stress is removed. Additionally, evolved communities as a whole could be 
tested for duloxetine sensitivity and thus show whether tolerance can evolve as a 
community trait. 
Another important aspect in the causes of a shift in community composition 
is the shift in metabolic state of the affected bacteria. If we can show how affected 
bacteria itself change and potentially how they change their respective 
environment, we could start to understand how they impact a community. For 
example, if duloxetine is blocking import of certain nutrients or induces excretion 
of nutrients, this might explain why E. rectale unexpectedly gains a growth 
advantage in community as to monoculture alone. Thus, another potential route 
to be explored experimentally is investigation of the metabolic response towards 
duloxetine exposure. 
In conclusion, duloxetine induces a consistent change in microbial 
communities. This change cannot be fully explained by the observed behavior of 
bacterial species in monoculture. Duloxetine-sequestering bacteria potentially 
additionally alter this change, as duloxetine bioaccumulation is stronger in 
communities consisting of more duloxetine sequestering bacteria. However, as all 
tested communities consist of duloxetine-sequestering bacteria before further 
conclusions are made additional experiments should be undertaken. 
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3.4 Clarification of contribution 
I planned and conducted the duloxetine dilution growth curves assay and the 
community assembly assay. For the dilution curves I also did the computational 
analysis and visualization. For the community assembly assay, I extracted DNA 
from the bacteria pellets together with Melanie Tramontano (Patil group, EMBL), 
subsequently Melanie prepared the 16S DNA library for sequencing in the EMBL 
GeneCore facility. Yongkyu Kim (Patil group, EMBL) analyzed and partially 
visualized the resulting data. I analyzed and visualized data from duloxetine 
depletion. 
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4 Human gut bacteria change their native 
metabolism upon duloxetine exposure 
In this chapter I investigate the change in the extracellular metabolome of two 
bacteria exposed to duloxetine. I explain why and how I use untargeted 
metabolomics approaches, before describing the experimental set up consisting of 
an NMR and a mass spectrometry approach. In the result section I first describe 
the NMR experiment, give a short summary and explanation as to why I moved to 
a more sensitive mass spectrometry approach, and then describe the results from 
this approach in detail. In the end, I discuss different explanations for the 
upregulation of metabolic features from the purine pathway before concluding a 
likely oxidative stress response. 
4.1 Introduction 
4.1.1 Why investigate bacterial duloxetine metabolism?  
Results from bacteria-drug interaction screen and depletion-mode assay 
(Chapter 2) suggest that bioaccumulation of drug compounds from the medium 
might be a common and specific feature of many bacteria-drug interactions. The 
community assembly assay (Chapter 3) indicates that duloxetine does affect 
bacteria in community and change their behavior resulting in differences in 
composition. Bioaccumulation of duloxetine affects the bacterial community 
additionally. Detailed reasons why I focused on the antidepressant duloxetine are 
outlined in the introduction to the previous chapter. In short, gut bacterial 
interactions with duloxetine, both for depletion and growth impairment, were 
plenty and reproducible. In general, antidepressants are of great interest as 
changes in gut microbiome composition have been associated with depression 
(Jiang et al., 2015) and a study found changes in gut microbiome composition 
associated with antidepressive treatment (Zhernakova et al., 2016). On top, 
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bioaccumulation can change the pharmacokinetics and efficacy of drugs (Niehues 
& Hensel 2009; Pierantozzi et al. 2006). To study the molecular basis of bacteria-
duloxetine interactions, I focused on two bacteria, B. uniformis and C. 
saccharolyticum. Because metabolites are the intermediates or end products of 
multiple enzymatic reactions and therefore are the most informative proxies of the 
biochemical activity of an organism, I focus first on the metabolic interaction 
between bacteria and duloxetine (Alonso et al. 2015; Reaves & Rabinowitz 2011). 
Investigating changes in the metabolic state of the bacteria upon drug exposure 
can aid in generating hypothesis about the way duloxetine and bacteria interact. 
4.1.2 How to investigate bacterial metabolism: Untargeted 
metabolomics 
Untargeted metabolomics can be a great approach to explore a potential 
uncharacterized interaction and generate hypotheses about its underlying 
mechanism. In contrast to targeted approaches untargeted metabolomics avoids 
the need for a prior specific hypothesis on a particular set of metabolites (Alonso 
et al. 2015). In particular, untargeted metabolomics is a useful approach to 
investigate microbial drug interactions and mammalian-bacterial co-metabolism 
(Nichols et al. 2016). Many potential features can be reviewed at once and then 
promising candidates can be characterized further by isolation and identification. 
Untargeted metabolomics studies are characterized by the simultaneous 
measurement of a large number of metabolites or potential metabolic features 
from each sample. Therefore, there is a need to use high performance 
bioinformatics tools (Booth et al. 2013). One of the most critical processes in 
untargeted metabolomics studies is the identification of metabolites, which is a 
prerequisite to relating the quantitative metabolomics data to its underlying 
biochemical role (Alonso et al. 2015). Identification of metabolites is regularly 
done by comparing the recorded spectra or masses to data found in public 
libraries like KEGG (Kanehisa et al. 2012) or ECMDB (Guo et al. 2013).  
Untargeted metabolomics is commonly implemented with NMR spectroscopy 
or mass spectrometry (Alonso et al. 2015). NMR allows direct structural 
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elucidation of potential metabolites and their relative concentration, but is limited 
in its sensitivity as well as by difficulties in working with complex 
multicomponent mixtures. Advantages of NMR spectroscopy are that it is not 
selective for any compound, all compounds are measured at once and amounts 
estimated are truly relative to each other, which means intensities of different 
peaks are comparable (Alonso et al. 2015). Mass spectrometry is a powerful 
method as it is very sensitive and allows quantification of many small compounds 
in the same run (Fuhrer & Zamboni 2015). However, identification of compounds 
is harder than in NMR spectroscopy as only masses and their elution time from 
LC can be measured and very little information about the chemical structure of 
the compound can be assessed (Alonso et al. 2015). Thus, true identification of 
compounds can only be achieved by comparison to standards. With an exact mass 
it is possible to narrow down potential compounds to a few sum formulas, which 
might correspond to only a handful of compounds. This is the reason mass 
accuracy is an important factor in mass spectrometry (Fuhrer & Zamboni 2015). 
Also exact relative quantification can be problematic, as different molecules have 
different ionization efficiencies, thus also true quantification can only be achieved 
in comparison to a standard (Alonso et al. 2015). 
4.1.3 Experimental Outline and Aims 
I first used an NMR spectroscopy approach to investigated potential drug 
metabolites, which I later complemented with a more sensitive mass spectrometry 
approach (Figure 17). The aims of all untargeted metabolomics approaches were 
first to confirm bacterial drug depletion and thus to confirm the interaction of the 
bacteria-drug pairs found in the interaction screen (see chapter 2), which had so 
far only been assessed by a UPLC-UV method. Secondly, untargeted 
metabolomics was used to aid in generating hypothesis about the way drug and 
bacteria interact, based on an observable shift in the bacterial metabolome or on 
the appearance of potential drug metabolites.  
Besides a mix of bacteria for an NMR study, two bacteria were selected for 
further in depth characterization of interaction with duloxetine. B. uniformis is 
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gram negative bacterium of the phylum Bacteroidetes with a high abundance and 
prevalence across healthy human microbiomes (Li et al. 2014). In the bacteria-
drug interaction screen, it showed a strong sequestration of duloxetine but was 
not affected in growth (Figure 11). C. saccharolyticum is a gram positive 
bacterium of the phylum Firmicutes, the other phylum prevalent in the gut. It is 
less abundant but as prevalent as B. uniformis in the microbiome of healthy 
human individuals (Li et al. 2014). In the screen, C. saccharolyticum also strongly 
depletes duloxetine from the medium, but different to B. uniformis it is affected in 
its growth (Figure 11). The duloxetine IC50 values are 100 µM and 40 µM for B. 
uniformis and C. saccharolyticum respectively (see Figure 13 for B. uniformis, 
appendix C for C. saccharolyticum).  
 
 
Figure 17: Outline of untargeted metabolomics experiments. 
Two methods for untargeted metabolomics are used to investigate bacterial interactions with duloxetine: 
NMR and mass spectrometry. The mix of depleting bacteria in the NMR experiment consisted of F. 
nucleatum, C. saccharolyticum, C. bolteae, C. ramosum, B. uniformis, B. longum subsp. longum. All incubation 
was anaerobic at 37°C. In all cases bacteria are removed by centrifugation from the sample and the remaining 
supernatant is extracted with a mixture of ACN:MethOH. Experiments for mass spectrometry were 
performed in triplicates. 
 
All experiments were conducted on resting bacterial cells or lysates, after 
washing the bacteria to remove extracellular metabolites and compounds from 
 77 
growth medium (Figure 17). A drug-free bacteria control and a control containing 
only the drug but no bacteria are essential for this type of experiment, to exclude 
any potential confounders changing bacterial metabolism independent of the drug 
response. All experiments also include an extraction step to remove proteins and 
other debris and to concentrate low abundant metabolites. For more details please 
refer to method sections 7.6 and 7.7 on page 143 and 144 respectively. 
4.2 Untargeted metabolomics of duloxetine 
interactions using 1H NMR spectroscopy 
4.2.1 Experimental setup 
For NMR spectroscopy I performed two different experiments: I tested the 
depletion of duloxetine in a mixture of 6 bacteria (B. longum longum, B. uniformis, 
C. bolteae, C. ramosum, C. saccharolyticum, F. nucleatum) potentially depleting it, 
and I tested one specific interaction of duloxetine with B. uniformis. All 
experiment were resting cell assays (see Methods 7.5.3), comparing bacteria 
treated with duloxetine to bacteria not treated with duloxetine and a bacteria-free 
control containing only duloxetine. The bacterial mix was tested with 1mM 
duloxetine, the B. uniformis only samples with 100µM duloxetine. To record a 
one-dimensional proton spectrum of the molecules of interest, all samples were 
reconstituted in a mixture of 80% D2O and 20% deuterated acetonitrile with half 
the original volume, thus doubling the concentration. 1D proton spectra for all 
samples were then recorded on a 500 MHz Bruker DRX NMR spectroscope. 
4.2.2 Results 
For exploration of the samples we first recorded few scans which resulted in 
less sensitive spectra. Comparing the duloxetine only spectra to spectra available 
in literature, we confirmed which peaks are derived from duloxetine and ensured 
the quality of the samples. In comparison to bacteria samples the duloxetine 
spectrum is less noisy, and peaks can be clearly identified. We found that peaks 
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belonging to duloxetine are less intense in bacteria treated samples (Table 3). A 
depletion of intensity of about 70% to 80% was observed on average in bacteria 
treated samples for both the mix of bacteria and for B. uniformis alone. The 
spectra were too noisy to look for newly appearing peaks, which might correspond 
to drug metabolites, in bacteria samples treated with duloxetine in comparison to 
non-treated bacteria. 
Table 3: Duloxetine depletion in NMR spectroscopy samples. Interference indicates duloxetine peaks, 
which partially interfered with peaks in bacteria only treated sample. 
Peak ppm Intensity Control Intensity Treated % Depletion Interference? 
B. uniformis     
8.3926 66618879 12473273 81.28  
7.9636 71192313 24288092 65.88 yes 
7.6373 214566844 48974963 77.17 yes 
7.4354 117082914 47424538 59.49 yes 
7.2739 66015450 13959370 78.85  
7.1646 81267273 33554120 58.71 yes 
7.0418 58789654 13145173 77.64  
6.1098 83133977 9079887 89.08  
Bacteria Mix     
8.6014 231244554 69008722 70.16  
8.1448 260833964 80145756 69.27  
7.845 546049193 139189689 74.51  
7.7796 325619482 173526042 46.71 yes 
7.6366 415219595 136583147 67.11 yes 
7.4859 242977509 84612077 65.18 yes 
7.3307 312083857 89942505 71.18  
7.2576 239460962 68593682 71.35  
6.273 376143332 92262036 75.47  
 
Thus, after quality control we recorded many scans of the resonance spectra 
to increase the signal-to-noise ratio and with this the sensitivity of the 
measurement. These spectra show that none of the peaks in the bacteria treated 
with duloxetine sample is new, as all peaks are already present either in the 
bacteria control or the duloxetine only control (shown for B. uniformis in Figure 
18). These hold true for the mix of bacteria as well as for the B. uniformis samples. 
In conclusion, no potential drug metabolites were found with NMR spectrometry. 
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Figure 18: NMR spectra comparing B. uniformis treated with duloxetine to controls. 
Spectra are recorded with a 500 MHz Bruker DRX NMR. Duloxetine only sample is scaled for better visibility. 
Concentration of duloxetine during experimental exposure for 4h was 100µM, but samples are reconstituted 
with a mixture of 80% D2O and 20% deuterated acetonitrile in half the original volume doubling the effective 
concentration of metabolites for NMR study. Shapes in duloxetine treated B. uniformis samples indicate peaks 
originating from duloxetine (green diamond) or B. uniformis (red dot) respectively. NMR spectra recorded by 
Leo Nesme (Carlomagno group, EMBL). 
 
4.2.3 Summary 
There are two likely reasons a potential metabolite was not detected: either 
NMR spectroscopy is not a suitable method in this case or there simply is no 
metabolite produced in the interaction of duloxetine with bacteria. One NMR 
specific reason why a potentially existing drug metabolite could not be detected is 
sensitivity. A main challenge in these experiments was the low concentration of 
drug and metabolites in the samples. For small molecule NMR spectrometry the 
typical concentration ranges for structural elucidation start from 1mM. In this 
experiment the concentration of duloxetine is around 2mM, and potential 
metabolites can range from 1.6mM (80% of duloxetine is depleted), if there is 
exactly one, to much lower concentrations. As we are operating on the lower end 
of NMR detection, potential metabolites could be below our detection limit. While 
it is possible to increase NMR sensitivity (signal-to-noise ratio) through recording 
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many scans of a spectrum, a limit is reached fast as signal-to-noise only doubles 
each time the number of scans is squared. The time needed for recording each 
spectra in figure was 16h, and since biological samples also degrade with time we 
did not use a higher number of spectral scans. Another factor is that new peaks 
from potential drug metabolites can be hidden behind peaks from other 
molecules. As seen in Figure 18 the spectra from bacteria treated samples are 
relatively noisy containing many different peaks, even though only the aromatic 
range of peaks is shown. In shift ranges below 5ppm corresponding to single 
molecular bonds, the spectra are often consisting of many overlapping double or 
triple peaks, suggesting many different underlying compounds. Hence, I decided 
to explore the metabolic space further using a more sensitive approach with 
higher resolution of compounds: mass spectrometry. 
4.3 Untargeted metabolomics of bacterial duloxetine 
depletion using LC-MS/MS 
4.3.1 Experimental setup 
For the mass spectrometry approach I tested the interaction of duloxetine 
with two bacteria, B. uniformis as before and C. saccharolyticum. Both interactions 
were strong, reproducible and robust in tests before and had also show depletion 
of duloxetine in lysate and resting cell assays (data not shown). I investigated the 
small molecule metabolome of a lysate and an extracellular fraction. A lysate 
exposes all bacterial enzymes at once to the drug and allows exploration of all 
possible enzymatic interactions. New features in the drug treated sample are more 
likely to be directly derived from duloxetine, and not to be a secondary effect of 
bacteria secreting metabolites in response. In contrast, the extracellular fraction of 
a resting cell assay explores the impact duloxetine can have on the whole bacterial 
metabolome. The experiment was conducted as described in short as follows, 
more details can be found in method section 7.7. 
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Bacteria were tested as lysate or resting cell assay in buffer and incubated for 
30min (lysate) or 2h (intact cells) espectively. Then, debris/cells were removed by 
centrifugation and metabolites were extracted in ice-cold 1:1 methanol:acetonitrile 
containing 10µM Amitriptyline as a internal standard. Samples were vacuum 
dried, and reconstituted in 20% acetonitrile containing 250µM caffeine. Lysates 
were reconstituted in the same volume as extracted, whereas the extracellular 
extractions were reconstituted in half the volume, effectively doubling the 
concentration of metabolites. Samples were measured on a Q Exactive Plus-
Orbitrap Mass Spectrometer (Thermo Fisher) in positive mode using a Kinetex 
C18 column for LC. Using the xcms R package from the Scripps Center for 
Metabolomics (Mahieu et al. 2016), I performed feature selection, peak alignment 
and retention time correction. Samples for lysate and extracellular fraction have 
been processed independently. A strict univariate analysis taking the uncertainty 
of the feature intensity into account followed. 
4.3.2 Duloxetine is depleted in all conditions 
As described before, untargeted metabolomics is sensitive to little variations 
in the method, because it only observes features without having a standard run 
side-by-side. Thus, internal standards from extraction and injection become more 
important to judge the quality of the mass spectrometry data. The overall variance 
of caffeine intensity, the internal standard for injection and run quality, is low 
across both fractions (extracellular: coefficient of variation (CV) = 0.054; lysate: 
CV=0.111) and variance was not biased to a treatment condition. The intensity of 
internal standard for extraction amitriptyline has also a low CV in extracellular 
fraction (CV=0.043) but in the lysate fraction it is slightly higher (CV=0.127). The 
higher variance in amitriptyline was caused by a bias in extraction towards 
samples containing lysed bacteria, hence I normalized the data set by the intensity 
of amitriptyline rather then caffeine. After normalization, the intensities of 
features from technical and biological replicates showed a high correlation with 
each other (Figure 19) in lysate and extracellular extraction respectively. 
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Figure 19: Technical and biological replicates of untargeted metabolomics. 
Shown are log10 values for LC peak intensity of detected features normalized by LC peak intensity of internal 
standard amitriptyline (m/z 278.18). Technical replicates represent two different mass spectrometry injections 
of the same biological sample, biological replicates are replicated samples of the same tested condition. Only 
two biological replicates are shown here for reasons of brevity, but each condition has been tested in three 
biological replicates. 
 
Duloxetine is depleted in all tested conditions, but strongest in the lysate of B. 
uniformis (Figure 20). However, depletion was only roughly 20-30%, by far not as 
strong as the depletion in the extracellular fraction in the NMR samples. This 
might be explained by the shorter incubation times (2h MS samples, 4h NMR 
samples). All treatment groups separate spatially into different cluster after 
principle component analysis (Figure 21). The first two principle components 
explain 38.8% and 45.8% of the observed variability for extracellular and lysate 
fractions respectively. In the lysate, PC1 seems to separate the different bacteria 
from each other whereas PC2 clearly separates the bacteria from the drug. In the 
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extracellular fraction, no clear dominating factor is obvious for separation along 
PC1 axis, whereas PC2 seems to drive the separation of technical replicates. In all 
cases, when looking at the weights of the components, not a few features drive 
separation but many different features contribute (data not shown). This can 
indicate a global difference in the small molecule metabolome, especially in the 
case of extracellular extraction, as separation here is clearer than in the lysates.  
 
Figure 20: Depletion of duloxetine in untargeted metabolomics. 
Lysates or whole cells were exposed to 1mM duloxetine, and after centrifugation to remove debris/cells 
soluble metabolites were extracted in MethOH/ACN. LC peak intensity of duloxetine (m/z 298.15) is 
normalized by LC peak intensity of internal standard amitriptyline (m/z 278.18) in respective duloxetine 
treated samples. Box plot represents mean and standard deviation of 3 biological replicates each injected 
twice.  
 
 
Figure 21: PCA of mass features from untargeted metabolomics. 
In lysate extraction 5995 features were detected, in extracellular extractions 6270 features were detected in 
total. All feature intensities are normalized by amitriptyline and scaled to unit variance before analysis. Each 
biological replicate is injected twice, except in the case of biological replicates 1 and 2 from C. saccharolyticum 
lysates. Principle components 1 and 2 are shown, explaining 45.8% and 38.2% of total variance for lysate and 
extracellular extractions respectively. 
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4.3.3 Systemic investigation of changes in mass features 
To explore this further, I compared the fold changes in the drug treated 
bacteria to its controls. Figure 22 shows mass features significantly changed in 
comparison to both controls (FDR: a<0.05; between treatment group CV>0.2; 
within treatment group CV<0.2) and their respective fold change. At first 
impression, as expected more changes occur in the extracellular fraction than in 
the lysate fraction. Only metabolites that are directly derived from interaction 
with duloxetine should significantly differ between drug-free and treated lysates. 
That is additionally pronounced as more features are found in extracellular 
samples (~6300) than in lysates (~6000), probably due to doubling of 
concentration in the extracellular samples when reconstituted. In general in all 
conditions, duloxetine has a high fold change in comparison to non-treated 
bacteria, and a negative fold change in comparison to the drug control as it is 
depleted. Other similarly behaving features might be related to the drug too, e.g. 
ions of adducts or fragments of duloxetine or impurities in the drug solution.  
A common aspect in both extracellular extractions is that many features have 
a high fold change in comparison to duloxetine alone: those are likely bacteria 
derived molecules as they tend to have a low fold change in comparison to the 
bacteria control. This does not necessarily mean a difference in metabolite 
secretion in response to duloxetine, as despite the normalization by an extraction 
standard a higher amount of bacteria extracted in the treated sample could also 
explain the fold change. In the case of B. uniformis this is a possible explanation 
for the differences found. However, not most but only 1273 features out of 6279 
total features showed a significant change in the duloxetine treated B. uniformis 
samples in comparison to the bacteria only control, which makes a 
methodological error unlikely (1218 out of 6279 for C. saccharolyticum). 
Additionally, in the case of C. saccharolyticum it is unlikely to be a methodological 
error, since many features are not only higher but also lower expressed than in the 
bacteria only control. This indicates a strong change in the metabolite profile of C. 
saccharolyticum and B. uniformis in response to duloxetine treatment.  
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Figure 22: Comparing fold changes of duloxetine treated bacteria to controls. 
Log 10 of significant (Student’s t-test, FDR < 0.05) fold changes between samples treated with duloxetine and 
the respective drug or bacteria control. Each dot represents a m/z feature, which is significantly differentially 
expressed in comparison to both controls. Features have been filtered for variation before testing: CV>0.2 
between conditions, CV<0.2 within one condition. Uniqueness of features has been checked for features with 
For mass features with a fold change above 10 in comparison to both controls and in extracellular and lysate 
extraction respectively, features representing the same mass in both conditions are indicated in blue. 
  
 
4.3.4 Feature annotation and pathway analysis 
A main aim of the metabolomics approaches was to look for potential 
duloxetine metabolites. Especially the experiments with lysates of bacteria were 
aimed to look into any enzymatic interaction with duloxetine resulting in a 
degradation product. Here, spectrometric features, which have the same fold 
change in comparison to both controls, are especially interesting as this could 
indicate that they are new features not observed in the controls. If the same 
features are also appearing in the extracellular fraction, it could be an indication 
for a potential duloxetine derived metabolite. 
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As shown in Figure 22 in B. uniformis lysates only one feature (674.461m/z; 
1497s) is significantly and strongly upregulated (FC>10) in the duloxetine treated 
lysates in comparison to untreated lysate or duloxetine alone. It can be found in 
the extracellular extraction as well and is on the diagonal axis showing an equal 
fold change to both controls. This mass features is annotated in METLIN (Smith 
et al. 2005) as annonisin with acetonitrile adduct. However, it is likely to be an 
artifact and not a duloxetine derived metabolite, as no adducts similarly 
upregulated are found. 
In C. saccharolyticum treated with duloxetine however, 26 features are 
strongly upregulated (FC>10) and found in lysate and extracellular extraction 
(Figure 22). In general, in C. saccharolyticum lysate many features are differently 
expressed in comparison to B. uniformis lysate, which can hint to improper lysis 
of bacteria resulting in an active metabolism with secondary effects of duloxetine 
treatment. The applied lysis protocol is comparatively mild (1min bead beating in 
PBS buffer), thus it is indeed possible that gram-positive C. saccharolyticum is not 
as effectively lysed as the gram-negative B. uniformis. This means that features 
found in C. saccharolyticum lysate are not directly derived from duloxetine, but 
could be of secondary effect. When the 26 interesting features are matched against 
METLIN database more than 18,000 potential metabolites are suggested, never 
more than two mass features having the same suggested metabolite. If compared 
to potential duloxetine metabolites of human detoxification metabolism described 
in (Lantz et al. 2003), no mass is overlapping. Thus, the search space is either too 
big or too small to result in a meaningful conclusion. Since an improper lysis 
could not be excluded as a confounding factor, no further analysis of the potential 
masses has been conducted. 
To investigate what kind of metabolic pathways could be affected in the 
bacteria by duloxetine treatment, I investigated the mass features significantly 
changed in the extracellular fraction. I used PATHOS (Leader et al. 2011) to 
annotate mass features, which are differentially expressed in comparison to both 
controls, with metabolites from KEGG metabolic pathways. I annotated the 
extracellular fraction, as those show the metabolic response and include secondary 
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effects of duloxetine on the whole metabolism. I allowed 12 different adducts to be 
formed, and considered metabolites within a mass range of 5ppm. Results shown 
here in Table 4 show mapping against E. coli pathways from the KEGG database. 
In both cases roughly 14% of differentially expressed peaks could be annotated 
with metabolite masses. Mass feature to metabolite is not a one-to-one 
annotation, as many metabolites have the same mass e.g. sugars, and different 
masses can match to one metabolite due to different adducts. Thus, disturbed 
pathways are not ordered by their significance but rather by the number of unique 
ions found for that pathway. Both bacteria share many of the affected pathways, 
which seem to relate to amino acid and nucleotide metabolism, specifically to 
purine nucleotide and cysteine/methionine metabolism. 
I further analyzed the data by annotating the mass features with species-
specific metabolites. Data to do so was kindly provided by Daniel Sevin 
(Cellzome). He generated lists of species-specific metabolites by building genome-
scale models for all organisms available in KEGG, and predicting their potential 
metabolome from the model. Unfortunately, B. uniformis is not available in 
KEGG, so instead I used the metabolome of its close relative B. thetaiotaomicron. 
For adduct-formation I used a stricter cutoff as with PATHOS, only allowing H+ 
and ACN+H+ adducts to be formed to annotate a mass with its potential 
metabolite. I used a mass accuracy of +/- 5ppm.  
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Table 4: KEGG Pathways enriched in significantly changed mass features.  
Ordered by unique ions found as part of the pathway. Purine metabolism pathway included for B. uniformis 
because of high number of unique masses found. 
KEGG Pathway Name 
Mtbls 
found in 
Pathway 
Total 
Mtbls in 
Pathway 
Unique 
Masses 
found 
Unique 
Ions 
found 
p-value 
hypergeo. 
test 
B. uniformis 123/900 masses annotated     
Purine metabolism 10 90 8 15 0.15 
Cysteine and methionine metabolism 12 54 12 14 6.3^10-4 
Methane metabolism 12 60 10 12 1.7^10-3 
Phenylalanine, tyrosine + tryptophan biosynt. 10 31 10 11 4.3^10-5 
Glycine, serine and threonine metabolism 10 45 9 11 1^10-3 
Arginine and proline metabolism 14 67 10 10 0.031 
Histidine metabolism 9 44 8 9 4^10-3 
Glyoxylate and dicarboxylate metabolism 9 55 8 9 0.02 
Aminoacyl-tRNA biosynthesis 8 24 7 9 1.4^10-4 
Ascorbate and aldarate metabolism 13 45 7 7 1.8^10-5 
Tyrosine metabolism 10 75 7 7 0.06 
Phenylalanine metabolism 13 64 6 6 1^10-3 
Pentose and glucuronate interconversions 12 50 6 6 2.8^10-4 
C5-Branched dibasic acid metabolism 13 32 5 5 1.6^10-7 
      
C. saccharolyticum 116/804 masses annotated     
Methane metabolism 15 60 13 16 1.6^10-5 
Purine metabolism 13 90 12 14 0.013 
Ascorbate and aldarate metabolism 17 45 10 13 4.2^10-9 
Cysteine and methionine metabolism 11 54 11 12 1.3^10-3 
Pentose and glucuronate interconversions 15 50 9 12 1.2^10-6 
Arginine and proline metabolism 14 67 10 10 2.5^10-4 
Amino- and nucleotide sugar metabolism 18 77 7 10 6.8^10-6 
Tyrosine metabolism 13 75 9 9 2.6^10-3 
Glyoxylate and dicarboxylate metabolism 11 55 9 9 1.5^10-3 
Galactose metabolism 13 41 7 9 2.7^10-6 
Pentose phosphate pathway 13 34 6 9 1.9^10-7 
Porphyrin and chlorophyll metabolism  9 93 8 8 0.23 
C5-Branched dibasic acid metabolism 15 32 7 7 6.7^10-10 
Naphthalene and anthracene degradation  9 60 7 7 0.025 
Alanine, aspartate and glutamate metabolism 8 25 7 7 1.3^10-3 
1,4-Dichlorobenzene degradation 9 74 5 5 0.08 
Italic letters indicate pathways not shared between B. uniformis and C. saccharolyticum 
 
For B. uniformis 38 out of 900 unique mass features were annotated with 75 
potential metabolites out of 686 possible metabolites. For C. saccharolyticum 42 
out of 804 unique mass features were annotated with 93 potential metabolites out 
of 775 possible metabolites. A pathway enrichment analysis was not performed as 
many pathways were insufficiently covered by the species-specific dataset already. 
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The top ten significantly changed mass features with their respective potential 
metabolites can be found in Table 5. Sugars with the same sum formula have been 
summarized within one descriptive term.  
 
Table 5: Species-specific annotations of top 10 changed mass features. 
Mass feature Name Sum formula 
FC bacteria 
(log10) 
B. uniformis   
252.1090 Deoxyadenosine C10H13N5O3 3.018 
268.1035 Adenosine C10H13N5O4 2.973 
268.1035 Deoxyguanosine C10H13N5O4 2.973 
284.0989 Guanosine C10H13N5O5 2.515 
230.1858 7,8-Diaminononanoate C9H20N2O2 2.348 
182.0808 L-Tyrosine C9H11NO3 2.327 
298.0969 5'-Methylthioadenosine C11H15N5O3S 2.204 
270.1088 Deoxyuridine C9H12N2O5 1.630 
134.0446 L-Aspartate C4H7NO4 1.627 
244.0928 Cytidine C9H13N3O5 1.620 
384.1492 Disaccharides C12H22O11 1.445 
384.1492 b-D-Mannosyl-1,4-N-acetyl-D-glucosamine C14H25NO11 1.445 
C. saccharolyticum   
269.0881 Inosine C10H12N4O5 3.099 
284.0989 Guanosine C10H13N5O5 2.884 
261.0366 Hexose monosaccharide phosphates C6H13O9P 2.750 
244.0928 Cytidine C9H13N3O5 2.576 
112.0507 Cytosine C4H5N3O 2.251 
231.0259 Pentose monosaccharide phosphates C5H11O8P 2.198 
296.0646 Aminoimidazole ribotide C8H14N3O7P 1.984 
74.06074 Aminoacetone C3H7NO 1.851 
291.0470 Glycero-manno-Heptose 7-phosphates C7H15O10P 1.786 
291.0470 Sedoheptulose 7-phosphate C7H15O10P 1.786 
220.0811 O-Succinyl-L-homoserine C8H13NO6 1.531 
220.0811 2,4,6/3,5-Pentahydroxycyclohexanone C6H10O6 1.531 
220.0811 2-Deoxy-5-keto-D-gluconic acid C6H10O6 1.531 
220.0811 1-Keto-D-chiro-inositol C6H10O6 1.531 
220.0811 5-Deoxy-D-glucuronate C6H10O6 1.531 
220.0811 2-Dehydro-3-deoxy-D-gluconate C6H10O6 1.531 
220.0813 3-Keto-beta-D-galactose C6H10O6 1.531 
 
In congruency with the pathway analysis in both bacteria the purine 
(deoxy)ribonucleosides are strongly upregulated upon duloxetine treatment, but 
also the pyrimidine nucleoside cytidine is upregulated in both cases. Other 
nucleosides like deoxyuridine or inosine are also upregulated in one of the 
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bacteria respectively. While in B. unifomis unphosphorylated disaccharides are 
strongly upregulated, the sugars upreglated in C. saccharolyticum are 
phosphorylated pentose and hexose monosaccharides. B. uniformis has indeed a 
strong expression of amino acids tyrosine and aspartate upon duloxetine 
treatment, in C. saccharolyticum however no amino acid is within the top ten most 
changed metabolites. Amino acids and sugars are main members of the KEGG 
pathway “Methane metabolism” which are found enriched. It is noteworthy that 
in the complete list of significantly changed, annotated metabolites of B. uniformis 
and C. saccharolyticum a part of the Metacyc polyamine biosynthesis 1 pathway is 
found: agmatine ! putrescine ! spermidine/5’-methyl-thioadenosine (Caspi et 
al. 2016). In C. saccharolyticum aminoimidazole ribotide, a metabolite upstream 
of purine synthesis and unique to this pathway is also upregulated. 
4.4 Summary and Discussion 
One aim of the presented experiments was to confirm bacterial duloxetine 
depletion and thus to confirm the interaction of the bacteria-duloxetine pairs 
found in the interaction screen with a method complementary to UPLC-UV 
detection. All tested interactions showed depletion of duloxetine, both in NMR 
spectroscopy and mass spectrometry. However, depletion was not consistent 
across different samples. A strong depletion of 80% was observed in B. uniformis 
resting cell samples for NMR, and less strong in samples for mass spectrometry. 
As mentioned before this might be due to different incubation periods (NMR: 4h, 
MS: 2h) or simply due to differences in the amount of bacteria as samples were 
not normalized before duloxetine treatment. B. uniformis seems to be slightly 
more effective in duloxetine depletion, both in resting cell and lysate assay, but B. 
uniformis cultures often grow more dense than C. saccharolyticum cultures. As 
results from the depletion-mode assay (Figure 10) suggest that duloxetine 
depletion is likely not metabolic biotransformation, a difference in number of 
bacteria can account for a difference in depletion if a similar strength of 
duloxetine accumulation is assumed for both species. 
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Another aim of untargeted metabolomics was to aid in finding hypothesis 
about the way drug and bacteria interact, based on the appearance of potential 
drug metabolites or on an observable shift in the bacterial metabolome. In NMR 
spectroscopy, no new spectral peaks could be observed in B. uniformis samples, 
thus suggesting not one or two duloxetine metabolites but either no direct 
duloxetine metabolite or many with a concentration below the detection limit of 
NMR spectroscopy. In the mass spectrometry approach only one mass feature was 
differentially changed in B. uniformis lysates. In C. saccharolyticum samples 28 
mass features are changed but are likely not directly derived from duloxetine, but 
of secondary effect, as improper lysis could not be excluded as confounding factor. 
Taking into account that also the depletion-mode assay (Figure 10) does suggest a 
binding without modification of duloxetine rather than a metabolic 
biotransformation, it is very unlikely that duloxetine is metabolically modified by 
B. uniformis or C. saccharolyticum.  
Instead the data from mass spectrometry suggests a global difference in the 
extracellular small molecule metabolome of bacteria treated with duloxetine. The 
first two principle components separate treated bacteria well from their controls 
despite capturing less than 40% of the variability. Extracellular fold changes show 
strong differences in many features indicating a strong change in the metabolite 
profile of C. saccharolyticum and B. uniformis in response to duloxetine treatment. 
Mass feature annotation and pathway enrichment show that both bacteria share 
many of the affected pathways. Metabolic pathways seem to relate to amino acid 
and nucleotide metabolism, specifically to purine nucleotide and 
cysteine/methionine metabolism. A look on the species-specific annotated 
metabolites confirms nucleosides and sugars are strongly upregulated in both 
bacteria (Table 5). While in B. uniformis maybe part of polyamine biosynthesis is 
stronger affected, C. saccharolyticum seems to be clearly affected in its purine 
metabolism or synthesis. 
One question, which directly arises when doing this kind of untargeted 
metabolomics studies, is if we just capture the most abundant metabolites in the 
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cell. Recently a study by Bennett et al. (2009) measured the absolute 
concentrations of around 100 common metabolites in whole-cell extracts of 
glucose-fed E. coli. The most abundant metabolites with a concentration of above 
15mM are glutamate, glutathione and fructose-1,6-bisphosphate, followed by 
ATP, UDP-N-acetyl-glucosamine and hexose phosphates (Bennett et al. 2009). 
The latter two can be found upregulated in C. saccharolyticum. However, in 
extracellular extractions of E. coli hexose and pentose phosphates range around 
200nM (Moses & Sharp 1972). The least abundant metabolites with a 
concentration below 200nM were adenosine, deoxyguanosine, adenine, guanosine 
and NADP+ (Bennett et al. 2009). All of these nucleosides except NADP+ are 
strongly upregulated in both bacteria in my experiment. Thus, I do not observe an 
experimental artifact but more likely a real impact of duloxetine on the purine 
metabolism of the two bacteria. 
Duloxetine might act similar to an antibiotic as other antidepressant show 
antimicrobial effects, stressing or weakening the bacterial cell wall, hence the 
strong upregulation of extracellular compounds (Munoz-Bellido et al. 2000; 
Kalaycı et al. 2015). In the bacteria-drug interaction screen a slight growth defect 
is observed in C. saccharolyticum, but not B. uniformis. However, other bacteria 
like E. rectale are strongly affected in their growth (Figure 13, page 64). Upon 
administration of cell wall targeting antibiotics like ampicillin E. coli 
downregulates intracellular nucleotide levels (Belenky et al. 2015). Other 
antibiotics which interact with DNA or bacterial ribosome have the same effect 
(Belenky et al. 2015). Hoerr et al. (2016) looked into the extracellular stress 
response of E. coli respectively, and found an upregulation of thymine and alanine 
in response to cephalexin, and putrescine, 2-oxogluterate, 2-phenylproprionate 
and 3-hydroxyisovalerate in response to ampicillin. Of those metabolites, I only 
found putrescine to be upregulated in my study. Duloxetine is likely not inducing 
a bacterial cell wall stress response and an increase in extracellular metabolite 
levels is not due to a leaky cell wall. 
A different stress the bacteria could experience is oxidative stress upon 
addition of duloxetine. A study recently characterized the H2O2 stress response in 
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anaerobically grown E. coli using transcriptomics and found similar pathways 
affected, e.g. KEGG purine metabolism, alanine, aspartate and glutamate 
metabolism, amino sugar and nucleotide sugar metabolism pathways (Kang et al. 
2013). In particular, putrescine metabolism seems to be transcriptionally 
upregulated and purine metabolism transcriptionally downregulated upon 
oxidative stress. If mainly the catabolism is affected, an accumulation and 
consequently secretion of purines could be the consequence. Those pathways and 
pattern fit best to C. saccharolyticum, as only one of the mentioned pathways is 
affected in B. uniformis. Interestingly, pentose phosphate pathway, which is also 
affected in C. sacchaolyticum, feeds metabolites directly into purine pathway. 
Disruption of the pentose phosphate pathway has been shown to increase 
oxidative stress as it provides NADPH for ROS decomposition (Wang et al. 2014). 
B. uniformis might be less affected by duloxetine because it is a gram-negative 
bacterium and its additional cell membrane prevents duloxetine from entering the 
cell. However, its oxidative stress response consisting of upregulation of 
putrescine and spermidine seems to be active as well (Tkachenko et al. 2012). 
However, it should also be noted that oxidative stress response is linked to 
starvation in bacteria and bacterial cells in this assay have been kept in nutrient-
less buffer for 2h (Nguyen et al. 2011). 
On an interesting side note, it can be speculated that many of the drug related 
mass features changed in the lysates are due to autodegradation of duloxetine. 
Pure duloxetine is known to have a strong autodegradation in aqueous solutions 
(Sinha et al. 2009). Thus, some of the effects of duloxetine on bacteria might not 
be direct effects of duloxetine but of its auto-metabolites as well. 
In conclusion, these untargeted metabolomics data from NMR spectroscopy 
and mass spectrometry suggest a global change in the metabolome of the tested 
bacteria rather than a specific metabolic degradation of duloxetine. Duloxetine 
might act as an inhibitor of a protein involved in purine nucleoside synthesis or 
metabolism or induce a regulation of this pathway in another way. A changed 
metabolic state of key bacteria in the microbiome might lead to a distinct change 
of the microbiota composition. A change in microbiota composition is associated 
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with disease development: e.g. weight gain and metabolic syndrome but also 
psychiatric diseases like depression or autism (Heijtz et al. 2011; Foster & McVey 
Neufeld 2013; Jiang et al. 2015; Davey et al. 2013). The microbiome might thus 
contribute to some of the side effects of duloxetine treatment because it is 
influencing the gut-brain axis in an unfavorable way. 
4.5 Clarification of contribution 
I designed and conducted all experiments in this chapter. Samples for NMR 
were measured, analyzed and interpreted in collaboration with Leo Nesme 
(Carlomagno group, EMBL) and Bernd Simon (NMR core facility, EMBL). 
Samples for mass spectrometry were measured in the metabolomics core facility at 
EMBL, the MS method was setup in collaboration with Prasad Phapale (MCF, 
EMBL). I analyzed and interpreted the mass spectrometry data alone. Daniel Sevin 
(Cellzome) kindly shared data for additional feature annotation and KEGG 
pathway analysis. 
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5 Duloxetine binds to a NADH:quinone 
dehydrogenase and purine pathway members 
In this chapter I investigate the bacterial protein targets of duloxetine in 
C. saccharolyticum using click-chemistry based methods and proteomics. I will 
first explain why I want to investigate the underlying mechanism of bacterial 
duloxetine interaction and then present the experimental outline consisting of an 
exploratory proteomics approach, and subsequently overexpression of candidate 
proteins. After presenting results from the proteomics experiments and 
exploratory statistical analysis, I will present duloxetine-depletion results from 
homo- and heterologous overexpression of duloxetine-binding protein 
candidates. In the end I will discuss limitations of the selected approach and 
suggest two molecular mechanisms for duloxetine’s impact on bacterial 
metabolism. 
5.1 Introduction 
5.1.1 Why investigate protein interactions of duloxetine? 
Results from the bacteria-drug interaction screen and the depletion-mode 
assay (Chapter 2) suggest that bioaccumulation of drug compounds from the 
medium might be a common and specific feature of many bacteria-drug 
interactions. Detailed reasons why I focused on the antidepressant duloxetine are 
outlined in the introduction to the previous chapters (section 3.1.1 and 4.1.1). In 
short, gut bacterial interactions with duloxetine, both for bioaccumulation and 
growth impairment, were plenty and reproducible. In general, antidepressants are 
of great interest as changes in gut microbiome composition have been associated 
with depression (Jiang et al. 2015) and a study found changes in gut microbiome 
composition associated with antidepressive treatment (Zhernakova et al. 2016). 
On top, bioaccumulation can change the pharmacokinetics and efficacy of drugs 
(Niehues & Hensel 2009). The metabolomics study described in the preceding 
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chapter suggests that duloxetine is not biotransformed by B. uniformis or C. 
saccharolyticum, but instead changes their native metabolism, likely affecting 
purine metabolism.  
Untargeted metabolomics as applied in the previous chapter can only be one 
pillar where upon we should base a hypothesis about bacteria-duloxetine 
interaction. Metabolomics can give clues about the consequences of a disturbance 
on the whole metabolism of an organism, and potentially pinpoint the most 
affected metabolic pathway. However, it cannot directly point at the underlying 
molecular mechanism as extensive regulation and redundancies in the metabolic 
network often obscure the primary cause of the disturbance (Reaves & Rabinowitz 
2011). Instead, the proteome is the layer of functionality a small molecule 
compound is usually acting on and how it is able to perturb the underlying system 
of regulations and functions (Szklarczyk et al. 2016). Thus, we searched for direct 
targets of duloxetine using a click chemistry-enabled protein pull-down and 
proteomics. I focused on C. saccharolyticum as it, in addition to sequestering 
duloxetine, is negatively affected in its growth upon duloxetine exposure (Figure 
11 on page 52). Additionally, it is better described in KEGG and other databases, 
which allows for better validation of findings, and proteomics results can be 
complemented by the previous investigation on how duloxetine affects its 
metabolome. 
5.1.2 Aims and Experimental Outline 
The first step of exploring duloxetine interactions mechanistically on a 
protein level was to enrich for proteins that bind to it. This was implemented by 
employing click chemistry-based reactions to bind duloxetine to immobile beads 
and then pulling down binding proteins from a C. saccharolyticum lysate. The 
proteins were identified using mass spectrometry. After exploratory statistical 
analysis of the enriched proteins, I selected candidate proteins, which were 
overexpressed in E. coli and subsequently their ability to sequester duloxetine 
from the growth medium was assessed. I overexpressed 31 E. coli homologues and 
heterologously four C. saccharolyticum proteins. Homologous overexpression 
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mutants were readily available from a mutant library, whereas heterologous 
overexpression plasmids had to be newly designed. The aims of these experiments 
were to find potential duloxetine interacting proteins, reinforce the evidence for 
interaction by overexpression and accompanying functional assessment of 
duloxetine sequestration to consequently suggest a potential mechanism for how 
duloxetine interacts with C. saccharolyticum and potentially other gut bacteria.  
5.1.3 Pull-down and proteomics of duloxetine binding proteins 
Investigating protein-drug interactions is highly facilitated if one of the 
interaction partners can be bound to a surface and thus the other one can be 
locally enriched. This enables pull-down assays, metabolite enrichment and many 
other forms of protein-ligand elucidation techniques. Click chemistry is an easy 
way for combining two compounds of interest if they contain an alkyne or an 
azide group. In collaboration with Schultz group (EMBL), we decided to introduce 
an alkyne group at the methyl group of duloxetine (Figure 23). After synthesis and 
clean up, the functionalized duloxetine allowed us to implement a pull down of 
duloxetine interacting proteins from a C. saccharolyticum lysate.  
 
 
Figure 23: Alkynated duloxetine. 
Duloxetine tagged with an alkyne containing group (highlighted in yellow) to enable click reactions. Synthesis 
by Felix Hövelmann (Schultz group, EMBL). 
 
Felix Hövelmann (Schultz group, EMBL) synthesized the functionalized 
duloxetine and linked it to desthiobiotin. The molecule was consequently 
captured on a streptavidin beads to enable a pull down of binding proteins. 
Bacterial lysates of C. saccharolyticum were prepared by bead beating and 
additional ultrasound treatment. After spinning down debris from lysis, the lysate 
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was incubated anaerobically under agitation on streptavidin beads overnight at 
4°C. As control, lysates with 50µM free duloxetine were also incubated on 
streptavidin bound duloxetine beads. After washing the beads with PBS, to release 
the captured proteins desthiobiotin could be substituted through biotin and the 
whole protein-duloxetine-desthiobiotin complex was eluted. The pull down was 
carried out in quadruplicates. Subsequently, Marie-Therese Mackmull (Beck 
group, EMBL) measured the proteins from the eluents using mass spectrometry, 
and analyzed the resulting data matching the measured peptides back to C. 
saccharolyticum’s in silico proteome. She also performed a data imputation step to 
increase the statistical power for proteins that were missing from the controls, and 
as such particular interesting. I executed the following statistical and 
bioinformatical analysis as described in the result section. More details of the 
methods can be found in section 7.8 of the method chapter. 
5.1.4 Overexpression of candidate proteins 
Protein enrichment from a pull down is not sufficient to demonstrate a 
potential mechanism for bacterial duloxetine interaction. Thus, we decided to 
overexpress homologues of the protein candidates in E. coli BW25113 ΔtolC and 
measure if duloxetine is sequestered from the medium in anaerobic conditions. 
Sequestration would indicate a potential binding of duloxetine to the respective 
overexpressed protein. To ensure that duloxetine molecules that enter the bacteria 
cell is not directly exported again, I chose the tolC deletion mutant as a genetic 
background for overexpression in E. coli. TolC is one of the major efflux pumps in 
E. coli (Zgurskaya et al. 2011). Additionally, for a few candidates we decided to 
overexpress C. saccharolyticum proteins heterologously to test if binding is 
improved with the original protein structure. Homologous overexpression 
mutants were readily available from a mutant library, whereas heterologous 
overexpression plasmids had to be newly designed. 
Not all candidates could be overexpressed, as some gene overexpressions are 
not viable. For other candidates no potential homologue could be found in E. coli 
BW25113. In some cases, all members of a complex have been overexpressed, even 
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though the third member was not enriched in the pull down, e.g. since proteins 
homologous to XdhB and XdhC were enriched, XdhA was also overexpressed. 
Additionally, selection for overexpression was based on an older analysis of 
protein enrichment based on one unique peptide for protein identification instead 
of two. Thus not all potential candidates from the pull down were considered. 
For heterologous overexpression I selected four proteins: HisF/HisH form a 
complex in E. coli. They are part of the histidine pathway and catalyze the last step 
before their product 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR) 
is entering the purine pathway. The other two proteins PyrD and PyrF are part of 
the pyrimidine pathway but do not form a complex. In silico predictions using the 
BNICE framework from a collaborator (Finley et al. 2009) suggested interaction of 
duloxetine with the same enzyme class as PyrF. They are one catalytic step up- 
and down stream respectively after Phosphoribosyl pyrophosphate (PRPP) is 
entering the pyrimidine pathway. PRPP is a product of the pentose phosphate 
pathway. 
5.2 Results 
5.2.1 Duloxetine binding protein enrichment 
The aim of the pull-down assay was to enrich for C. saccharolyticum proteins, 
which can bind to and thus interact with duloxetine. With a threshold of at least 2 
unique peptides per protein and detection in at least three out of four replicates in 
either control or treatment samples we detected a total of 591 proteins in the 
samples using mass spectrometry based proteomics. Still, many proteins were only 
detected in treatment samples but not controls. Thus, after log2 transformation 
we performed a data imputation step to estimate missing intensities from the 
average intensities in samples with protein detection. Then, data was quantile 
normalized before calculating significant differential expression using Student’s t-
test controlling the false discovery rate at an alpha level below 0.1 (Figure 24).  
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With a threshold in log2 fold change between control and pulled down 
proteins of at least 2, 55 proteins were significantly enriched in the pull down. Of 
those 55 hits six proteins are so far uncharacterized. Of the five strongest hits (log2 
fold change > 6) three proteins are uncharacterized and have homologues only to 
other uncharacterized proteins. The remaining two strong hits (Uniprot ID: 
D9R9H8, D9R9G9) contain both an iron-sulfur cluster and are part of a 
NADH:ubiquinone dehydrogenase complex.  
 
 
Figure 24: Volcano plot of proteins detected in pull down. 
Fold change of proteins detected in duloxetine pull down of C. saccharolyticum lysate. Presented values are 
reached after imputing for not-missing-at-random from controls and correcting for an overall higher 
intensity in test samples in comparison to control samples. Four replicates each were tested. Color refers to: 
not significantly enriched proteins (grey); significantly (FDR, alpha<0.1, log2(Fc)>2) enriched proteins 
(black); heterologous proteins overexpressed in E. Coli BW25113 (blue), and a respectively significant 
depletion (>20%) of duloxetine (red). Mass spectrometry and data imputation by Marie-Therese Mackmull 
(Beck group, EMBL). 
 
To further link the enriched proteins from C. saccharolyticum to their 
“duloxetine bioaccumulation” function, I compared their amino acid sequence 
similarity (Figure 25) to other species from the bacteria-drug interaction screen 
described in chapter 2 (Figure 11 on page 52). In there, the two E. coli strains IAI1 
and ED1a behaved differently, with E. coli IAI1 sequestering duloxetine and being 
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slightly affected in its growth on the one hand, and E. coli ED1a not sequestering 
duloxetine nor being affected in its growth on the other hand. I included the lab E. 
coli strain BW25113 as further experiments had shown that duloxetine also affects 
its growth. 
 
 
Figure 25: Heatmap of protein blast alignment. 
Amino acid sequences from enriched proteins align with NCBI pblast tool to most similar sequences in target 
bacteria. pBlast bitscore used as distance measure, scores scaled by row. Clustering by average linking, 
annotation from Blast2GO analysis. Identifier is Uniprot ID. Highlighted names show divergent proteins in 
closely related E. coli strains, correlating with their diverging duloxetine response. 
 
All E. coli strains have a similar phylogenetic distance to C. saccharolytium, 
thus their protein alignments show high similarity within E. coli strains and very 
little similarity towards C. saccharolyticum (Figure 25). However, for four proteins 
the little similarity they do have is correlated with their divergent response to 
duloxetine (highlighted in Figure 25). This subunit of xanthine dehydrogenase 
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(XdhB) is strongly enriched in the pull down with a log2 fold change over 5. This 
enzyme is part of the purine metabolism pathway as annotated by KEGG. Albeit 
peptidase C26 has the strongest divergence in its alignment similarity, and its 
matching gene sequence is annotated as puuD in E. coli BW25113. The respective 
protein is a gamma-glutamyl-gamma-aminobutyrate hydrolase, which is part of 
the KEGG Arginine and proline metabolism pathway and involved in putrescine 
degradation. The other two protein sequences map to no or to uncharacterized 
proteins in E. coli. 
To enable analysis of the functionality of these enriched proteins I used 
Blast2GO (Conesa et al. 2005) to annotate proteins with their respective GO terms 
and EC numbers. I used Blast2GO to align the enriched proteins against the NCBI 
database restricted to Firmicutes only, and used the top five hits and their 
respective annotation to annotate the query proteins. Enrichment analysis of 
annotated GO terms can be directly done within Blast2GO (Table 6). To analyze 
enrichment for KEGG metabolic pathways (Table 7), I extracted the annotated EC 
numbers from Blast2GO (33 complete EC numbers in total) and used the 
EC2KEGG tool (Porollo 2014). 
 
Table 6: GO term enrichment (most specific) for 55 enriched proteins. 
GO-ID Term Category FDR #Enrich #Ref Uniprot ID 
GO:0048037 Cofactor binding Function 4.41E-03 10 19 D9R7S8; D9R4N8; 
D9R6Y5; D9R0M8; 
D9R8B3; D9R9G9; 
D9R9C5; D9R1R5; 
D9R8P2; D9R6Q6 
GO:0008137 NADH 
dehydrogenase 
(ubiquinone) activity 
Function 2.60E-02 3 0 D9R9H8; D9R9H0; 
D9R9G9 
GO:0006120 Mitochondrial 
electron transport; 
NADH to ubiquinone 
Process 2.60E-02 3 0 D9R9H8; D9R9H0; 
D9R9G9 
GO:0006744 Ubiquinone 
biosynthetic process 
Process 2.60E-02 3 0 D9R9H8; D9R9H0; 
D9R9G9 
 
The GO term enrichment indicates that many of the enriched proteins bind to 
cofactors. A closer look into the annotation reveals that those cofactors are 
pyridoxal 5’-phosphate, flavin mononucleotide, FAD, NADP and NAD. While 
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pyridoxal-5’-phosphate is mainly involved in the transfer of amino and carboxyl 
groups, the other cofactors are all involved in electron transfer. The remaining 
three GO terms all refer to the same three proteins and in each case cover all 
potential members of the respective GO term. They indicate a strong enrichment 
for proteins of the NADH dehydrogenase with ubiquinone as an electron 
acceptor. Two out of the three members are strongly enriched in the pull down 
(log2 FC>6). In the same genomic region (Biocyc access NC_014376-66) in total 
six enriched proteins can be found, distributed across three operons. Besides the 
NADH dehydrogenase and a hydrogenase, the other proteins are a ferredoxin like 
protein and a protein serine/threonine phosphatase, and the imidazole glycerol 
phosphatase subunits HisH and HisF. 
The KEGG pathway enrichment analysis reveals that many enzyme classes 
enriched in the duloxetine pull down are part of the purine pathway or the 
cysteine and methionine pathway (Table 7). The enzyme classes in the purine 
pathway are represented by seven different proteins, in the methionine pathway 
by three different proteins. The same pathways were also enriched in the 
metabolomics data for C. saccharolyticum (Table 4, p. 88). Four enriched enzyme 
functions (2.6.1.1; 2.6.1.5; 2.6.1.57; 2.6.1.9) are shared in several amino acid 
metabolic pathways. However, these four enzyme annotations are based on one 
protein only: Histidinol-phosphate aminotransferase (Uniprot: D9R8B3). The 
NADH:quinone dehydrogenase proteins mentioned before are the only enriched 
proteins involved in oxidative phosphorylation. Albeit it is important to notice 
that EC2KEGG does not take incomplete EC numbers into account. Thus, for 
example the histidine pathway proteins D9R9F0/HisF and D9R9F1/HisH with 
EC:4.1.3.- and EC:2.4.2.- respectively are not considered for enrichment analysis 
even though a identification by sequence similarity is possible. 
The pathway analysis also shows nicely why species-specific comparisons are 
important, especially when working with relatively little described organisms. Of 
33 EC numbers annotated for the 55 enriched proteins only 20 could be mapped 
to KEGG pathways for C. saccharolyticum. As an example, only 46 proteins are so 
far annotated as members of the purine pathway in KEGG, while in total 107 
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potential proteins are known. A comparison to a general pathway map would 
underestimate the enrichment for any given pathway in C. saccharolyticum. It also 
indicates that some significant pathway enrichments like “Isoquinoline alkaloid 
biosynthesis” are not meaningful, as so far no protein has been found to be part of 
that pathway in C. saccharolyticum. However, for reasons of completeness they are 
listed here.  
 
Table 7: KEGG Pathway enrichment analysis for 55 enriched proteins represented by 33 EC numbers. 
KEGG Pathway Name 
Total in 
KEGG 
Total 
in Csh 
In 55 
enriched ECs enriched P-value FDR 
Purine metabolism 107 46 6 1.17.1.4; 2.4.2.7; 
3.2.2.1; 3.6.1.15; 
3.6.1.3; 6.3.3.1 
0 0 
Cysteine and methionine 
metabolism 
74 22 6 2.6.1.1; 2.6.1.5; 
2.6.1.57; 3.2.2.16; 
3.2.2.9; 4.3.1.17 
0 0 
Tyrosine metabolism 61 5 4 2.6.1.1; 2.6.1.5; 
2.6.1.57; 2.6.1.9 
0 0 
Phenylalanine metabolism 66 7 4 2.6.1.1; 2.6.1.5; 
2.6.1.57; 2.6.1.9 
0 0 
Novobiocin biosynthesis 12 3 4 2.6.1.1; 2.6.1.5; 
2.6.1.57; 2.6.1.9 
0 0 
Isoquinoline alkaloid 
biosynthesis 
51 0 3 2.6.1.1; 2.6.1.5; 
2.6.1.57 
0 0 
Tropane; piperidine and 
pyridine alkaloid biosynthesis 
27 0 4 2.6.1.1; 2.6.1.5; 
2.6.1.57; 2.6.1.9 
0 0 
Phenylalanine; tyrosine and 
tryptophan biosynthesis 
39 17 4 2.6.1.1; 2.6.1.5; 
2.6.1.57; 2.6.1.9 
0.00001 0.00008 
Oxidative phosphorylation 11 4 2 1.6.5.3; 1.6.99.3 0.0008 0.00587 
Fatty acid biosynthesis 17 7 2 1.1.1.100; 2.3.1.85 0.00188 0.01273 
Thiamine metabolism 23 12 2 2.8.1.7; 3.6.1.15 0.00465 0.02728 
Pantothenate and CoA 
biosynthesis 
30 12 2 1.1.1.169; 2.2.1.6 0.00465 0.02728 
Biosynthesis of unsaturated 
fatty acids 
16 1 1 1.1.1.100 0.01487 0.06887 
Ubiquinone and other 
terpenoid-quinone 
biosynthesis 
40 3 1 2.6.1.5 0.02953 0.11298 
Pyrimidine metabolism 63 32 2 1.3.5.2; 4.1.1.23 0.02611 0.11298 
D-Glutamine and D-
glutamate metabolism 
12 3 1 6.3.2.8 0.02953 0.11298 
C5-Branched dibasic acid 
metabolism 
21 3 1 2.2.1.6 0.02953 0.11298 
Glutathione metabolism 38 5 1 1.1.1.42 0.04397 0.15477 
Biotin metabolism 20 5 1 1.1.1.100 0.04397 0.15477 
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5.2.2 Homologous overexpression of protein candidates 
The aim of overexpressing candidate proteins was to reinforce the evidence 
for duloxetine interaction by functional assessment of duloxetine sequestration. 
For homologous overexpression, I selected 31 candidate proteins, which might 
potentially interact with duloxetine. Selection was mainly based on a preliminary 
analysis of protein enrichment and limited to matching homologues in E. coli, 
thus only 17 of the 55 enriched proteins in the final bioinformatics analysis were 
part of the overexpressed proteins.  
Homologous overexpression showed a significant depletion of duloxetine in 
all cases (Figure 26). If a minimal depletion of at least 20% is required, 19 out of 30 
overexpressed genes sequester duloxetine from the medium (highlighted in Figure 
24). The two strongest candidates with a depletion of over 30% are AroK, a 
shikimate kinase I that is part of the phenylalanine, tyrosine and tryptophan 
biosynthesis pathway, and CpdB, a 3’-nucleotidase or 2':3'-cyclic-nucleotide 2'-
phosphodiesterase, which is part of purine and pyrimidine pathways. Both of 
these candidates were not strongly enriched in the pull-down assay in the final 
bioinformatics analysis, but showed rather strong enrichment in a preliminary 
analysis, which was based on one unique peptide per protein identification instead 
of two. As depletion is not corrected for strength of protein overexpression and 
bacterial cell density, differences in depletion strength need to be interpreted 
carefully. Additionally, none of the hits was stronger than 35% depletion, 
indicating that maybe unspecific binding might play a role. E. coli BW25113 ΔtolC 
was tested before and did not show any depletion of duloxetine. Albeit in 
comparison to wild type E. coli BW25113 it had stronger growth impairments at 
50 µM duloxetine. Interestingly, the two different clones of norW overexpression 
showed differently strong depletion of duloxetine. One clone was not impaired in 
growth by duloxetine and depletes duloxetine stronger than the clone that is 
impaired in growth.  
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Figure 26: Duloxetine depletion in E. coli homologous overexpression. 
Homologues of candidate proteins are overexpressed in E. coli BW25113 tolC deletion mutant. Results from 
48h incubation, induction by 200 µM IPTG from beginning, 50 µM duloxetine added after 8h. Depletion of 
duloxetine after indirect extractions, in comparison to plate-specific control. Bacteria-free control indicated 
in red. Experiment performed in biological triplicates. 
5.2.3 Heterologous overexpression of protein candidates 
To test if binding is improved with the original protein structure, I 
overexpressed C. saccharolyticum protein heterologously in E. coli TOP10. I 
selected four genes for heterologous overexpression (Figure 27). As mentioned 
before in C. saccharolyticum the operon of HisF/HisH protein complex is located 
close to the NADH:quinone dehydrogenase complex operon, which are the 
strongest enriched proteins. They are part of the histidine pathway. The other two 
proteins PyrD and PyrF are part of the pyrimidine pathway but do not form a 
complex. They are one catalytic step up- and down stream respectively after PRPP 
is entering the pyrimidine pathway. PRPP is a product of the pentose phosphate 
pathway. 
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Figure 27: Duloxetine depletion in E. coli heterologous overexpression. 
Overexpression of C. saccharolyticum candidate proteins in E. coli Top10. Depletion of duloxetine after 
indirect extraction in comparison to controls. Results from 48h incubation, induction by 200 µM IPTG after 
5h, 50 µM duloxetine from beginning. Bacteria-free control indicated in red. 
 
In all four cases heterologous overexpression of the candidates proteins lead 
to a depletion of duloxetine from the medium. Depletion is relatively strong in 
comparison to homologous overexpression and reached up to 45%. Interestingly, 
even though HisH and HisF form a complex separate overexpression of each gene 
does sequester duloxetine from the medium. However, since the wild type strain 
of E. coli was not available and thus not tested in the assay, results should be 
interpreted with care. 
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5.3 Summary and Discussion 
5.3.1 Summary 
The aims of these experiments were to find potential duloxetine interacting 
proteins and reinforce the evidence for interaction by overexpression and 
functional assessment of sequestration. Consequently, a potential mechanism for 
how duloxetine interacts with C. saccharolyticum and potentially other gut 
bacteria might come to light. 
The five strongest enriched proteins from the duloxetine pull down are either 
part of a NADH:quinone dehydrogenase or proteins with unknown function. 
Many of the moderately to strongly enriched proteins are part of purine 
metabolism or other proteins involved in nucleotide metabolism. Additionally, 
the sequence alignment with pBlast showed a divergent similarity in the purine 
pathway member xanthine dehydrogenase (XdhB) corresponding to a divergent 
duloxetine response in E. coli strains. A different NADH dependent 
dehydrogenase also showed a similar behavior. The homologous overexpression 
of another purine pathway member showed a strong sequestration of duloxetine: 
CpdB, a 3’-nucleotidase or 2':3'-cyclic-nucleotide 2'-phosphodiesterase. 
Heterologous overexpression of pyrimidine and histidine pathway members also 
showed duloxetine sequestration. Metabolomics analysis had beforehand also 
suggested an effect in the same metabolic pathways (Table 4 on page 88). 
Experimental support from the overexpression experiments should overall be 
considered weak as important controls are missing within the same assay. Clearly, 
the experiments need to be replicated with better controls like an empty vector 
mutant for depletion control, but also growth should be more tightly monitored to 
be able to correct for biomass differences. Additionally, growth might recover in 
mutants overexpressing duloxetine-binding proteins as the deleterious effect is 
titrated out. Thus, different induction strengths of protein overexpression should 
also be tested. Ideally, IC50 values and respective duloxetine depletion curves are 
determined for each overexpressed protein and induction strength to allow for 
assertion of the impact of the respective protein in duloxetine bioaccumulation or 
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functional relevant inhibition. Consequently, the following discussion is mainly 
based on results from the duloxetine pull-down assay, and thus rather speculative. 
 
There are many potential mechanistic explanations possible for the observed 
results. Particularly as three of the five strongest enriched proteins are of unknown 
function there is room for speculation. I will present shortly two major thoughts 
in the next few paragraphs based on the two different binding site of 
NADH:quinone dehydrogenase (Figure 28). The underlying idea for the first is an 
inhibition of NADH:quinone dehydrogenase through duloxetine binding on its 
quinone binding site. The resulting NADH excess could lead to a change in 
pentose phosphate metabolism and other downstream pathways like purine 
metabolism. The second idea emphasizes that duloxetine itself might act as an 
electron acceptor, as it binds many proteins with a redox cofactor. It could bind in 
competition to NADH at its binding site on the NADH:quinone dehydrogenase, 
as the naphthalene-derived group of duloxetine could be modified into a electron 
donating naphtoquinone. In the end I will mention some other aspects and give a 
short conclusion. 
 
Figure 28: NADH:quinone dehydrogenase. 
Figure adapted from KEGG reference pathway for Oxidative Phosphorylation (map00190). 
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5.3.2 Duloxetine as NADH:quinone dehydrogenase inhibitor at 
quinone binding site 
NADH dependent quinone dehydrogenase is part of oxidative 
phosphorylation in the respiratory chain and thus part of the energy metabolism 
of most organisms (Haddock & Jones 1977). It is a complex consisting of several 
proteins containing iron-sulfur clusters to form an electron transport chain within 
the bacterial membrane build to tunnel electrons from NADH+H+ to a electron 
acceptor, usually ubiquinone (Brandt 2006). The final electron acceptor depends 
on the type of fermentation or respiration employed in the bacterium. The energy 
freed by reducing ubiquinone is used to pump protons or Na+ ions out of the 
cytosol into the periplasm to establish a proton motive force, which in turn is used 
to produce ATP via the ATP synthase (Brandt & Müller 2015). Ubiquinone is 
hydrophobic and hence embedded in the bacterial membrane, facing the cytosol. 
Duloxetine is also a hydrophobic potentially inserting itself into the bacterial 
membrane as well. As such it could potentially inhibit the electron transfer to 
ubiqinone and block the whole electron transport chain like the inhibitor 
rotenone (Singer & Ramsay 1994). NADH dehydrogenase inhibition at the 
ubiquinone binding side is common and other small molecule drugs like 
antidepressant nefazodone have been shown to act in this way (Dykens et al. 
2008). Additionally, duloxetine is moderately sequestered by many bacteria with 
diverse phylogeny (Figure 7), which suggest a binding in the membrane rather 
than through a specific protein. Binding to and inhibition of the NADH:quinone 
dehydrogenase though might be relatively specific, as only few mainly gram-
positive bacteria show growth defects upon duloxetine sequestration (Figure 11). 
Usually, in aerobic respiration a high toxicity through reactive oxygen species 
caused by leaked electrons is observed (Fato et al. 2008). As the tested conditions 
are anaerobic the only effect might be an energetic loss through electron leakage, 
which might manifest as the decreased growth capacity of C. saccharolyticum. 
Another reason for a growth disadvantage might be that NADH cannot be 
oxidized by NADH dehydrogenase anymore, causing a rearrangement of 
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metabolic fluxes in the downstream pathways and less than optimal energy 
expenditure into growth. Downstream pathways like the purine, pyrimidine and 
histidine metabolic pathways, all depend on Phosphoribosyl pyrophosphate 
(PRPP) generated in the pentose phosphate pathway. They also produce NADH 
along the synthesis of their final metabolites. Indeed Minato and colleagues found 
when knocking out NADH:quinone dehydrogenase symporting sodium in Vibrio 
cholera in anaerobic conditions there was no effect on pathways related to Na+ use 
but a change in purine metabolism (Minato et al. 2014).  
One drawback of this explanation is that purine pathway member proteins are 
enriched in the pull down, which suggest a binding to duloxetine rather than a 
regulation in response to it. Although the pull down was implemented overnight 
at 4°C, so the formation of larger protein complexes was possible, it is unlikely 
that pathways several metabolic steps downstream of the original binding partner 
are enriched in this way. Aside from this, there are different NADH:(ubi)quinone 
dehydrogenases potentially acting under different conditions or with different 
functional history in different bacterial phyla or families (Haddock & Jones 1977; 
Brandt 2006; Reyes-Prieto et al. 2014). For example, some are Na+ symporters, 
some do not link electron transport to proton or Na+ transport at all (Reyes-Prieto 
et al. 2014). The described mechanism is only one of several possibilities, and a 
detailed sequence alignment analysis and biochemical characterization has to be 
undertaken before making any conclusions about the function of this specific 
NADH:quinone dehydrogenase from C. saccharolyticum. 
5.3.3 Duloxetine as nucleotide mimicking electron acceptor 
Many purine pathway members but also other proteins from the pyrimidine 
pathway or cysteine and methionine pathway are enriched in the pull down. As 
those proteins do not directly interact with the NADH:quinone dehydrogenase 
another explanation seems also plausible. Several of the enriched proteins have a 
nucleotide-binding domain for redox cofactors. Most redox cofactors like FAD 
and NAD are based on adenine structures, and this might explain why enrichment 
occurs especially in the purine pathway. This nucleotide-binding motif is called a 
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Rossmann fold. It is conserved for binding dinucleotides, is widely found across 
kingdoms and still allows for flexibility in its structure potentially accommodating 
different molecules (Hanukoglu 2015) It is noteworthy that the part of the 
NADH:quinone dehydrogenase complex enriched is not the quinone binding 
protein but rather the part which binds to NADH.  
Disturbing so many binding sites of redox factors should lead to a strong 
growth deficiency (Deris et al. 2014). This might not occur simply because 
duloxetine binding affinity is not high and only in a artificial environment with 
reduced complexity and energetic levels as in the pull down experiment binding 
occurs. In many cases binding in purine-binding sites might be facilitated because 
purines are planar double ring molecules like the naphthol ring in duloxetine, and 
the binding site forms a stack with planar aromatic amino acid side groups (B-Rao 
et al. 2012). However, unlike purines it cannot form hydrogen bonds with nearby 
amino acids. Thus, duloxetine affinity is low and native substrates will bind more 
likely than duloxetine, resulting in no to little growth defects.  
Another more speculative idea why no strong growth defects occur is that 
duloxetine itself is used as an electron acceptor. It has a naphthol group, which 
might be prone to reduction. Naphthalene is degraded in anaerobic conditions by 
adding a carboxyl group and then reducing the ring structure by adding protons 
and ketone groups (Meckenstock & Mouttaki 2011; Mouttaki et al. 2012; Mihelcic 
& Luthy 1988; Xu et al. 2007). The in the pull-down enriched xanthine 
dehydrogenase is capable of catalyzing addition of ketone groups to ring 
structures, but usually at purine bases on a C atom situated between two N atoms. 
If two ketone groups are added, duloxetine might resemble the isoalloxazine 
group of FAD and FMN. As such it is a quinone, which can be used for electron 
shuttling switching between quinone and quinol states similar to ubiquinone. 
PyrD has a FMN binding site and preliminary experiments show a binding of 
duloxetine to PyrD (Vladimir Rybin (EMBL), personal communication). Docking 
studies suggest that duloxetine does bind in the FMN pocket (Vinita Periwal (Patil 
group, EMBL), personal communication). The enriched pathway co-member 
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PyrF is a carboxylase and could potentially activate the naphthol structure of 
duloxetine. In the heterologous overexpression both of them sequester duloxetine. 
However, before modification duloxetine does not possess similar chemical 
properties to NAD or FAD. Besides the amine group close to the click chemistry 
linker it does not consist of any nitrogen. It is hydrophobic whereas nucleotides 
are highly hydrophilic. Under anaerobic conditions it is hard to modify, as it is 
energetically unfavorable (Meckenstock et al. 2016), although naphthene 
modification by gut bacteria have been described (Van de Wiele et al. 2005). 
Additionally, as mentioned before the discovered binding might only occur in less 
competitive in vitro environments. And finally, I found no evidence that 
duloxetine is biotransformed in C. saccharolyticum. Thus, duloxetine might bind 
in the suggested redox cofactor binding sites, but not be modified. A low affinity 
for duloxetine and strong occupation of the binding site by the native redox 
cofactors might explain why little growth defects occur in vivo. 
5.3.4 Alternative explanations 
Duloxetine might act in a complete different way as described here. One of the 
enzymes enriched was a xanthine dehydrogenase, which also showed a divergent 
alignment correlating with duloxetine response in E. coli. Clostridiales have been 
shown to be able to ferment purines (Durre & Andreesen 1983). The xanthine 
dehydrogenase is the first step in purine fermentation, and has been show to be 
relatively promiscuous (Coughlan 1980). Another idea is that duloxetine blocks 
not the NADH or quinone binding sites of NADH:quinone dehydrogenase but a 
potential sodium pump function (Reyes-Prieto et al. 2014). Duloxetine could be 
considered a sodium pump blocker as the serotonin and noradrenaline 
transporters it inhibits in the mammalian brain are sodium dependent. 
5.3.5 Conclusion 
The protein pull down and following overexpression showed that duloxetine 
binds a diverse set of proteins, often associated with the purine pathway or in 
general with nucleotide or nucleoside binding. The strongest enrichment was seen 
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for a NADH:quinone dehydrogenase and duloxetine might act as an inhibitor of 
its electron transport function, which in turn affects oxidative phosphorylation 
and other downstream pathways like purine metabolism. A more detailed 
investigation into the structure of duloxetine binding proteins and metabolic 
consequences of enzyme inhibition through duloxetine should follow. 
5.4 Clarification of Contribution 
I designed the pull down experiment and organized the implementation. Felix 
Hövelmann (Schultz group, EMBL) synthesized duloxetine bound to 
desthiobiotin with a click chemistry enabled linker. Thomas Bock (Beck group, 
EMBL) conducted the pull down experiment, while I provided the bacterial lysate. 
Marie-Therese Mackmull (Beck group, EMBL) measured the samples with mass 
spectrometry and performed the peptide matching and data imputation step. I did 
statistical analysis and further bioinformatics.  
For homologous overexpression I had help from Lucia Herrera (Typas group, 
EMBL) for cloning overexpression plasmids from a clone library into the ΔtolC 
background strain. Otherwise I designed and implemented the homologous and 
heterologous overexpression and accompanying duloxetine depletion analysis 
myself.
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6 Discussion and Outlook 
I will first give a short summary of all findings in this thesis, and then discuss 
potential implications in the context of the contemporary state of research on gut 
bacterial drug interactions. When discussing a specific point, I will also suggest 
additional paths of investigations. Finally I will give a conclusion of the findings 
from my PhD work. All following parts are structured by the two main thoughts 
behind this work: i) prevalence of drug interactions of gut bacteria and their 
relevance in the (host) microbiota context, and ii) mechanistic elucidation of 
duloxetine interactions and its effects on bacterial physiology.  
6.1 Summary of Results 
6.1.1 Bioaccumulation of xenobiotics is a wide-spread 
characteristic of the human gut bacteria and affects 
community dynamics 
Our knowledge of the biochemical capabilities of gut bacteria to interact with 
or metabolize therapeutic drugs is largely incomplete (Sousa et al. 2008; Koppel & 
Balskus 2016). Towards filling this gap, I planned and conducted a systematic in 
vitro screen of xenobiotic-microbial interactions elucidating how wide-spread 
bacterial drug bioaccumulation or biotransformation is across therapeutic drugs 
or the gut microbiota. I tested, under anaerobic conditions, 450 drug-bacteria 
interactions covering 25 metabolically diverse gut bacteria and 18 structurally 
diverse FDA-approved drugs. This revealed almost 50 novel bioaccumulation or 
biotransformation links between 19 bacterial species and 10 drugs (Figure 11 on 
page 52). The implicated bacteria are phylogenetically diverse, including 
commensals, probiotics and bacteria associated with diseases. The affected drugs 
span diverse indication areas, from asthma (montelukast) to depression 
(duloxetine and aripiprazole). Among the identified interactions, around 20 could 
be classified as bioaccumulation and seven as potential biotransformations. Drugs 
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like duloxetine and montelukast showed a strong tendency to get bioaccumulated 
by several bacteria. Drugs like levamisole and donepezil are likely biotransformed. 
Interestingly, bacteria, which deplete drug compounds from the medium, are 
usually not affected in their growth by those compounds (at the screening 
concentration of 50µM). However, drugs like loperamide and duloxetine do affect 
a broader bacteria spectrum in their growth, and act both as inhibitor and 
promoter of bacterial growth in a strain dependent manner. Considering up to 
1000 gut bacterial strains and a few thousand existing host-targeted drugs, I only 
tested a small part of all possible bacteria-drug interactions, and that too at only 
one drug concentration. Even in this limited sampling space, the number of hits 
found is quite high. As both the bacterial species and the affected drugs span a 
wide diversity, these results suggest that bioaccumulation of drugs is a common 
and hitherto underappreciated mode of bacteria-drug interactions.  
As a case in point, the results from this bacteria-drug interaction study are 
followed upon in more details through investigation of interactions involving 
duloxetine – a widely used antidepressant. I found that duloxetine induces higher 
diversity in synthetic bacterial communities, and its bioaccumulation by 
community members affects the community dynamics (Figure 15 on page 66). 
The shift in community composition upon duloxetine exposure cannot be fully 
explained by the observed growth defects of bacterial species in monoculture as 
derived from duloxetine IC50 estimations. Duloxetine-depleting bacteria 
additionally alter the dynamics of this shift, as duloxetine concentration is lower 
in communities consisting of more duloxetine depleting bacteria.  
6.1.2 Bacterial NADH:quinone dehydrogenase and purine 
metabolism are likely affected by duloxetine 
As I found gut bacteria-duloxetine interactions to be common in vitro and 
having an impact on bacterial community assembly, I aimed to investigate the 
underlying mechanisms. Using an untargeted metabolomics approach to 
characterize extracellular metabolites, I found that duloxetine affects the native 
metabolism of B. uniformis and C. saccharolyticum, in particular the purine 
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metabolism (Table 4 on page 88). These effects might in turn influence bacterial 
behavior in a community. To find the direct protein targets of duloxetine in C. 
saccharolyticum, I used click chemistry-based methods and proteomics. Two of 
the five strongly enriched duloxetine-binding proteins are part of a 
NADH:quinone dehydrogenase complex (Table 6 on page 102). Other moderately 
enriched proteins are part of the purine pathway (Table 7 on page 104). Figure 29 
summarizes findings in the purine pathway from both metabolomics and 
proteomics experiments for C. saccharolyticum. Enriched enzymes in the purine 
pathway are AIR synthase, adenine phosphoribosyltransferase (ARPT), xanthine 
dehydrogenase (Xdh) and nucleoside-triphosphatase. Additionally, one protein of 
the xanthine dehydrogenase (XdhB homolog) showed a divergent sequence 
homology in E. coli strains corresponding to their divergent duloxetine response 
(Figure 25 on page 101). Metabolites that are products of enriched proteins like 
AIR or otherwise closely connected in the pathway like guanosine or pentose 
phosphates are enriched too. Thus, duloxetine is likely to affect bacterial 
metabolism in the purine pathway by directly binding to nucleotide or nucleoside 
binding proteins like xanthine dehydrogenase as well as by inhibiting the 
NADH:quinone dehydrogenase directly. 
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6.2 Discussion 
For a more detailed discussion on effects of specific drugs see the respective 
discussion 2.3 on page 53. Here I will focus on more general effects and highlight 
implications for pharmacokinetics and gut microbiome ecology. I will mention 
interesting findings from other drugs but in general focus more on the case of 
duloxetine and depression as it has been intensively investigated in this PhD work. 
For each discussion point, I will also suggest further experimental approaches to 
test the discussed effects or mechanisms. 
Albeit in general, as gut bacteria are neither functionally nor biochemically 
well characterized yet in comparison to model organisms like E. coli or B. subtilis 
and the found bacteria-drug interactions are likely sensitive to media and oxygen 
differences, any follow-up study will suffer from a limitation of tools. For example, 
genetic tools like generation of knockouts or overexpression mutants are often not 
easily transferable to bacteria from environmental isolates. Defined or minimal 
media to efficiently characterize the metabolic state of bacteria using tracer 
methods have not been described yet or many bacteria-drug interactions were 
sensitive to a change in media condition when tested. Thus, in many cases further 
investigations will require the adaptation of molecular biological methods to the 
respective investigated bacterial strain, or even strain-drug interaction. 
6.2.1 Side effects of host-targeted drugs are mediated through 
the gut microbiota 
In recent years the connection between microbiota and drug side effects has 
often been discussed and many links and examples have been found 
(Spanogiannopoulos et al. 2016; Sousa et al. 2008; Wilson & Nicholson 2016; 
Swanson 2015). In a few cases, drug dosages or drug side effects could be linked to 
bacterial drug bioaccumulation or metabolism (Hashim et al. 2014; Wallace et al. 
2010). In other cases, comorbidity due to an induced shift in gut microbiota 
composition seems likely (Bahr et al. 2015; Bahra et al. 2015). Furthermore, the 
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gut microbiota can influence hepatic host drug metabolism directly (Claus et al. 
2011; Selwyn et al. 2015) and indirectly through bile acid metabolism (Klaassen & 
Cui 2015; Sun et al. 2016). 
Here, I showed that gut microbial bacteria specifically sequester drugs in 
many cases, and that they are affected in growth in other, often different cases. 
However, differences between bioaccumulation and an effect on bacterial growth 
might be concentration dependent as seen for duloxetine. Thus, a gut microbiota-
mediated sponge-like effect altering drug dosage might occur already before a 
direct antimicrobial effect is observed. Furthermore, bioaccumulation did change 
bacterial native metabolism and community composition dynamics suggesting 
that drug side effects might occur through a change in microbiota composition 
already at comparatively low drug concentrations. It should be noted that bacteria 
considered probiotic like Bifidobacteria show the same tendencies for 
bioaccumulation as normal commensals. If we assume that gut microbiota-drug 
interactions are the norm rather than exception as potentially indicated by my 
study, then bioaccumulation is the basic bacteria-drug interaction mode and 
xenobiotic metabolic biotransformation of drugs are potentially more severe but 
also more exceptional cases. 
Side effects like increased risk of heart attacks cannot always be linked to a 
shift in gut microbiota composition only. Often the native gut microbiota 
metabolism directly plays a role as is the case of bacterial trimethyl amine 
production from dietary choline and subsequent conversion to pro-
atherosclerotic metabolite TMAO by the host (Wang et al. 2011). As 
bioaccumulation of drugs can lead to a change in bacterial metabolism, as shown 
in this study for the case of duloxetine, it can consequently cause long lasting but 
hard to detect side effects. Most of the tested drug compounds in this study treat 
chronic diseases like arteriosclerosis, asthma, or depression and patients use them 
for years at a time. Thus, implications of drug bioaccumulation in bacteria on 
development of heart diseases, obesity and other metabolic disorders in patients 
should be considered carefully. 
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As only 3 out of 12 growth affected bacteria are gram-negative, the bacteria-
drug interaction screen indicates that gram-negative bacteria are better protected 
from growth defects than gram-positive bacteria. Of the two major phyla in the 
gut microbiome, Bacteroidetes is gram-negative, and Firmicutes is gram-positive.  
Thus, upon regular drug exposure a shift towards Bacteriodetes might occur in the 
gut microbiome of patients. However, as observed in the synthetic community 
assembly upon duloxetine exposure in this study, community dynamics can 
overrule expectations, and instead lead to rise in gram-positive bacteria. A high 
ratio of Firmicutes to Bacteroides has been associated with unfavorable 
developments like metabolic syndrome or obesity, and mouse models and one 
human case study suggests that this is causative (Musso et al. 2011; Alang & Kelly 
2015). In many cases however, there is still conclusive evidence missing that a 
change in microbiome composition is a cause for rather than a consequence of 
disease development in humans. In vitro studies might help to point to 
mechanisms through which the gut microbiota interacts with the host. 
For potential xenometabolic interactions like R. gnavus with montelukast or 
B. thetaiotaomicron and duloxetine, an untargeted metabolomics study of a time 
course experiment would be needed to identify bacterial drug metabolites and 
potential reaction mechanisms. With mutagenesis assays like the Ames test 
(Mortelmans & Zeiger 2000; Gatehouse 2012), cell viability assays (Hansen & 
Bross 2010) or Caco2 cell permeability assays (Press 2011), crude extracellular 
metabolite mixes of bacteria-drug interactions or specific bacterial drug 
metabolites once identified can be tested for host toxicity. Also effects on the 
protective mucus layer should be investigated in vitro (Liu et al. 2014; Li et al. 
2015). Drug compounds with indications for strong deleterious effects in in vitro 
assays can then be further tested in in vivo mouse models to investigate host 
immune system-gut microbiota feedback interactions (Claus et al. 2011). 
Additionally, the same assays can be used to investigate if a shift in bacterial native 
metabolism or microbial community composition as caused by bioaccumulation 
is associated with production of toxic or otherwise unfavorable compounds.  
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6.2.2 Duloxetine influences depression symptoms through 
impact on gut microbiota 
Recent research suggest that the gut microbiome is able to influence the 
development of depression through the immune system and the hypothalamo-
pituitary-adrenocortical (HPA) axis (Kelly et al. 2015; Foster & McVey Neufeld 
2013). Kelly et al. (2015) suggest a weakening of the gut barrier, respective low-
grade inflammation and its influence on the HPA axis as causative in some 
instances of depression. Probiotics have been shown to improve barrier function 
and lighten mood (Kelly et al. 2015). Additionally, a diverse set of bacteria have 
been shown to increase production of serotonin, a major regulator in mood 
disorders like depression, especially by spore forming bacteria like Clostridiales 
species (Ridaura & Belkaid 2015).  
In my study, duloxetine favored the rise of Eubacterium rectale in the bacterial 
community assembly. This bacterium is associated with short chain fatty acid 
production and consequently with increase in barrier function (Kelly et al. 2015; 
Swanson 2015). Furthermore, side effects of duloxetine like decreased appetite or 
constipation might be caused by a change in bacterial metabolism, which control 
or produce hormones controlling appetite and gut motility in the host (O’Mahony 
et al. 2015; Clarke et al. 2014). Side effects of antidepressants like weight gain have 
already been linked to a change in microbiota composition (Bahra et al. 2015). 
While it is possible that duloxetine directly influences serotonin production in 
host cells, it is also possible that duloxetine indirectly modulates serotonin levels 
through influencing the metabolism of Clostridiales species producing serotonin 
(O’Mahony et al. 2015). Thus, it is likely that duloxetine not only directly mediates 
relief from depression by inhibition of the serotonin reuptake in the brain, but 
also indirectly through the microbiota composition, which in turn can alleviate 
depression. In conclusion, the therapeutic targeting of the gut microbiota to 
alleviate depression symptoms, for example as suggested by O’Mahony et al. 
(2015), might already be one of the mechanisms underlying the mode of action of 
the antidepressants in current use. Further research in this area including 
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population cohort studies and placebo-controlled intervention trials as well as 
more mechanistic approaches in mice will likely clarify the impact of the gut 
microbiota on depression and respectively the impact of antidepressants on the 
gut microbiota in the near future. 
6.2.3 Deprotonated, negatively charged drugs are less likely to 
be sequestered 
The bacteria-drug interaction screen showed a broad potential of gut bacteria 
to sequester drugs from the medium. At the same time, only comparatively few 
bacteria were found to be affected in growth. In particular, gram-positive bacteria 
were more often affected (9 out of 12 affected bacteria) than gram-negative 
bacteria (3 out of 12 affected). It has been shown before that gram-negative 
bacteria are often protected from antibiotics because they possess two cell 
membranes instead of one like the gram-positive bacteria (Delcour 2009). 
Additionally, gram-negative bacteria tend to have many efflux pumps increasing 
their resilience (Nikaido 1996). Many of the drugs have a higher pKa than the pH 
of the medium in the bacteria-drug interaction screen. This means that one or 
several functional groups of the drug compounds are protonated in the screen and 
possess a positive charge. Bacterial cells walls on the other hand possess negative 
charge due to the deprotonation of their teichoic acids or LPS compounds. The 
positive charge of the drugs might facilitate binding to the negatively charged 
bacteria cell wall. All drugs that are not sequestered and do not affect growth in 
the bacteria-drug interaction screen (rosuvastatin, tolmetin, tenofovir) are likely 
deprotonated and thus at least partially negatively charged in screening 
conditions. As most drugs are also lipophilic, once they are attached to the cell 
wall they might easily pass into or even through the cell membrane. In gram-
positive bacteria, this means that drugs reached the cytoplasm and might interfere 
with essential cellular functions. In gram-negative bacteria, they are more likely to 
get stuck in the periplasm, due to the second membrane (Delcour 2009). 
Additionally, gram-negative bacteria tend to have more efflux pumps increasing 
their resilience (Nikaido 1996). However, this balance might be overcome with a 
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higher concentration of the respective drug and pushed towards growth arrest in 
gram-negative bacteria as well. In support of this idea, IC50 values would be 
expected, on average for a specific drug respectively, to be higher in gram-negative 
bacteria than in gram-positive bacteria, but bioaccumulation should be equally 
strong across all affected bacteria as long as they grow equally well. Tendencies of 
this mechanism were found for duloxetine in this study, but the idea is speculative 
so far. Other experiments like testing for drug sequestration through cell-free LPS 
or teichoic acids in different pH conditions could clarify the relevance of this idea 
beforehand. 
6.2.4 Potential of host-targeted drugs as antibiotic adjuvants  
Many compounds in the bacteria-drug interaction screen have growth 
inhibitory effects on specific bacterial strains. Potentially, also many drugs that are 
sequestered can have growth inhibitory effects in a higher concentration on the 
same species as demonstrated for the case of duloxetine and B. uniformis (Figure 
13 on page 64). Others, like montelukast might not influence the growth of 
bacteria at physiological concentrations at all, but still have an effect on bacterial 
physiology as they are sequestered. These compounds could potentially aid 
antibiotics to overcome resistant bacteria, target antibiotics more specifically to 
certain strains, and have additionally the advantage of being already tried and 
tested for use as pharmaceuticals.  
This potential has long been realized (Kristiansen & Amaral 1997) and has 
recently amidst the antibiotic crisis come more into focus of research again (Ejim 
et al. 2011; Wright 2016). Currently, other screens in our institute are aimed at 
finding how prevalent gut bacterial growth defects through a wide-range of host-
targeted drugs are or how prevalent their antibiotic adjuvant effects are (personal 
communication, Typas group, EMBL). For loperamide, an antibiotic adjuvant 
effect has already been described, and the underlying mechanism is likely the 
disruption of electron potential across bacterial membranes, which facilitates 
uptake and effect of antibiotics (Ejim et al. 2011). A good adjuvant should induce 
little to no growth defect itself as to avoid adaption and evolution of resistance 
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mechanisms in bacteria (Wright 2016). Under aerobic conditions, loperamide 
induced growth defects only at concentrations in the upper mM range fulfilling 
the proclaimed property (Ejim et al. 2011). In anaerobic conditions however, it 
affects the growth of many bacteria already at a low concentration of 50 µM 
(Figure 11 on page 52), giving potentially leeway to development of resistance 
when not used in combination with antibiotics. Nevertheless, it might also 
increase its efficiency as antibiotic adjuvant when used to target species in the gut. 
Interestingly, duloxetine affects similar species as loperamide, but in contrast 
to loperamide it is also sequestered from the medium. Thus, it is possible that 
duloxetine has a similar destabilizing effect on the bacterial cell membrane but 
caused by a different mechanism than in loperamide. Indeed I could show that 
duloxetine potentially binds the NADH:quinone dehydrogenase, a key enzyme 
responsible for the establishment of proton motive force across the bacterial 
membrane. In this case, duloxetine might also work as an antibiotic adjuvant just 
like loperamide. Other antipsychotics have already been shown to have potential 
as antibiotic adjuvant (Jeyaseeli et al. 2012; Munoz-Bellido et al. 2000). To explore 
such possibilities, duloxetine and other candidates like montelukast should be 
tested in combination with antibiotics, and their effects on growth should 
determined for individual bacterial strains. Then, it would be interesting to test 
the combinatorial effect of adjuvant and antibiotic in a synthetic community 
assembly experiment to investigate if specific bacteria can be targeted in a 
community. 
Additionally, the bacteria-drug interaction screen indicates that bacteria, 
which are resistant to a certain compound, are potentially less so under anaerobic 
conditions. Thus, besides being a reservoir for antibiotic resistance (Penders et al. 
2013), the gut microbiota is potentially also an active site for the development of 
bacterial resistance, which might explain its high diversity of resistance genes. 
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6.2.5 Duloxetine inhibits bacterial NADH:quinone 
dehydrogenase and affects purine metabolism 
As described in the discussion of the respective chapter 5.3 on page 108 in 
more detail, I suggested two potential binding sites for duloxetine on the bacterial 
NADH:quinone dehydrogenase at the quinone binding site or the NADH binding 
site. Inhibiting the electron transport chain commonly occurs at the quinone-
binding site (Fato et al. 2008; Singer & Ramsay 1994), and a knockout does lead to 
a feedback into the purine pathway and excretion of those metabolites in bacterial 
species (Minato et al. 2014). Indeed, duloxetine with its naphthol group shows 
some similarity to a known inhibitor of the quinone-binding site (Dykens et al. 
2008). Thus, it would also explain the findings from the untargeted metabolomics 
experiment. However, not proteins of the potential quinone-binding site of the 
dehydrogenase complex in the membrane were enriched in the pull-down, but 
proteins of the respective cytosolic NADH-binding site. Furthermore, other redox 
factor binding proteins like AIR synthase, xanthine dehydrogenase (Xdh) and 
adenine ribosylphosphotransferase (ARPT), key players of the purine pathway, 
were also enriched in the pull-down. Additionally, homologs of Xdh but not 
NADH:quinone dehydrogenase show divergent sequence similarity in E. coli 
strains divergently responding to duloxetine. Xdh is comparatively promiscuous; 
several inhibitors at the active site have been synthesized so far (B-Rao et al. 2012; 
Takano et al. 2005). Deficiency in Xdh leads to accumulation of adenine (Kojima 
et al. 1984), deficiency of APRT to accumulation of adenine or 2,8-
dihydroxyadenine (Terai et al. 1995). Adenine was not strongly enriched in C. 
saccharolyticum in the untargeted metabolomics experiments, but was enriched in 
B. uniformis. 
A targeted quantitative metabolomics study of intracellular and extracellular 
metabolites in C. saccharolyticum to reveal which part of the purine metabolism is 
strongly affected could support these ideas, and potentially differentiate between 
the two explanations pointing to the primary (bacterial) target of duloxetine. Also 
metabolites like 2,8-dihydroxyadenine, which is produced upon inhibition of 
ARPT, and other indicative non-standard metabolites can be found with this 
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method. The metabolomics data could be used to build a metabolic model 
describing the expected effects of NADH:quinone dehydrogenase or purine 
pathway members inhibition and rearrangements in the metabolic fluxes in the 
downstream pathways. 
Additionally, after a stringent and detailed comparison of gene homology, an 
improved assay of gene knockout and overexpression of C. saccharolyticum 
homologs of NADH:quinone dehydrogenase or purine pathway members in E. 
coli could give indications of binding. Overexpression mutants for proteins 
inhibited by duloxetine, might escape growth defects induced by duloxetine as 
inhibition is titrated out. If bioaccumulation is protein dependent as well, 
knockout mutants of proteins causative for bioaccumulation should deplete less 
duloxetine from the medium as non-causative protein knockout mutants. 
Furthermore, protein candidates from C. saccharolyticum can be overexpressed 
and purified and their duloxetine binding affinity and further biochemically 
properties can be characterized directly. For in vivo relevance, duloxetine needs to 
be able to bind in competition to or at least in presence of the native substrate, 
which can be tested in a competition assay on the purified enzyme. 
6.3 Conclusion  
In my PhD work, I identified almost 50 novel gut bacteria-drug interactions 
suggesting that similar interactions are likely to be more prevalent than expected 
so far. For most of the identified interactions, the drugs were bioaccumulated 
rather then biotransformed. Bioaccumulation is thus potentially a widespread but 
so far underappreciated mode of bacteria-drug interaction. My study also shows 
that drug bioaccumulation can impact bacterial metabolism without strong or 
even no effect on bacterial growth. Within a bacterial community the 
consequences of these effects, bioaccumulation and growth defects, are hard to 
predict from monoculture growth alone. For example, exposure to Duloxetine, a 
widely used antidepressant, led, unexpectedly, to a higher diversity in a synthetic 
community. As bacteria can affect the effective dose of a host-targeted drug 
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through bioaccumulation, and/or change its activity spectrum through 
biotransformation, the findings from this study have broad and far-reaching 
relevance for drug dosage decisions and personalized medicine. Consequently, 
potential bacterial off-target effects as cause for drug side effects also need to be 
taken into account during drug design and clinical trials. 
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7 Materials and Methods 
7.1 Growth conditions and media 
Unless otherwise indicated, all bacteria were grown as liquid cultures in Gut 
Microbiota Medium (GMM) (Goodman et al. 2011). Cultivations were carried out 
in a Vinyl Anaerobic Chamber (COY, USA) at 37°C with oxygen below 20ppm, 
15% carbon dioxide and 1.8-2% hydrogen. Main gas in the anaerobic chamber is 
nitrogen. All experimental cultures were started from the second passage culture 
after inoculation from a glycerol or DMSO stock. Depending on the bacterial 
species, one passage might take up to 48h to grow. The recipe for GMM can be 
found in Table 8. All media, buffer, glass and plastic ware used had been exposed 
to anaerobic conditions at least 12h prior usage. 
Table 8: Gut Microbiota Medium (GMM) 
Component Amount/L Concentration Comments 
Tryptone Peptone 2 g 0.2% 
 Yeast Extract 1 g 0.1% 
 D-glucose 0.4 g 2.2 mM 
 L-cysteine 0.5 g 3.2 mM 
 Cellobiose 1 g 2.9 mM 
 Maltose 1 g 2.8 mM 
 Fructose 1 g 2.2 mM 
 Meat Extract 5 g 0.5% 
 KH2PO4 100 mL 100 mM 1M stock solution pH 7.2 
MgSO4-7H20 0.002 g 0.008 mM 
 NaHCO3 0.4 g 4.8 mM 
 NaCl2 0.08 g 1.37 mM 
 CaCl2 1 mL 0.80% 0.8g/100mL stock 
Vitamin K (menadione) 1 mL 5.8 mM 1 mg/mL stock solution 
FeSO4 1 mL 1.44 mM 0.4 mg FeSO4/mL stock solution 
Histidine Hematin Solution 1 mL 0.1% 1.2 mg hematin/mL in 0.2M histidine 
Tween 80 2 mL 0.05% 25% stock solution 
ATCC Vitamin Mix 10 mL 1% 
 ATCC Trace Mineral Mix 10 mL 1% 
 Acetic acid 1.7 mL 30 mM 
 Isovaleric acid 0.1 mL 1 mM 
 Propionic acid 2 mL 8 mM 
 Butyric acid 2 mL 4 mM 
 Resazurin 4 mL 4 mM 0.25 mg/mL stock solution 
pH 7.2 corrected with 10M KCl 
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For conjugation of overexpression plasmids bacteria were grown in LB liquid 
medium or on LB agar plates (2% w/v). LB recipe can be found in Table 9. 
Table 9: Recipe for LB medium. 
LB medium 
1% (w/v) Bacto tryptone 
0.5 % (w/v) Bacto yeast extract 
 0.5 % (w/v) NaCl 
  
7.2 UPLC methods 
7.2.1 UPLC-UV methods 
Liquid chromatography is a method widely used to separate specific 
compounds from a mixture and identify them based on comparisons to standards. 
The methods used here use UV absorption and elution time for identification. To 
be able to measure all selected drugs within one screen with the available 
instrument, chromatographic conditions needed to be optimized using a 
maximum of 4 different mobile phases, while two of them needed to be water and 
an organic phase respectively. Another parameter for optimization was time. For 
optimal separation of compounds a longer chromatography with a less steep 
gradient is usually preferable. However, this would increase the measurement time 
for the whole screen strongly since approximately 6000 injections were to be 
expected. Once established, the same methods were used throughout the whole 
study. 
All liquid chromatography methods are run on a Waters Acquity UPLC H-
Class instrument with a PDA detector and a quaternary solvent system. All 
established methods are 5 minutes long, have a flow rate of 0.5ml/min and run on 
a CSH C18 column (Waters, Part number 186005297) in reverse mode. The 
column is heated to 40°C and samples are kept at 6°C. All methods use 50% 
acetonitrile (Biosolve, ULC grade) for washing buffer, and 50% methanol 
(Biosolve, ULC grade) for purging buffer. As organic mobile phase acetonitrile 
was used. The assay was optimized using only two buffers besides water as 
hydrophilic mobile phase: 5mM formic acid (Biosolve, ULC grade) of pH 3.2 and 
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5mM ammonium formate (Ammonium hydroxide, ACS grade, Sigma) with pH 
adjusted to 8.3 using the formic acid buffer. Table 10 lists the five different 
chromatographic methods established for the different drugs. The specific 
chromatographic method used for identification of each drug compound can be 
found in Table 11. 
 
Table 10: UPLC methods. 
 
From min To min Acetonitrile 
Formic 
Acid Buffer 
Ammonium 
Formate Buffer Water 
Method A 0 1.5 5% 0% 65% 30% 
 2.5 3 60% 0% 40% 0% 
 3.5 5 5% 0% 65% 30% 
Method B 0 1.5 5% 65% 0% 30% 
 2.5 3 60% 40% 0% 0% 
 3.5 5 5% 65% 0% 30% 
Method C 0 1.5 20% 60% 0% 20% 
 2.5 3 80% 20% 0% 0% 
 3.5 5 20% 60% 0% 20% 
Method D 0 1.5 5% 0% 95% 0% 
 2.5 3 50% 0% 50% 0% 
 3.5 5 5% 0% 95% 0% 
Method E 0 1.5 40% 60% 0% 0% 
 2.5 3 95% 5% 0% 0% 
 3.5 5 40% 60% 0% 0% 
 
Table 11: UPLC method description by drug 
Drug 
compound 
UV absorption 
(nm) 
Second 
channel (nm) 
UPLC 
Method 
Peak elution 
time (min) 
Caffeine elution 
time (min) 
Acetaminophen 244 - A 1.5 3 
Aripiprazole 255 - B 3.3 3 
Donepezil 268 - B 3.2 3 
Duloxetine 230 - B 3.3 3 
Digoxin 220 - B 3.5 3 
Ezetimibe 234 - C 3.5 0.7 
Loperamide 220 - B 3.5 3 
Metformin 234 - D 0.7 3.1 
Montelukast 344 274 E 3.8 0.5 
Metronidazole 330 274 A 1.9 3 
Levamisole 225 - A 3.5 3 
Ranitidine 313 274 A 3.3 3 
Roflumilast 245 - C 3.6 0.7 
Rosiglitazone 247 - B 3.1 3 
Rosuvastatin 241 - C 3.3 0.7 
Simvastatin 247 - E 3.7 0.5 
Sulfasalazine 254 - C 3.7 0.7 
Tenofovir 260 - B 3.4 3 
Tolmetin 320 274 C 3.4 0.7 
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7.2.2 Data analysis 
A general approach to analysis data from UPLC methods is described here. If 
not indicated otherwise, all chromatographic data is handled this way. For data 
analysis of the bacteria-drug interaction screen, see respective method 7.3.3. 
All chromatograms are annotated with the vendor specific program Empower 
3, and manually curated for peak identification. Readout for all chromatograms is 
baseline corrected area under the curve of the drug peak and the internal standard 
peak respectively. This raw data is further analyzed using statistics softwar 
environment R and respective packages. 
Each drug peak is normalized by the respective caffeine peak (used as internal 
standard) from the same chromatogram. If a new peak appeared in the drug-free 
bacteria control, which is coeluting with the drug peak, the mean of the 
normalized values from the control was subtracted from the mean of the 
normalized values from the experimental samples. Corrected normalized means 
of the experiment samples were then compared to the mean of the respective 
bacteria-free drug control and a Student’s t-test was used to assess if they are 
significantly different. If more than 10 interactions were tested in one assay, the 
false discovery rate was controlled at alpha level 0.05 using Benjamini-Hochbergs 
method (Benjamini & Hochberg 1995). 
If samples from different experimental batches or different UPLC runs were 
compared with each other, all samples were normalized by the mean of the 
bacteria-free control from the respective batch. This allows statistical testing 
comparisons by keeping the relative mean and variation of the respective batch, 
but adjusting for differences in absolute means caused by methodological 
differences. 
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7.3 Bacteria-Drug Interaction Screen 
7.3.1 Drug Selection 
As a starting point I used the SIDER database (Kuhn et al. 2010), listing 4492 
unique side effects for 996 medical drugs as accessed on 7.2.2014. The SIDER 
database extracts these side effects from publicly available websites and patient 
information leaflets.  I defined two sets of side effects: one loosely associated with 
symptoms related to the gut or gut microbiome including symptoms like 
“Vitamin B deficiency” or “Atherosclerosis” (190 terms in Appendix A), the other 
one more strict only focusing on terms directly related to the gut like “Flatulence” 
or “Weight fluctuations” (36 terms in Appendix A). For 121 of the 996 drugs, 
more than 10% of their respective side effects were loosely associated with the gut, 
and for 93 drugs more than 5% of their respective side effects were strictly 
associated with the gut. 63 drugs fulfilled both conditions, and were further 
scrutinized.  
I enriched the list with drugs that have a high sales volume (indicative of 
clinical relevance), drugs that had been withdrawn from the market for side effects 
that might involve the microbiome as a cause, and drugs that are on the WHO list 
of essential medicine (World Health Organization 2015). Additionally, drugs that 
had already been shown to impact the gut microbiome as collected by the 
Pharmacomicrobiomics database (Saad et al. 2012) were considered for the screen. 
I manually curated this list of approximately 120 drugs, and annotated it with data 
from CHEMBL (Bento et al. 2014) and DrugBank (Law et al. 2014). 
From these compounds I selected only drugs that are administered orally to 
the patient. This could increase the chance of exposure of the gut microbiome to 
the drug before first pass metabolism, especially if the drug is poorly absorbed in 
the stomach. Thus, I prioritized drugs with a long biological half-life and low 
bioavailability. I excluded antibodies or other peptide-like drugs as I assumed a 
high likelihood of them being metabolized as nutritional source. Also drugs with a 
molecular weight higher than 500 Dalton were generally excluded to focus on 
small molecule drugs. The resulting roughly 60 drugs were manually curated and 
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selected for availability from vendors and implementation of UPLC methods 
within a screening context. For the 18 drugs listed in Table 2 on page 40 I 
established reliable chromatographic methods as described in the previous 
method section 7.2. 
7.3.2 Experimental setup 
For all drugs, I used a fixed concentration of 50 µM, which in most cases 
approximates the concentration of one pill (0.02-3 mmol) diluted in the volume of 
the gut (approx. 2.5 L). As shown in the plate outline in Figure 30, I used one 
bacteria-free control per plate and drug, but triplicates for each bacteria-drug 
interaction. The screen was carried out under anaerobic conditions in 96-well 
plates (Nunclon Delta Surface 163320, NUNC) with 150 µl GMM as the growth 
medium sealed with a Breathe-Easy® sealing membrane (Z380059, Sigma-
Aldrich). Plates containing 100 µl of the medium and 75 µM of the drug were 
prepared beforehand, stored at -20°C and used as needed.  
 
Figure 30: Outline of bacteria-drug interaction screening plates. 
Each sample involving the growth of bacteria is tested in triplicates per plate. Drug controls, which are 
bacteria-free, are tested in singlets per plate. Per plate one bacterium is tested with all drugs in the screen. 
 
Frozen plates were introduced into the anaerobic chamber the evening before 
inoculation. Wells were inoculated with 50 µl of a second overnight culture with 
an end OD578 of 0.01. Growth was monitored with measurements of the optical 
density at 578 nm using an Eon Microplate Spectrophotometer (BioTek) 
approximately every 2h for the first 10h, then approximately every 6h. After 48h, 
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plates were removed from the anaerobic chamber and the bacteria spinned down 
(4000 rpm, 10 min). Then, 100 µl of the supernatant was extracted in 300 µl ice 
cold acetonitrile:methanol (Biosolve, ULC grade) in 500 µl polypropylene plates 
(Corning Costar 3957) to remove compounds interfering with liquid 
chromatography. Plates were closed with a lid (Corning, storage mat 3080) and 
after shaking and 15 minutes incubation at 4°C, samples were centrifuged at 4000 
rpm for 10 min at 4°C and 300 µl of the supernatant were transferred to a new 
plate (Corning Costar 3362). All liquid handling outside of anaerobic chamber 
was done using a liquid handling robot (FXp, Biomek). Sample plates were then 
left overnight in a chemical hood to evaporate the organic phase, before being 
stored at -20°C. For estimating the drug concentration in the samples with the 
UPLC, samples were reconstituted in 50 µl 20% acetonitrile solution containing 
250 µM caffeine (Sigma) as an internal standard. The bacteria-drug interaction 
screen was conducted with two biological replicates. Table 1 contains a list of 
bacteria in the screen. 
Under the same conditions I tested also two different mixes of five bacteria 
each. One mix consisting of bacteria depleting many drugs: C. saccharolyticum, C. 
ramosum, B. uniformis, B. animalis lactis, and F. nucleatum; the other mix 
consisting of bacteria not depleting drugs: L. plantarum, L. paracasei, B. fragilis, 
L.lactis, and B. vulgatus. Second overnight cultures from those bacterial strains 
were mixed before inoculation, and wells were inoculated with 50 µl of the premix 
resulting in an end OD578 of 0.01 for each bacterium. Otherwise, mixes were 
treated as described above for monocultures. 
7.3.3 Data analysis 
For dug depletion analysis, area under the curve (AUC) from drug peak was 
normalized by AUC from the internal standard caffeine (corresponding peak of 
the same chromatogram). Then for the triplicates for each bacteria-drug 
interaction the mean was compared to the bacteria-free control from the same 
plate. If the bacteria-free control was contaminated for that interaction, the 
triplicates were compared to the median of controls from the same column batch 
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(all plates measured on the same LC column). If for both biological replicates the 
difference was 30% or more, the interaction was considered a hit. For each hit the 
mean depletion from both biological replicates was then calculated. 
For growth effect analysis, growth curves were manually annotated with 
maximum OD reached, to correct for irreproducible “overgrowing” for certain 
species of bacteria. Triplicates of bacteria-drug samples were then compared to 
triplicates of solvent control with Student’s t-test, and if differences were 
significant in both biological replicates, the interaction was considered a hit. For 
each hit, the mean of the differences of maximum OD from both biological 
replicates was then calculated as the effect size. 
7.4 Community Assembly Assay 
7.4.1 Experimental Setup 
Two different species mixes were prepared, one with B. uniformis and one 
without. Other species in the mix were B. thetaiotaomicron, E. rectale, L. gasseri, R. 
torques and S. salivarius. Overnight cultures of the bacteria were diluted to OD578 
0.5 and 500 µl of each species culture was mixed in a 5ml eppendorf tube 
(5+GMM or 6 species respectively). A 10 mM working solution of duloxetine and 
DMSO in PBS was prepared to be used throughout the assay. 5 mL polystyrene 
tubes (round bottom, Falcon, Corning Mexico) were prepared with 1950 µl GMM 
plus 10 µl drug/DMSO solution plus 40 µl species mixture for each transfer 
respectively. Tubes were incubated for 48h non-shaken anaerobically at 37°C. 
After the first inoculation, the transferred species mix was from the end point of 
the earlier cultivation. For DNA extraction, 1mL of the remaining culture was 
centrifuged for 10 min 14.000 rpm in 1.5 mL eppendorf tube. 200 µl supernatant 
was transferred to a new 1.5 ml eppendorf tube, rest of supernatant was removed 
and then the bacteria pellet was frozen at -80°C until DNA extraction. For drug 
extraction 600 µl of cold ACN:MethOH was added to supernatant and incubated 
for 15 min in fridge. Then samples were centrifuged for 10 min 14.000 rpm 4°C, 
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700 µl of sample was transferred to new tube and then samples were dried in a 
speedvac (Eppendorf Vacuum Concentrator Plus) for 5h at 30°C at V-AL mode. 
For UPLC measurement samples were reconstituted in 116 µl 20% ACN 
containing 250 µM caffeine. 
7.4.2 DNA extraction and 16S barcode sequencing library 
preparation 
Bacteria pellets were dissolved in lysis buffer and transferred into a 96 
Polypropylene Deep Well plate (3959, Corning). An in-house protocol was used 
for DNA extraction. The GNOME DNA isolation Kit (MP Biomedicals) was 
adapted to be used with the Biomek® FXp Liquid Handling Automation 
Workstation (Beckman). Subsequently, purified DNA was obtained using ZR-96 
DNA Clean & Concentrator™-5 (D4024, Zymo Research). 
After the integrity of the DNA was verified by agarose gel electrophoresis, 
DNA concentration of the samples was determined using the Qubit dsDNA BR 
assay kit (Q32850, life technologies) in combination with the Infinite® M1000 
PRO plate reader (Tecan). The 16S V4 amplicons were generated using an 
Illumina-compatible 2-step PCR protocol: In a first PCR the 16S V4 region was 
amplified with the primers F515/R806 (Caporaso et al. 2011) and then in a second 
PCR barcode sequences were introduced using the NEXTflex 16S V4 Amplicon-
Seq Kit (4201-05, Bioo Scientific). 
After multiplexing equal volumes of PCR products from each sample, 
SPRIselect reagent kit (B23318, Beckman Coulter) was used for left-side size 
selection. Prior to Illumina sequencing the quality of the library was controlled 
using the 2100 BioAnalyzer (Agilent Technologies) and the DNA concentration 
was determined using the Qubit dsDNA HS assay kit. 
Sequencing was performed using a 250 bp paired-end sequencing protocol on 
the Illumina MiSeq platform (Illumina, San Diego, USA) at the Genomics Core 
Facility (EMBL Heidelberg). 
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7.4.3 16S barcode sequencing analysis 
The raw Illumina paired-end reads were quality trimmed and length filtered 
using CUTADAPT with quality threshold of 30 and length cutoff of 150 bp 
(Martin 2011). The forward and reverse pairs were subsequently merged using 
Paired End 138ead MergerR with minimum overlap of 20 bp (Zhang et al. 2014). 
The merged amplicon sequences were compared to the 16S rRNA gene of the 
species mixed for coculture using UCLUST (Edgar 2010). Only those that have 
minimum 98% identity were clustered into the operational taxonomic units 
(OTUs). The species abundance was normalized by the 16S rRNA gene copy 
numbers. Data was visualized using the plotly library (Dimitrov 2014). 
7.5 Other in vitro assays  
7.5.1 Depletion-mode assay 
The bacteria-drug interaction screen is designed to find potential drug 
interactions by screening for depletion of the drug from the medium. However, 
since in the screen the bacteria are removed before the extraction this leaves the 
question whether the drug is bound to or accumulated by the bacteria or if it is 
also biotransformed or metabolized. To distinguish between these two 
possibilities, bioaccumulation and xenometabolism, and also to further confirm 
the screening hits, I designed a depletion-mode assay.  
Bacteria from an overnight culture are inoculated with an OD578 of 0.01 in 1 
mL GMM containing 50 µM drug of interest in 2 mL eppendorf tubes and 
incubated for 48h while shaking. After finishing growth, the cultures were 
removed from the anaerobic chamber. 800 µl of each sample was transferred to a 
new eppendorf tube, while the remaining 200 µl were directly extracted by adding 
600 µl ice-cold acetonitrile:methanol solution and incubated for 15 min at 4°C. 
For the indirect extraction, the transferred culture was centrifuged for 5 min at 
14.000 rpm to pellet the bacteria, and 200 µl of the bacteria-free supernatant was 
extracted in a new eppendorf tube respectively. After the 15 min 4°C incubation 
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period, all samples were centrifuged for 10min, 14.000rpm at 4°C and 700µl of the 
supernatant was transferred to a new eppendorf tube. Samples were dried for 5-7h 
at 30°C in a speedvac (Eppendorf Vacuum Concentrator Plus, V-AL mode) and 
stored at -20°C until used for UPLC measurement. Samples were reconstituted in 
116µl 20% acetonitrile containing 250µM caffeine. All interactions and controls 
were tested in triplicates. 
7.5.2 Growth curves for IC50 determination 
A dilution curve of duloxetine ranging from 1mM to 5mM was prepared in 
DMSO and then added to GMM. End concentration of DMSO was 1%. Bacteria 
from second overnight culture were diluted to an OD578 of 0.5. 100 µL of medium 
was distributed in 96 well plates (Nunclon Delta Surface 163320, NUNC), 
inoculated with 1 µl to a final OD578 of 0.005 and sealed with a Breathe-Easy® 
sealing membrane (Z380059, Sigma-Aldrich). Growth was monitored every hour 
for 24h using an Eon Microplate Spectrophotometer (BioTek) equipped with 
BioStack Microplate Stacker (BioTek) and a surrounding self-designed incubator. 
For IC50 calculation a local regression curve was fitted to data from triplicates 
using R’s loess function with a span parameter of 0.5. From this half the maximum 
OD was inferred. Then the closest time point was selected were bacteria growth 
first passed half the maximum OD, being a close estimate to the turning point of 
the exponential growth phase. For this time point the fitted ODs from the 
duloxetine dilution curve were used for estimation of 50% of total the 
concentration inhibiting 50% of the growth (IC50). 
7.5.3 Resting Cell and Lysate assay 
For further characterization of hits from the bacteria-drug interaction screen 
with metabolomics and proteomics methods, interactions were tested in media-
free conditions. The use of media-free conditions allowed reducing the complexity 
due to media components and highly active endogenous bacterial metabolism. 
Bacteria were grown in a volume of 30 mL or more in standard conditions to 
maximum OD578, approaching or reaching stationary phase. Cultures were pooled 
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in 50 mL falcons and pelleted by centrifugation (2000-4000 rpm, 10 min). Media 
was discarded; cells were resuspended in 2 mL buffer and transferred to an 
eppendorf tube. Cells were washed 2 more times in 2 mL buffer (centrifugation 
9.000 rpm, 5 min, 4°C) before used further.  
For a resting cell assay, cells were resuspended in buffer, and exposed to 
experimental conditions as indicted. At the end of the experiment, all samples 
were extracted indirectly in a ratio of 1:3 sample:organic phase, as described in 
the depletion-mode assay method 7.5.1.  
For a lysate assay, up to 1mL cell suspension was added to 500µl 300µm 
glassbeads in a screw cap tube and cells were lysed for 1min at 4°C using a bead 
beater. Then, cell debris and beads were spinned down (14.000 rpm, 5min). The 
cell lysate was then exposed to experimental conditions as indicated.  
While all transfers were anaerobic, centrifugation, bead beating and 
ultrasound steps had to be implemented outside the anaerobic chamber. 
Eppendorf and screw cap tubes close tight enough for minimal oxygen exposure 
during these steps. 
7.5.4 Duloxetine pull down assay 
To enable a pull down of proteins interacting with duloxetine we decided in 
collaboration with Schultz group at EMBL to introduce an alkyne group at the 
methyl group of duloxetine. Felix Hövelmann (Schultz group, EMBL) synthesized 
the molecule. After synthesis and clean up, he linked the functionalized duloxetine 
to desthiobiotin using a click-chemistry enabled reaction. In collaboration with 
Thomas Bock (Beck group, EMBL) we could consequently captured the 
functionalized desthiobiotin-duloxetine on streptavidin magnetic beads.  
Bacterial suspensions of Clostridium saccharolyticum (1 ml, anaerobic 
conditions) were lysed by bead disruption (lysate preparation see method 7.5.3) 
and additional sonication at 4 C (two times at 75% amplitude/0.5 s cycle for one 
minute, Hielscher sonicator). Supernatant after centrifugation at 20000 x g at 4 C 
for 10 minutes containing protein lysate was recovered and protease inhibitors 
(aprotinin 10 μg/mL, leupeptin 5 μg/mL) were added. 
 141 
For all duloxetine-protein pull-downs, Strep-Tactin® Sepharose® 50% 
suspension (#2-1201-025, IBA) was used. For each sample, 400 µl Strep-Tactin 
Sepharose (50% suspension) was pre-washed three times using 400 µl PBS (pH=7) 
at room temperature. Beads were bound to duloxetine before addition of the 
protein lysate by resuspension in 400 µl PBS containing 50 µM duloxetine 
(control) or 50 µM duloxetine linked to desthiobiotin (for pull-down) on a 
rotating wheel at room temperature for 30 minutes. Unbound drug was removed 
by three PBS wash cycles (400 µl each).  
Protein lysates were incubated with drug-bound beads on a rotating wheel at 
4°C over night. Unbound proteins were removed by washing the beads with cold 
PBS. Bound proteins were recovered by competitive elution using PBS containing 
5 mM Biotin. After an SDS gel using stain-free SDS-PAGE imaging technology 
(BioRad) showed protein integrity, samples were further processed for mass 
spectrometry-based protein identification. The pull down was conducted in 
quadruplicates for each treated and control sample. 
7.5.5 Homologous overexpression of protein candidates 
First, selected strains from an overexpression plasmid library were conjugated 
into E. coli BW25113 ΔtolC::aphT background. The low copy expression plasmid 
clone library (Transbac library (Otsuka et al. 2015)) in the diaminopimelic acid 
(DAP) auxotrophic BW38029 (Hfr by CIP8) background was grown on LB agar 
plates supplemented with 10 μg ml-1 tetracycline and 0.3 mM DAP. The selected 
donor strains were manually picked from the library and arrayed in 96-format 
onto one LB agar plate.  
The receiver strain (BW25113 ΔtolC::aphT) was grown to stationary phase, 
diluted to an OD578 of 1 and streaked out on a mating plate (LB supplemented 
with DAP). Plates were dried for 1 hour at 37°C and the donor strains were 
pinned on top of the donor strain layer using a Singer robot. Conjugation was 
carried out at 37°C for 5 – 6 hours. After conjugation mixtures were pinned on LB 
plates supplemented with tetracycline. Three selection rounds ensured successful 
mating events. For glycerol stocks conjugated bacteria were inoculated in 100 µl 
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LB supplemented with 10 μg ml-1 tetracycline in a 96 well plate and after overnight 
incubation at 37°C 20µl of a sterile 80% glycerol solution was added. Glycerol 
stocks were kept at -80°C. 
Overexpression was conducted in 96-well plates (Nunclon Delta Surface 
163320, NUNC) in 100µl GMM supplemented with 10µg/ml tatracycline. Bacteria 
from second pre-culture in GMM supplemented with 10µg/ml tetracycline and 
200µM IPTG were inoculated with a final OD578 of approximately 0.01 and plates 
were sealed with a Breathe-Easy® sealing membrane (Z380059, Sigma-Aldrich). 
After 8h incubation at 37°C membranes were removed, 50µl of the same media 
additionally containing 50µM duloxetine or respective amount of DMSO as 
control was added and plates were sealed again for a further 43h incubation. Plates 
were then extracted and further treated as described for the bacteria-drug 
interaction screen, method section 7.3.2. 
For data analysis after normalization by caffeine internal standard, samples 
were normalized by mean of bacteria-free drug control from the respective plates 
and then compared using student’s t-test with an alpha level below 0.05. 
7.5.6 Heterologous overexpression of protein candidates 
E. coli TOP10 strains with a pET151/D-TOPO plasmid containing the codon-
optimized gene for the respective C. saccharolyticum protein candidate were 
designed at and ordered from Geneart (Thermo Scientific). Plasmids encoded for 
ampicillin resistance. Overexpression was conducted in 96-well plates (Nunclon 
Delta Surface 163320, NUNC) in 150 µl GMM supplemented with 100 µg/ml 
ampicillin. Bacteria from second pre-culture in GMM supplemented with 100 
µg/ml ampicillin and 50 µM duloxetine were inoculated with a final OD578 of 0.01 
and plates were sealed with a Breathe-Easy® sealing membrane (Z380059, Sigma-
Aldrich). After 5h incubation at 37°C membranes were removed, 1.5 µl 20 mM 
IPTG solution added to induce overexpression and plates were sealed again for a 
further 43h incubation. Plates were then extracted and further treated as described 
for the bacteria-drug interaction screen, method section 7.3.2.  
 143 
For data analysis after normalization by caffeine internal standard, samples 
were normalized by mean of bacteria-free drug control from the respective plates 
and then compared using Student’s t-test with an alpha level below 0.05. 
7.6 Untargeted Metabolomics with NMR 
For NMR spectroscopy I performed two different experiments. First, I tested 
one specific interaction, that of duloxetine with B. uniformis. Samples were 
collected from resting cell assays (method 7.5.3), and duloxetine concentration 
was 100 µM. Samples were exposed for 4h before further processed. Secondly, I 
tested the depletion of duloxetine in a mixture of 6 bacteria (B. longum longum, B. 
uniformis, C. bolteae, C. ramosum, C. saccharolyticum, F. nucleatum). For this 
resting cell assay PBS buffer was supplemented with 1 mM MgCl2 and pH was 
adjusted to 6.5 using 1 M HCl. For the bacteria mix, bacteria were grown to end of 
exponential phase/beginning of stationary phase before preparing the resting cell 
assay. For this cells were diluted and mixed in the same ratio at a final OD578 of 
3.75 before exposed to experimental conditions of 1 mM duloxetine for 4h and 
further processed.  
All experiments were resting cell assays (see Methods 7.5.3) with duloxetine 
or respective amount of DMSO in control, comparing bacteria treated with 
duloxetine to bacteria not treated with duloxetine and a bacteria-free control 
containing only duloxetine. To record a one-dimensional proton spectrum of 
duloxetine, proton containing water molecules, which make up almost 100% of 
the sample, need to be replaced by deuterated, heavy water with no protons. After 
drying in a speedvac (Eppendorf Vacuum Concentrator Plus), all samples were 
reconstituted in a mixture of 80% D2O and 20% deuterated acetonitrile with half 
the original volume, thus doubling the concentration. 1D proton NMR spectra for 
all samples were then recorded on a 500 MHz Bruker DRX at 27 degrees or 
equivalent. 
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7.7 Untargeted Metabolomics with LC-MS/MS 
7.7.1 Experimental setup 
I tested the depletion of duloxetine and change in the metabolome of 
Clostridium saccharolyticum and Bacteroides uniformis upon addition of the drug. 
Bacteria from a 20 mL overnight culture were washed and prepared for a resting 
cell and lysate assay as described in the method section 7.5.3. For the resting cell 
assay bacteria were reconstituted in 3.6 mL PBS, pH 6.5 containing 1 mM MgCl2, 
sample volume was 600 µl. For the lysate assay, bacteria were reconstituted in 1 
mL PBS, lysed, and then 360 µl of the recovered lysate was diluted with 1080 µl 
PBS. Thus, finale sample volume for each lysate replicate was 240 µl. Resting cells 
were incubated for 2h, lysates were incubated for 30 min with duloxetine or with 
DMSO as control respectively. As another control, buffer with duloxetine was 
incubated for the respective time in the respective sample volume. Duloxetine 
concentration was 1 mM for both assay, and all interactions were tested in 
triplicates. Extraction buffer contained 10 µM amitriptyline as internal standard, 
and all extractions were indirect, meaning cells/lysate was centrifuged (14.000 
rpm, 10 min, 4°C) and only the supernatant was extracted. Resting cell samples 
were reconstituted in 225 µl reconstitution buffer, doubling the respective 
concentration of small molecules in comparison to the original sample. Lysate 
samples were reconstituted in 187.5 µl, concentration in comparison to the 
original culture remained constant.  
7.7.2 Mass spectrometry method 
Samples were measured on a Q Exactive Plus-Orbitrap Mass Spectrometer 
(Thermo Fisher) in positive mode using a Kinetex C18 column for LC. The LC 
method used was 35 min long, and used acetonitrile and 5 mM formic acid as 
liquid phase. Gradient were. Injection volume was 5 µl, samples were injected in 
three rounds representing three technical replicates including washing injection 
every ten injections.  
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Scan mode was FTMS + p ESI Full ms and scan range was from 60-800 m/z. 
Resolution was set to 70.000, AGC target to 1.000.000 ions, maximum IT to 150 
ms. For secondary MS resolution was set to 17.500, AGC target to 100.000 ions, 
and maximum IT to 60 ms, allowing 5 secondary scans ranging from 200-2000 
m/z per full scan at a collision energy of 35. In any case unknown charges or 
charges higher than 2 were excluded from analysis. 
7.7.3 Data analysis 
Data analysis was aimed at comparing the two bacteria C. saccharolyticum and 
B. uniformis in two different experimental condition and trying to investigate if a 
potential drug metabolite is generated in the presence of bacteria and drug. After 
no potential drug metabolite could be isolated, data analysis switched to 
identifying mass features. 
Raw data was converted from ThermoFisher .raw format into the open 
mzXML format using RawConverter program (He et al. 2015). For feature 
selection, peak alignment, grouping and retention time shift correction from the 
raw data the XCMS R package was used. Parameters for first round of density 
grouping of peaks were bw=30, minfrac=0.5, minsamp=3, mzwid=0.025, max=50. 
For retention time correction parameters were family="symmetric", 
plottype="mdevden"; Lysates were corrected with span = .4 instead of default 
value. For second round of grouping parameters were bw=10, minfrac=0.5, 
minsamp=3, mzwid=0.025, max=50. Then missing peaks were filled using 
“chrom” method. Samples for lysate and extracellular fraction have been 
processed independently. One technical injection replicate was excluded as strong 
difference to other two injections was observed, potentially based on less washing 
injections between sample injection. Thus, following statistical analysis was based 
on three biological replicates with two technical replicates each. 
Statistical analysis was loosely based on Vinaixa et al. 2012 and Ortmayr et al. 
2017. Vinaixa et al. describe a general approach how to analyze untargeted 
metabolomics data focusing on statistical pitfalls and general workflow. Ortmayr 
et al. describe an alternative approach to the common Student’s t-test or variance 
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analysis approach, taking the uncertainty in fold change calculation into account. 
All data analysis and scripting was done in R. 
Using PATHOS (Leader et al. 2011) or other tools like MBROLE (Lopez-
Ibanez et al. 2016) for data exploration comparisons to databases like METLIN 
(Smith et al. 2005), Biocyc (Caspi et al. 2016) or KEGG (Tanabe & Kanehisa 2012) 
were based on 5ppm accuracy. As reference/background, C. saccharolyticum or B. 
uniformis was used if possible. Otherwise C. saccharobutilyticum or B. 
thetaiotaomicron was used respectively. If none of the options were given for data 
comparison, E. coli was used. For KEGG pathway enrichment using PATHOS I 
allowed all 12 ACN or H adducts to be formed, and compared to E. coli as a 
background for statistical tests (Fisher’s exact test). I further analyzed the data by 
annotating the mass features with species-specific metabolites. Data was kindly 
provided by Daniel Sevin (Cellzome). He generated lists of species-specific 
metabolites by building genome-scale models for all organisms available in 
KEGG, and predicting their potential metabolome from the model. For adduct-
formation I used a stricter cutoff as with PATHOS, only allowing H+ and 
ACN+H+ adducts to be formed to annotate a mass with its potential KEGG 
metabolite. 
7.8 Proteomics 
7.8.1 Sample preparation 
For the identification of recovered proteins by mass spectrometry, protein 
eluates were rebuffered into 4 M urea/0.2% rapigest (final concentration) and 
sonicated in a vial tweeter (Hielscher) for two times 30 seconds (100%/0.5 seconds 
cycle). Disulfide bridges between cysteins were disrupted by reduction with 10 
mM DTT at 37 C for 30 minutes. Following that, free cysteins were alkylated 
using 15 mM iodoacetamide at room temperature in the dark for 30 minutes. 
Protein digestion was performed using 1:100 (w/w) Lys-C endoproteinase (Wako 
Chemicals GmbH, Germany) at 37 °C for 4 hours and then finalized (after the 
urea concentration was diluted to 1.6 M) with 1:50 (w/w) trypsin (Promega 
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GmbH, Germany) at 37 °C over night. Rapigest was cleaved by acidification below 
pH=3 using 10% (v/v) TFA at room temperature for 30 minutes and removed by 
desalting of the peptide mixture using C18 spin columns (Harvard Apparatus, 
USA) according to the manufacturers procedures. Desalted peptides were vacuum 
dried and stored at -20 C until further use. 
 
7.8.2 Mass spectrometry method and protein identification 
For shot-gun experiments, samples were analyzed using a nanoAcquity UPLC 
system (Waters GmbH) connected online to a LTQ-Orbitrap Velos Pro 
instrument (Thermo Fisher Scientific GmbH). Peptides were separated on a 
BEH300 C18 (75 µm x 250 mm, 1.7 µm) nanoAcquity UPLC column (Waters 
GmbH) using a stepwise 90 min gradient between 3 and 85% (v/v) ACN in 0.1% 
(v/v) FA. Data acquisition was performed by collision-induced dissociation using 
a TOP-20 strategy with standard parameters. Charge states 1 and unknown were 
rejected.  
For the quantitative label-free analysis, raw files from the Orbitrap were 
analyzed using MaxQuant (version 1.5.3.28) (Cox & Mann 2008). MS/MS spectra 
were searched against the Clostridium saccharolyticum (strain ATCC 35040 / 
DSM 2544 / NRCC 2533 / WM1) entries of the Uniprot KB (database release 
2016_04, 7212 entries) using the Andromeda search engine (Cox et al. 2011).  
The search criteria were set as follows: full tryptic specificity was required 
(cleavage after lysine or arginine residues, unless followed by proline); 2 missed 
cleavages were allowed; carbamidomethylation (C) was set as fixed modification; 
oxidation (M) and acetylation (protein N-term) were applied as variable 
modifications, if applicable; mass tolerance of 20 ppm (precursor) and 0.5 Da 
(fragments). The reversed sequences of the target database were used as decoy 
database. Peptide and protein hits were filtered at a false discovery rate of 1% 
using a target-decoy strategy (Elias & Gygi 2007). Additionally, only proteins 
identified by at least 2 unique peptides were retained. Only proteins identified in 
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at least 2 replicates were considered when comparing protein abundances between 
control and drug treatment.  
7.8.3 Data analysis 
To reduce technical variation, data was quantile-normalized using the 
preprocessCore library (Gentleman et al. 2004). Protein differential expression 
was evaluated using the limma package. Differences in protein abundances were 
statistically determined using the Student’s t-test moderated by Benjamini-
Hochberg’s method (Benjamini & Hochberg 1995) at alpha level of 0.05. 
Significant regulated proteins were defined by a cut-off of log2 fold change ≥ 2 
and p-value ≤ 0.1. 
For gene ontology term and pathway enrichment analysis, significantly 
changed proteins were annotated using Blast2GO (Conesa et al. 2005) with default 
parameters using the NCBI blast search. GO term enrichment can be done within 
Blast2GO and significantly enriched (FDR corrected p-value<0.05) most specific 
GO terms were listed. For KEGG pathway enrichment analysis EC numbers from 
Blast2Go annotation were extracted and the EC2KEGG tool (Porollo 2014) was 
used to annotate respective species specific KEGG pathways and perform 
enrichment analysis (uncorrected p-value < 0.05). 
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Appendix 
A. Side effect keywords 
Table 12: Indirect gut related side effects from SIDER database. 
"Abdominal bloating", "Abdominal colic", "Abdominal cramps", "Abdominal discomfort", "Abdominal 
distension", "Abdominal distension gaseous", "Abdominal distress", "Abdominal infection", "Abdominal pain", 
"Abdominal pain generalised", "Abdominal pain lower", "Abdominal pain upper", "Abdominal rigidity", 
"Abdominal symptom", "Abdominal tenderness", "Abnormal bowel sounds", "Abnormal faeces", "Abnormal 
weight gain", "Acne", "Acne fulminans", "Acne infantile", "Acneiform eruption", "Acquired megacolon", 
"Acute abdomen", "Acute gastroenteritis", "Acute interstitial nephritis", "Aminoaciduria", "Anaemia vitamin 
B12 deficiency", "Anal atresia", "Anal discomfort", "Anal inflammation", "Anal pruritus", "Anorectal 
discomfort", "Anorectal disorder", "Anorexia", "Anus disorder", "Arterial stenosis", "Arterial thrombosis", 
"Arterial thrombosis limb", "Arteriosclerosis", "Arteriosclerosis coronary artery", "Arthritis bacterial", 
"Arthritis infective", "Atherosclerosis", "Atypical mycobacterial infection", "Avitaminosis", "Bacterial 
infection", "Bacterial prostatitis", "Bacteriuria", "Bloated feeling", "Blood gastrin increased", "Blood glucose 
abnormal", "Blood glucose decreased", "Blood glucose increased", "Body odor", "Borborygmi", "Bowel sounds 
decreased", "Bowel spasm", "Caecitis", "Carbohydrate craving", "Carbohydrate tolerance decreased", "Carotid 
bruit", "Central obesity", "Cerebral arteriosclerosis", "Change of bowel habit", "Cholangitis", "Cholangitis 
sclerosing", "Clostridial infection", "Clostridium colitis", "Clostridium difficile colitis", "Colicky", "Colitis", 
"Colitis ischaemic", "Colitis microscopic", "Colitis ulcerative", "Colon atonic", "Colonic obstruction", "Colonic 
pseudo-obstruction", "Constipation", "Constipation chronic", "Coronary artery occlusion", "Crohn's disease", 
"Defaecation urgency", "Delayed gastric emptying", "Diarrhoea", "Diarrhoea haemorrhagic", "Diarrhoea, 
Clostridium difficile", "Digestion impaired", "Discomfort rectal", "Distress gastrointestinal", "Diverticulitis", 
"Diverticulum", "Diverticulum intestinal", "Dysentery", "Encopresis", "Enlargement abdomen", "Enteritis", 
"Enterocolitis", "Epigastric discomfort", "Epigastric distress", "Epigastric fullness", "Epigastric pain", "Excessive 
flatulence", "Faecal incontinence", "Faecalith", "Faecaloma", "Faeces discoloured", "Faeces hard", "Flatulence", 
"Gas", "Gas in stomach", "Gas pain", "Gastric dilatation", "Gastric disorder", "Gastric erosions", "Gastric flu", 
"Gastric irritation", "Gastric pH decreased", "Gastric ulcer", "Gastric ulcer haemorrhage", "Gastric ulcer 
perforation", "Gastrin increased", "Gastrinoma", "Gastritis", "Gastritis erosive", "Gastritis haemorrhagic", 
"Gastroduodenitis", "Gastroenteritis", "Gastroenteritis bacterial", "Gastrointestinal candidiasis", 
"Gastrointestinal discomfort", "Gastrointestinal disorder", "Gastrointestinal infection", "Gastrointestinal 
obstruction", "Gastrointestinal pain", "Gastrointestinal sounds abnormal", "Gastrointestinal stoma 
complication", "Gastrointestinal symptom NOS", "Gastrointestinal toxicity", "Gastrointestinal tract irritation", 
"Gastrointestinal ulcer", "Helicobacter gastritis", "Helicobacter infection", "Hypovitaminosis", "Impaired 
gastric emptying", "Infection susceptibility increased", "Infrequent bowel movements", "Intestinal 
obstruction", "Intestinal stoma complication", "Intestinal ulcer", "Irritable bowel syndrome", "Large intestinal 
obstruction", "Lymphocytic colitis", "Malabsorption", "Malnutrition", "Markedly reduced dietary intake", 
"Megacolon", "Megacolon toxic", "Melaena", "Metabolic acidosis", "Metabolic alkalosis", "Metabolic disorder", 
"Mucous stools", "Neutropenic colitis", "Neutropenic enterocolitis", "Obesity", "Obstipation", "Pneumatosis", 
"Pneumatosis cystoides intestinalis", "Pneumatosis intestinalis", "Post procedural diarrhoea", "Proctocolitis", 
"Protein-losing gastroenteropathy", "Pseudomembranous colitis", "Pseudomembranous enterocolitis", "Serum 
gastrin increased", "Steatorrhoea", "Stools watery", "Tarry stools", "Ulcerative enterocolitis", "Unspecified 
disorder of intestine", "Vitamin B complex deficiency", "Vitamin B12 deficiency", "Vitamin B6 deficiency", 
"Vitamin D deficiency", "Vitamin K deficiency", "Watery diarrhoea", "Weight decreased", "Weight 
fluctuation", "Weight increased" 
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Table 13: Direct gut related side effects from SIDER database. 
"Abdominal bloating", "Abdominal distension gaseous", "Abnormal bowel sounds", "Abnormal faeces", 
"Bloated feeling", "Borborygmi", "Bowel sounds decreased", "Change of bowel habit", "Constipation", 
"Defaecation urgency", "Diarrhoea", "Diarrhoea, Clostridium difficile", "Digestion impaired", "Distress 
gastrointestinal", "Excessive flatulence", "Faecal incontinence", "Faeces discoloured", "Faeces hard", 
"Flatulence", "Gas", "Gas in stomach", "Gastrointestinal sounds abnormal", "Impaired gastric emptying", 
"Infection susceptibility increased", "Infrequent bowel movements", "Intestinal obstruction", "Malabsorption", 
"Malnutrition", "Obstipation", "Steatorrhoea", "Stools watery", "Tarry stools", "Watery diarrhoea", "Weight 
decreased", "Weight fluctuation", "Weight increased" 
B. Bacteria-Drug Interactions 
Table 14: Drug depletion in bacteria-drug interaction screen. 
Depleting bacteria Depleted drug Mean depletion in percent 
Escherichia coli ED1a Acetaminophen 100 
Fusobacterium nucleatum nucleatum Acetaminophen 100 
Bacteroides uniformis Aripiprazole 44.27540983 
Clostridium saccharolyticum Aripiprazole 41.06687518 
Escherichia coli iAi1 Aripiprazole 41.15933652 
Eggerthella lenta Digoxin 100 
Fusobacterium nucleatum nucleatum Donepezil 39.22195301 
Bacteroides uniformis Duloxetine 51.53810786 
Clostridium bolteae Duloxetine 48.68194393 
Clostridium saccharolyticum Duloxetine 53.84738298 
Coprococcus comes Duloxetine 37.43557749 
Escherichia coli iAi1 Duloxetine 40.60557131 
Lactobacillus paracasei Duloxetine 52.11007663 
Lactobacillus plantarum Duloxetine 44.54516384 
Ruminococcus gnavus Duloxetine 57.22155512 
Bifidobacterium animalis lactis Ezetimibe 57.34494054 
Clostridium ramosum Ezetimibe 62.76817906 
Mix Degrad Ezetimibe 66.779273 
Mix No Ezetimibe 50.61135839 
Bacteroides uniformis Levamisole 68.47070953 
Bacteroides uniformis HM716 Levamisole 74.79411704 
Bifidobacterium animalis lactis Levamisole 43.84127641 
Bifidobacterium longum infantis Levamisole 55.62754501 
Clostridium bolteae Levamisole 48.05907875 
Clostridium saccharolyticum Levamisole 58.2917914 
Coprococcus comes Levamisole 62.47539067 
Fusobacterium nucleatum nucleatum Levamisole 87.38600047 
Bacteroides vulgatus Metronidazole 100 
Bifidobacterium animalis lactis Metronidazole 98.69099719 
Clostridium bolteae Metronidazole 100 
Escherichia coli ED1a Metronidazole 100 
Escherichia coli iAi1 Metronidazole 100 
Lactobacillus plantarum Metronidazole 100 
Lactococcus lactis Metronidazole 100 
Mix Degrad Metronidazole 100 
Mix No Metronidazole 100 
Streptococcus salivarius Metronidazole 100 
Bacteroides uniformis HM715 Montelukast 39.14008877 
Bifidobacterium animalis lactis Montelukast 47.83326001 
Bifidobacterium longum infantis Montelukast 45.68743593 
Clostridium bolteae Montelukast 49.09396904 
Coprococcus comes Montelukast 43.2711665 
Fusobacterium nucleatum nucleatum Montelukast 42.07705466 
Lactobacillus plantarum Montelukast 43.4526419 
Mix Degrad Montelukast 46.00337988 
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Ruminococcus gnavus Montelukast 66.10601682 
Clostridium bolteae Ranitidine 39.85594525 
Eggerthella lenta Ranitidine 100 
Escherichia coli iAi1 Ranitidine 39.82398937 
Fusobacterium nucleatum nucleatum Ranitidine 32.7098203 
Lactobacillus gasseri Ranitidine 42.91659306 
Ruminococcus gnavus Ranitidine 45.6331274 
Fusobacterium nucleatum nucleatum Roflumilast 39.05930242 
Lactococcus lactis Roflumilast 79.83320576 
Mix No Roflumilast 53.1968065 
Ruminococcus gnavus Roflumilast 44.25472109 
Bacteroides thetaiotaomicron Rosiglitazone 35.28432013 
Bifidobacterium animalis lactis Rosiglitazone 44.48883462 
Fusobacterium nucleatum nucleatum Rosiglitazone 35.23351925 
Lactobacillus paracasei Rosiglitazone 41.88601157 
Bacteroides thetaiotaomicron Simvastatin 74.84471371 
Bacteroides uniformis Simvastatin 76.86857365 
Bacteroides vulgatus Simvastatin 69.9565144 
Bifidobacterium animalis lactis Simvastatin 69.83734966 
Clostridium bolteae Simvastatin 52.52299585 
Clostridium ramosum Simvastatin 66.26821933 
Clostridium saccharolyticum Simvastatin 56.35281086 
Eggerthella lenta Simvastatin 44.58606123 
Fusobacterium nucleatum nucleatum Simvastatin 54.77585933 
Lactobacillus plantarum Simvastatin 74.33695501 
Mix Degrad Simvastatin 54.37546604 
Bacteroides uniformis Sulfasalazine 100 
Bacteroides uniformis HM715 Sulfasalazine 100 
Bifidobacterium animalis lactis Sulfasalazine 100 
Bifidobacterium longum infantis Sulfasalazine 100 
Clostridium bolteae Sulfasalazine 100 
Clostridium ramosum Sulfasalazine 100 
Eggerthella lenta Sulfasalazine 100 
Escherichia coli iAi1 Sulfasalazine 100 
Fusobacterium nucleatum nucleatum Sulfasalazine 100 
Lactobacillus gasseri Sulfasalazine 100 
Lactococcus lactis Sulfasalazine 100 
Mix Degrad Sulfasalazine 99.64278195 
Mix No Sulfasalazine 100 
Streptococcus salivarius Sulfasalazine 100 
 
 
 
Table 15: Growth effects from bacteria-drug interaction screen. 
Drug Affected bacteria log2 fold change 
Aripiprazole E. coli IAI1 0.376486125 
Aripiprazole L. gasseri 0.229201218 
Digoxin E. coli IAI1 0.300498375 
Digoxin E. lenta 0.27439148 
Digoxin R. torques 0.764346284 
Duloxetine C. saccharolyticum 0.129106874 
Duloxetine E. coli IAI1 0.451924994 
Duloxetine E. rectale lethal 
Levamisole L. lactis 0.114455594 
Loperamide B. longum subsp. infantis lethal 
Loperamide E. coli IAI1 0.304640652 
Loperamide E. lenta lethal 
Loperamide E. rectale lethal 
Loperamide L. lactis 0.746548355 
Metronidazole B. fragilis lethal 
Metronidazole B. longum subsp. infantis lethal 
Metronidazole B. thetaiotaomicron lethal 
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Metronidazole B. uniformis lethal 
Metronidazole B. uniformis HM715 lethal 
Metronidazole B. uniformis HM716 lethal 
Metronidazole C. ramosum lethal 
Metronidazole C. saccharolyticum lethal 
Metronidazole E. lenta lethal 
Metronidazole E. rectale lethal 
Metronidazole F. nucleatum subsp. nucleatum lethal 
Montelukast B. uniformis HM715 0.167807495 
Ranitidine E. coli IAI1 0.4156723 
Rosiglitazone E. coli IAI1 0.365450851 
Rosuvastatin B. vulgatus 0.136144383 
Simvastatin B. uniformis HM716 0.286360254 
Sulfasalazine C. ramosum 0.297975223 
Sulfasalazine R. torques 1.239805299 
Tolmetin L. plantarum 0.11056823 
Tolmetin R. torques 0.25022290 
 
 
 
Table 16: Drug depletion in depletion-mode assay. 
Batch Extraction Drugs Bacteria Difference to Ctrl p-value 
2 dir aripiprazole B. uniformis -31.30972752 0.006731675 
3 dir aripiprazole C. bolteae -54.84344883 0.006634478 
3 ind aripiprazole C. bolteae -21.70746985 0.070838531 
3 dir digoxin E. lenta -19.75243723 0.013396957 
5 ind digoxin E. lenta -10.96501077 0.003940423 
1 dir donepezil F. nucleatum -22.97478742 0.000865049 
3 ind donepezil F. nucleatum -5.304484226 0.001339369 
2 dir duloxetine B. thetaiotaomicron -62.43641652 1.13E-05 
4 dir duloxetine B. thetaiotaomicron -46.26443258 0.000322 
5 dir duloxetine C. comes -6.048205727 0.002312058 
2 ind duloxetine B. thetaiotaomicron -38.54924883 1.08E-06 
3 ind duloxetine B. thetaiotaomicron -42.16501325 4.04E-05 
4 ind duloxetine B. thetaiotaomicron -62.78030703 5.27E-08 
2 ind duloxetine C. bolteae -10.65210459 0.056749628 
3 ind duloxetine C. bolteae -39.05784799 0.043926718 
5 ind duloxetine C. comes -31.77858065 3.53E-09 
2 ind duloxetine C. saccharolyticum -26.28156478 4.77E-05 
2 ind duloxetine R. gnavus -16.76114904 5.17E-05 
2 ind duloxetine S. salivarius -14.99328111 0.000827831 
3 dir ezetimibe B. animalis lactis -18.33791 0.000143792 
3 ind ezetimibe B. animalis lactis -14.63941392 0.002263293 
3 dir levamisole B. animalis lactis -70.63291266 0.001432845 
3 dir levamisole B. longum infantis -75.93690931 0.00109915 
4 dir levamisole B. longum infantis -74.15933736 1.85E-05 
3 dir levamisole B. uniformis -52.03567202 0.005418941 
1 dir levamisole C. comes -60.28240374 4.40E-08 
2 dir levamisole C. ramosum -52.09290375 0.001769814 
1 dir levamisole L. gasseri -42.75016138 4.81E-07 
3 ind levamisole B. animalis lactis -69.33489689 1.37E-06 
3 ind levamisole B. longum infantis -100 1.98E-06 
4 ind levamisole B. longum infantis -72.6262388 2.84E-07 
3 ind levamisole B. uniformis -46.70492127 5.34E-05 
1 ind levamisole C. comes -64.86468501 0.042616736 
2 dir montelukast B. longum infantis -46.99429855 3.18E-05 
3 dir montelukast C. bolteae -6.944421862 0.052709981 
1 dir montelukast C. comes -12.47607532 0.017622857 
1 dir montelukast E. rectale -28.2121751 0.002900849 
3 dir montelukast R. gnavus -32.73632476 1.50E-05 
5 dir montelukast R. gnavus -33.6912125 0.000223934 
3 dir montelukast S. salivarius -50.93947424 1.82E-07 
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3 ind montelukast B. animalis lactis -12.01544874 0.0018339 
2 ind montelukast B. longum infantis -37.33852858 4.15E-08 
3 ind montelukast B. longum infantis -20.95413808 0.014405127 
2 ind montelukast C. bolteae -35.22644616 5.89E-10 
3 ind montelukast C. bolteae -29.39436175 8.68E-07 
2 ind montelukast C. saccharolyticum -7.725129365 0.00295472 
2 ind montelukast R. gnavus -33.66419854 2.57E-06 
3 ind montelukast R. gnavus -33.72466057 2.90E-06 
5 ind montelukast R. gnavus -20.88527317 0.000556889 
2 ind montelukast S. salivarius -20.63055213 0.000367701 
3 ind montelukast S. salivarius -44.09876523 1.13E-07 
1 dir ranitidine F. nucleatum -33.18924222 0.000182851 
2 dir roflumilast S. salivarius -34.57741768 0.043745799 
3 dir roflumilast S. salivarius -49.94386202 0.002985216 
3 ind roflumilast F. nucleatum -32.32253541 4.37E-05 
2 ind roflumilast S. salivarius -60.05588551 0.010742064 
3 ind roflumilast S. salivarius -39.46763637 1.18E-06 
5 ind roflumilast S. salivarius -32.14895808 0.000185274 
2 ind rosiglitazone B. thetaiotaomicron -28.36986 1.80E-06 
2 ind rosiglitazone C. ramosum -15.67899709 3.30E-05 
2 dir sulfasalazine B. thetaiotaomicron -100 3.01E-09 
2 dir sulfasalazine B. uniformis -100 3.01E-09 
2 dir sulfasalazine C. bolteae -100 3.01E-09 
2 dir sulfasalazine C. ramosum -100 3.01E-09 
2 dir sulfasalazine C. saccharolyticum -100 3.01E-09 
2 dir sulfasalazine E. coli IAI1 -100 3.01E-09 
1 dir sulfasalazine F. nucleatum -100 5.31E-09 
1 dir sulfasalazine L. gasseri -100 5.31E-09 
2 dir sulfasalazine S. salivarius -100 3.01E-09 
2 ind sulfasalazine B. thetaiotaomicron -100 5.46E-06 
2 ind sulfasalazine B. uniformis -100 5.46E-06 
2 ind sulfasalazine C. bolteae -100 5.46E-06 
2 ind sulfasalazine C. ramosum -100 5.46E-06 
2 ind sulfasalazine C. saccharolyticum -100 5.46E-06 
2 ind sulfasalazine E. coli IAI1 -100 5.46E-06 
1 ind sulfasalazine F. nucleatum -100 8.03E-10 
1 ind sulfasalazine L. gasseri -85.63467369 0.000211314 
2 ind sulfasalazine S. salivarius -100 5.46E-06 
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C. C. saccharolyticum growth curves and IC50 
 
Figure 31: Growth curves of C. saccharolyticum exposed to a dilution series of duloxetine. 
24h growth curves in GMM with respective concentration of duloxetine with 1% DMSO as solvent. Curves 
fitted for triplicates with local regression using R’s loess function. 
 
 
 
Figure 32: Duloxetine IC50 determination for C. saccharolyticum. 
Dilution series of duloxetine in 1% DMSO. Underlying growth curves taken for 24h in GMM in triplicates. 
OD at half maximum OD time point of control used as effect response. Dashed line indicates 50% of half-
maximum OD, to estimate corresponding inhibitory concentration (IC50). Curves are fitted with R function 
“loess”, span parameter equals 0.5. 
